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Abstract 
The PDE 11 family of dual specificity phosphodiesterases was first identified in 2000, and 
has  not  been  well  characterised,  although  mutations  in  the  gene  have  been  linked  to 
multiple disorders, including major depressive disorder, and cancer. DmPDE11 is a dual 
specificity phosphodiesterase, which shows 96% similarity with the catalytic domain of 
HsPDE11A, and around 40% similarity along the length of the protein.  The focus of this 
project was to characterise this important enzyme using the model organism Drosophila 
melanogaster.  The  resources  available  to  Drosophila  researchers  are  unrivalled,  and 
include  a  sequenced  genome,  unparalleled  transgenic  technology,  of  which  stocks  are 
freely available, and Homophila, a database of human disease genes and their Drosophila 
orthologues.  Drosophila  is  genetically  tractable  to  an  extent  not  seen  in  any  other 
multicellular organisms. The genetic dissection of gene function in Drosophila has allowed 
the  identification  and  characterisation  of  numerous  cell  signalling  genes.  For  example, 
mutations to Dunce were shown to affect olfactory learning. This allowed the identification 
and  cloning  of  the  mammalian  dnc  homologue  PDE4.  cAMP  (and  cGMP)  were 
subsequently shown to modulate learning and memory in mammals. 
The 5.8 kb expressed sequence tag (EST) SD13096 had previously been shown to contain 
sequence present in the incomplete PDE11 RA ESTs previously released by Flybase, but 
also incorporating a 5‟ UTR, and an in-frame start codon within two novel 5‟ exons. A 
Northern  blot  of  DmPDE11  RA  produced  one  band  of  approximately  5.8kb;  as  this 
matches the size of the DmPDE11 RA ORF, was accepted that SD13096 encodes the entire 
PDE11 RA ORF (Day, unpublished). Expression of this EST in S2 cells revealed that the 
construct  produced  a  protein  of  the  accepted  size,  and  the  protein  localised  to  the 
cytoplasm. However, PDE assays of S2 cell lysate revealed that the enzyme did not appear 
to encode an enzyme with either cA- or cG-PDE activity. 
DmPDE11  RA  was  replaced  on  Flybase  by  the  new  isoforms  DmPDE11  RB  and 
DmPDE11 RC, which had two key changes to the RA isoform. Both new isoforms had 
different N termini, sharing a second exon, with distinct first exons. Furthermore, exon 11 
of the RA exon is not present in the newly predicted isoforms. These new isoforms were 
verified by reverse transcriptase- polymerase chain reaction analysis. In the course of this 
verification, two further novel isoforms were identified, which shared the novel N termini 
with the RB and RC isoforms, but include a novel exon/exon boundary within the original 
exon 19, which results in a truncated isoform. As such the four isoforms were named 3 
DmPDE11 RB long, DmPDE11 RB short, DmPDE11 RC long, and DmPDE11 RC short. 
The open reading frames of these isoforms were cloned from  Drosophila cDNA using 
high-fidelity DNA polymerase and sequenced for fidelity. The open reading frames were 
tagged  with  YFP,  and  this  tag  was  used  to  verify  expression  of  these  isoforms.  Each 
isoform  expressed  a  protein  of  the  predicted  size  when  expressed  in  Drosophila. 
DmPDE11 B and C proteins show distinct localisation in the Malpighian tubule, where the 
long and short isoforms of each isoform display indistinguishable localisations. DmPDE11 
B  localises  to  the apical  and basolateral  membranes,  and  DmPDE11 C  localises  to  an 
unknown organelle, or to vesicles. All 4 isoforms were verified as dual specificity cA- and 
cG- PDEs. 
The  previous  finding  (Day,  unpublished)  that  DmPDE11  co-immunoprecipitates  with 
cGMP dependent protein kinase activity, and that cGMP dependent protein kinases co-
immunoprecipitate with cG-PDE activity, and thus that cG-PDE(s) interact with at least 
one cGMP dependent protein kinase, directly or indirectly, was investigated. DmPDE11 C 
long and short were co-transfected in Schneider 2 cells with the cGKs DG1, DG2P1 and 
DG2P2. Co-immunoprecipitation of these showed that both the long and short isoforms of 
DmPDE11 C interact with every cGK screened. Time did not permit the application of this 
protocol to screen DmPDE11 B interaction with the cGKs. Whether this interaction is 
direct  or  indirect  was  screened  by  peptide  array.  Peptide  arrays  were  generated 
representing  the  sequence  of  DmPDE11,  DG1,  and  DG2,  and  proteins  were  generated 
fusing fragments of these proteins with HIS6 and Glutathione-S-Transferase tags. These 
were expressed in E. coli, and verified by western blotting. HIS6 tagged protein expression 
was shown to be of higher quality, and was thus affinity purified, and used to overlay and 
probe  the  peptide  arrays  for  putative  direct  interactions.  When  the  PDE11  array  was 
overlaid with tagged protein representing the C terminal half of DG1, and the N and C 
terminal  halves of DG2, a putative direct  interaction was  identified between DG1 and 
PDE11 on two separate regions of the PDE11 array, which both fell within the sequence of 
PDE11 represented by the Middle-HIS6 fragment. As such, this was used to probe the 
PDE11 array. A reciprocal putative interaction was identified on three regions of the DG1 
array,  representing  sequence  in  both  DG1N-HIS6  and  DG1C-HIS6  fragments. 
Unfortunately, although DG1-HIS6 was verified by western blotting at the analytical stage, 
attempts to affinity purify the protein failed. Time did not permit the probing of the array 
with DG1N-GST fusion protein, and so further putative interaction sites on PDE11 may 
remain. The generation of alanine substitution arrays, and subsequent mutagenesis analysis 
with yeast two hybrid or co-immunoprecipitation would be necessary to confirm this direct 4 
protein-protein interaction as bona-fide. The investigation into a putative direct interaction 
between PDE11 and DG2 did not yield conclusive data, and so further investigation is 
required.  
The role of DmPDE11 in immunity was investigated by the use of DmPDE11 RNAi and 
deletion lines. The DmPDE11 deletion line showed a qualitative reduction in survival in 
individual  survival  assays,  but  when  these  data  were  merged  a  significant  decrease  in 
survival compared to controls was seen. However, fly numbers did not permit the inclusion 
of  all  of  the  necessary  controls,  and  so  these  assays  should  be  repeated  with  these. 
However, upon immune challenge, progeny from a DmPDE11 RNAi (line 9) x Act5c (a 
ubiquitous  GAL4  driver  line)  cross  did  not  show  a  decrease  in  survival  compared  to 
parental lines. 
Transgenic  Drosophila  expressing  H.  sapiens  PDE11A3  were  generated.  The  protein 
localised  to  the  nucleus  at  low  levels  of  protein;  increased  expression  led  to  nuclear 
exclusion,  and  localisation  to  the  basolateral  and  especially  apical  membranes,  with 
cytosolic localisation also.  
The work has provided the tools needed to further research PDE11. The implication of this 
gene as a tumour suppressor gene, and its role in other processes, means that it is of the 
utmost importance that this enzyme is further characterised. 
 
 
 
 
 
 
 
 
 
 
 5 
Abbreviations 
AEQ      aequorin 
AKAP     A kinase anchoring protein 
APS      ammonium persulphate 
ATP      adenosine triphosphate 
BLAST    basic local alignment search tool 
bp      base pairs 
BSA      bovine serum albumin 
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[Ca
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g      gram 
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GFP      green fluorescent protein 
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GPCR     G-protein-coupled receptor 
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h      hours 
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IBMX     3-isobutyl-1-methylxanthine 
ICC      immunocytochemistry 
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IP3R      inositol 1,4,5-trisphosphate receptor 
IPTG      -D-thiogalactoside 
Kb      kilobases 
kDa      kiloDaltons 7 
lacZ      -galactosidase 
M      molar 
MBSU     Molecular Biology Support Unit 
mg      milligram 
min      minutes 
ml      millilitre 
mm      millimetre 
mM      millimolar 
Mn
2+      manganese 
mRNA     messenger RNA 
N-      amino- 
NO      nitric oxide  
NOS      nitric oxide synthase 
ng      nanograms 
nm      nanometre 
nM      nanomolar 
OD      optical density 
ORF      open reading frame 
PAGE     polyacrylamide gel electrophoresis 
PBS      phosphate buffered saline 
PBT      PBS, Triton X-100 
PCR      polymerase chain reaction 
PDE      phosphodiesterase 
PIP2      phosphatidylinositol 4,5-bisphosphate 
PKA      cyclic AMP-dependent protein kinase 
PKC      protein kinase C 
PLC      phospholipase C 
rGC      receptor guanylate cyclase 8 
RNA      ribonucleic acid 
RNAi      RNA interference 
RNAse     ribonuclease 
RT      room temperature 
RT-PCR    reverse transcriptase polymerase chain reaction 
s      second 
SDS      sodium dodecyl sulphate 
S.E.M.     standard error of the mean 
sGC      soluble guanylate cyclase 
TAP      tandem affinity purification 
TBS      tris buffered saline 
TE      tris-EDTA 
TEMED    N,N,N‟,N‟-tetramethylethylenediamine 
Tris      2-amino-2-(hydroxymethyl)-1,3-propanediol 
U      unit 
UAS      upstream activating sequence 
UTR      untranslated region 
UV      ultraviolet 
X-gal      5-bromo-4-chloro-3-indolyl- -D-galactopyranoside 
g      microgram 
l      microlitre 
M      micromolar 
C      degrees Celsius 
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One and three amino acid codes: 
 
A  Ala  Alanine 
C  Cys  Cysteine 
D  Asp  Aspartic acid 
E  Glu  Glutamic acid 
F  Phe  Phenylalanine 
G  Gly  Glycine 
H  His  Histidine 
I  Ile  Isoleucine 
K  Lys  Lysine 
L  Leu  Leucine 
M  Met  Methionine 
N  Asn  Asparagine 
P  Pro  Proline 
Q  Gln  Glutamine 
R  Arg  Arginine 
S  Ser  Serine 
T  Thr  Threonine 
V  Val  Valine 
W  Trp  Tryptophan 
Y  Tyr  Tyrosine 
*  Stop
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1.1 Summary of Cyclic Nucleotide Signalling 
The  cyclic  nucleotides  adenosine  3‟,5‟-cyclic  monophosphate  (cAMP)  and  guanosine 
3‟,5‟-cyclic monophosphate (cGMP) are second messengers that play important roles in 
virtually  all  cell  types  (Beavo  and  Brunton,  2002).  Since  the  purification  and 
characterisation of cAMP in 1957 as a second messenger for adrenaline (Rall et al., 1957; 
Sutherland and Rall, 1957; Wosilait and Sutherland, 1957), the enzymes responsible for 
the generation of cAMP, adenylate cyclase (Sutherland et al., 1962), and for the hydrolysis 
of cAMP to the inactive 5‟AMP, phosphodiesterase (PDE) (Butcher and Sutherland, 1962), 
were rapidly identified. Following this, however, it took more than a decade to identify the 
main downstream effector enzyme, cAMP-dependant protein kinase (PKA) (Walsh et al., 
1968b), and a further three decades to identify EPAC, or guanine nucleotide exchange 
factor directly activated by cAMP (de Rooij et al., 1998). cGMP was discovered in rat 
urine in 1963 (Ashman et al., 1963); it took until 1969 to identify guanylate cyclase and 
cGMP-PDEs (Hardman and Sutherland, 1969) cGMP dependent protein kinase (cGK) was 
discovered in 1970 (Kuo and Greengard, 1970). Any functional significance for cGMP 
besides regulation of cA-PDE activity (Beavo et al., 1971) was unknown until it was found 
to regulate light transduction (Miki et al., 1975). cGMP is typically present at a ten-fold 
lower physiological concentration than cAMP;  whereas PKA, the main cAMP effector 
enzyme, is  ubiquitous,  with  multiple identified targets,  cGK has  a more limited tissue 
expression profile, and, still, few identified  targets  (Hofmann  et  al.,  2006). Nucleotide 
gated channels for both cGMP (Fesenko et al., 1985) and cAMP (Nakamura and Gold, 
1987) were discovered later. Cyclic nucleotide signalling has since been shown to act as a 
second messenger for a great number of hormones and neurotransmitters. Mutations in 
cyclic nucleotide signalling genes have been shown to predispose to a number of diseases. 
The sheer number of genes involved – for example 21 vertebrate PDE genes – hints at a 
tightly  spatiotemporally  regulated  signalling  system,  with  multiple  inputs  and  specific 
downstream effects. Indeed, five Nobel prizes later, a great deal remains to be discovered. 
1.2 cAMP overview 
Upon binding of a hormone or neurotransmitter to their cognate G-protein coupled receptor 
(GPCR), a stimulatory G protein (Gs) stimulates adenylate cyclase, which produces cAMP 
from  ATP  (Sutherland,  1962).  At  elevated  concentrations,  cAMP  acts  as  a  second 
messenger,  effecting  downstream  signalling  via  the  stimulation  of  PKA  (Walsh  et  al., 
1968a),  CNG  channels  (Nakamura  and  Gold,  1987),  and  cAMP-activated  guanine 32 
nucleotide exchange factors (GEFs) (de Rooij et al., 1998; Kawasaki et al., 1998).  cAMP 
is hydrolysed to inactive 5‟AMP by cAMP-PDEs (Butcher and Sutherland, 1962) or is 
transported out of the cell by cyclic nucleotide transporters (Jedlitschky et al., 2000). A-
kinase  anchoring  proteins  (AKAPs)  serve  to  bind  PKA  in  an  isoform-specific  manner 
(Bregman  et  al.,  1989;  Bregman  et  al.,  1991;  Sarkar  et  al.,  1984),  and  place  these  at 
discrete  subcellular  localisations,  as  members  of  protein  complexes  incorporating  both 
substrates and PDEs to facilitate spatiotemporal control of cAMP signalling (Wong and 
Scott, 2004). cAMP signalling is summarised in figure 1.1. 
Figure  1.1:  The  cAMP  signalling  system.  Agonist  binding  to  a  Gʱs  coupled  GPCR 
activates adenylate cyclase, which generates cAMP from ATP. This then acts as a second 
messenger,  activating  the  downstream  effectors  PKA,  cAMP-gated  ion  channels,  and 
cAMP activated guanine nucleotide exchange factors. Intracellular cAMP concentration is 
reduced by hydrolysis by PDEs, and export from the cell by cyclic nucleotide transporters. 
AKAPs tether proteins to distinct subcellular locations. Abbreviations: GPCR = G-protein 
coupled  receptor;  GEF  =  Guanine  nucleotide  exchange  factor;  AKAP  =  A  kinase 
anchoring protein; PKA = cAMP dependent protein kinase. 
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1.3 cGMP overview 
cGMP is a second messenger for a number of primary messengers. cGMP is generated by 
guanylate cyclase from GTP. There are two types of guanylate cyclase. Receptor (also 
known  as  “transmembrane”  or  “particulate”)  guanylate  cyclase  (rGC)  is  stimulated 
following the binding of a primary, extracellular messenger to its extracellular binding 
domain  (Chinkers  et  al.,  1989)  (Schulz  et  al.,  1989).  Soluble  (cytoplasmic)  guanylate 
cyclase  is  stimulated  via  the  binding  of  a  primary  messenger,  but  via  an  indirect 
mechanism. A primary messenger binds to a cognate GPCR, resulting in the activation of a 
Gq  protein.  This  stimulates  phospholipase  C,  which  cleaves  phosphatidylinositol  4,5-
biphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-triphosphate (IP3). The 
increase in IP3 stimulates IP3 receptor (IP3R), resulting in the release of calcium (Ca
2+) 
from internal stores. This increase in intracellular Ca
2+ concentration in turn stimulates 
nitric  oxide  synthase  (NOS),  which  produces  nitric  oxide  (NO).  This  increase  in  NO 
stimulates soluble guanylate cyclase (sGC), which produces cGMP (Arnold et al., 1977). 
An atypical sGC has  also been shown to be stimulated by oxygen  (Gray et al., 2004; 
Morton,  2004).  cGMP  is  hydrolysed  to  inactive  5‟GMP  by  cGMP-PDEs  (Miki  et  al., 
1975), or is transported out of the cell by cyclic nucleotide transporters (Cropp et al., 2008; 
Dagger et al., 2001; Guo et al., 2003; Jedlitschky et al., 2000) . At elevated concentrations, 
cGMP stimulates cGK (Kuo and Greengard, 1970), CNG channels (Fesenko et al., 1985), 
and cAMP-PDEs (Beavo et al., 1971). cGMP signalling is summarised in figure 1.2. 
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Figure 1.2: The cGMP signalling system. cGMP is generated in response to a primary 
messenger,  which  either  binds  and  activates  rGC,  or  activates  sGC  via  an  indirect 
mechanism,  through  stimulation  of  a  GPCR-coupled  Gq  protein.  This  stimulates 
phospholipase C, which cleaves phosphatidylinositol 4,5-biphosphate (PIP2) into diacyl 
glycerol (DAG) and inositol 1,4,5-triphosphate (IP3). The increase in IP3 stimulates IP3 
receptor  (IP3R),  resulting  in  the  release  of  Ca
2+  from  internal  stores.  This  increase  in 
[Ca
2+]cyt in turn stimulates nitric oxide synthase (NOS), which produces nitric oxide (NO). 
This increase in NO stimulates sGC, which produces cGMP. This then acts as a second 
messenger,  activating  the  downstream  effectors  cGK  and  cGMP-gated  ion  channels. 
Intracellular cGMP concentration is reduced by hydrolysis by PDEs, and export from the 
cell.  GPCR  =  G-protein  coupled  receptor;  NOS  =  Nitric  oxide  synthase;  NO  =  Nitric 
oxide; sGC = Soluble guanylate cyclase; rGC = Receptor guanylate cyclase; cGK = Cyclic 
GMP-dependent protein kinase. 
 
 35 
1.4 Drosophila  melanogaster  as  a  genetic  model 
organism 
The use of Drosophila as a genetic model organism was pioneered by Thomas Morgan, 
who was awarded a Nobel prize for his discovery of the white mutation (Morgan, 1910), 
and subsequent work. The benefits of Drosophila are well known. These include a short 
generation  time,  low  cost,  complex  body  plan,  multiple  physical  and  behavioural 
phenotypes, and a high relevance to mammalian systems due to high levels of homology, 
from  gene  sequence  to  protein  function.  Where  Drosophila  excels,  however,  is  the 
availability of incredible genetic resources. The Drosophila genome has been sequenced, 
and the annotation is  constantly updated  (Adams  et  al.,  2000).  Balancer  chromosomes 
prevent  homologous  recombination,  and  are  lethal  when  homozygous;  as  they  carry 
dominant  genetic  markers,  stable  heterozygote  transgenic  flies  can  kept  as  stocks  for 
generations.    The  P-element,  a  mobile  genetic  element,  has  been  instrumental  in 
establishing  Drosophila  as  an  unrivalled  genetic  model  organism.  Initially  used  for 
mutagenesis, it was modified to allow enhancer trapping (O'Kane and Gehring, 1987), and 
later to generate transgenic flies under the control of yeast promoters and transcription 
factors, to deliver cell specific overexpression, or downregulation via RNAi, of a gene of 
choice, thus allowing the dissection of gene function at the level of cellular, tissue, and 
whole organism function (Figure 1.3) (Brand and Perrimon, 1993).  
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Figure 1.3: The GAL4/UAS binary system. A driver line carrying the yeast transcription 
factor GAL4 downstream of an endogenous promoter showing tissue specific expression 
of interest is used to drive expression of a transgene (“gene X”) under the control of a UAS 
(Upstream Activation Sequence) GAL4 responsive promoter, in a tissue specific manner. 
Adapted from (Dow and Davies, 2003b). 
               GAL4 driver line                                      GAL4 responsive transgenic 
                 
 
 
 
Genetic manipulation at the cellular level with the aim of understanding entire tissues has 
been termed integrative physiology (Dow and Davies, 2003b). The vast complexity and 
high levels of redundancy within mammalian cyclic nucleotide signalling networks leads 
to difficulties in the understanding of these pathways. Drosophila melanogaster has fewer 
signalling  components  in  a  typical  signalling  network,  yet  homologues  within  these 
pathways  frequently  perform  the  same  tasks.  With  reduced  redundancy  comes  clearer 
phenotypes; coupled with Drosophila genetics, e.g., cell-specific up- or down-regulation of 
a protein of interest, the elucidation of function is achievable where in mammalian systems 
it may not be. 
 
1.5 cGMP signalling in Drosophila 
cGMP signalling has been the focus of intense research for several decades. Individual 
components of the cGMP signalling pathway have mostly been identified by work in cell 
culture systems. Understanding of the role of cGMP signalling in physiology has been 
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advanced  through  the  use  of  two  main  model  organisms,  mouse  and  fruit  fly.  Mouse 
deletion and transgenic models have greatly extended understanding of cGMP signalling. 
NOS isoforms have been attributed roles through the use of NOS knockouts (Mashimo and 
Goyal, 1999) and transgenics (Mungrue et al., 2003), as have natriuretic peptide (ANP) 
receptors (transmembrane guanylate cyclases) (Lopez et al., 1997). The use of mouse cGK 
deletion models led to the identification of several cGK substrates (Hofmann et al., 2006). 
The many advantages of Drosophila, discussed above, have led to novel discoveries in 
cGMP signalling. cGMP has been shown to affect learning and memory in larval (Osborne 
et  al.,  1997)  and  adult  (Pereira  and  Sokolowski,  1993)  Drosophila.  cGMP  was 
subsequently shown to have a role in learning and memory in mammals (Kleppisch and 
Feil, 2009; Prickaerts et al., 2002). 
 
1.5.1 Dm NOS 
Nitric oxide synthase is a membrane bound enzyme that generates nitric oxide in response 
to a rise in cytosolic Ca
2+, which is generated in response to an extracellular hormone or 
neurotransmitter binding to a cognate Gq-coupled GPCR. Activation of the Gq protein 
leads  to  the  stimulation  of  phospholipase  C,  a  membrane  bound  enzyme  that  cleaves 
phosphatidylinositol 4,5-biphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-
triphosphate  (IP3).  The  increase  in  IP3  stimulates  IP3  receptor  (IP3R),  resulting  in  the 
release of Ca
2+ from internal stores, typically the endoplasmic reticulum. (Regulski et al., 
2004;  Regulski  and  Tully,  1995).  In  turn,  this  increase  in  NO  stimulates  sGC,  which 
produces cGMP (Arnold et al., 1977). Drosophila contains one NOS gene, dNOS, which 
has  10  transcripts  (NOS  RA-RJ),  encoding  6  novel  polypeptides 
(http://flybase.org/reports/FBgn0011676.html).  dNOS  shows  closest  homology  with 
vertebrate neuronal NOS (NOS1) (Davies, 2000; Regulski and Tully, 1995). Generation of 
a null allele leads to embryonic and larval lethality (Regulski et al., 2004). Overexpression 
affects behaviour, where flies demonstrate a reduction in motility (Broderick et al., 2003). 
NO has also been shown to modulate Malpighian tubule function. dNOS is expressed in 
principal cells, and increases fluid secretion in response to the neuropeptides capa-1 and 
capa-2 by the stimulation of cGMP production via sGC (Davies et al., 1997). NOS also has 
a role in immunity; activation leads to the production of immune peptides in the fat body 
(Foley  and  O'Farrell,  2003),  the  canonical  immune  tissue  of  the  fly,  and  also  in  the 
Malpighian tubule, a tissue also of great importance to fly immunity (Davies and Dow, 38 
2009; McGettigan et al., 2005). dNOS has been shown to play vital roles in imaginal disc 
development,  regulation of organ growth, negative regulation of DNA replication and cell 
proliferation  (Kuzin  et  al.,  1996),  synaptogenesis  and  nervous  system  development 
(Bicker, 2005), and the defence response (http://flybase.org/reports/FBgn0011676.html). 
Not all of these are necessarily modulated by the cGMP signalling pathway, but this array 
of processes clearly underlies the importance of cGMP signalling in Drosophila. 
 
1.5.2 Dm soluble guanylate cyclase 
Soluble (cytoplasmic) guanylate cyclase generates cGMP from GTP in response to NO 
(Arnold  et  al.,  1977).  Drosophila  sGC  exists  as  a  heterodimer,  composed  of  an  alpha 
(guanylate cyclase ʱ-subunit at 99B/ Gycʱ99B) and a beta (guanylate cyclase β-subunit at 
100B/Gycβ100B) subunit, which generates cGMP upon NO binding (Stone and Marletta, 
1996). A homodimer composed of two beta2 subunits was subsequently shown to bind NO 
and produce cGMP  (Koglin et  al.,  2001).  Gyc-88E, Gyc-89Da,  and Gyc-89Db encode 
atypical  guanylate  cyclase  subunits,  which  probably  form  Gyc-88E/89Da  and  Gyc-
88E/89Db  heterodimers  in  vivo  (Morton  et  al.,  2005).  Gyc-88E  also  forms  active 
homodimers. All atypical subunits were shown to generate cGMP under anoxic conditions 
(Morton, 2004), which suggests a potential role in feeding behaviour (Vermehren et al., 
2006).  Gyc-89Da and Gyc-89Db express in neurons responsible for adult eclosion and 
ecdysis respectively (Morton et al., 2008). Drosophila and mammalian sGCs are highly 
similar, showing similar structure and enzymatic properties (Shah and Hyde, 1995). A 
soluble  GC  hypomorph  displays  altered  photoreceptor  development,  which  can  be 
phenocopied by inhibiting dNOS (Gibbs et al., 2001). sGC and NOS have been shown to 
regulate  vesicle  release  at  the  larval  neuromuscular  junction  (Wildemann  and  Bicker, 
1999).  
1.5.3 Dm Receptor guanylate cyclase 
Receptor guanylate cyclase generates cGMP from GTP following the binding of a primary, 
extracellular messenger to its extracellular binding domain (Schulz et al., 1989). There are 
at least 7 receptor/receptor like guanylate cyclases encoded by the Drosophila genome 
(Davies, 2006). These are not well characterised, with no identified ligands. However, they 
share high sequence similarity with mammalian transmembrane guanylate cyclases. They 
have  been  linked  to  a  number  of  phenotypes  in  Drosophila.  Gyc32E  is  involved  in 39 
oogenisis  and egg chamber development (Malva et al., 1994). Gyc76C has been shown to 
mediate  semaphorin-1a  (Sema-1a)-plexin  A  repulsive  axon  guidance  of  motor  axons 
(Ayoob et al., 2004). A unique rGC was identified in Drosophila that is inhibited by O2, 
CO, and NO, and appears to function as an oxygen sensor (Huang et al., 2007). Flyatlas 
reveals that multiple rGCs are expressed in the Malpighian tubule (Chintapalli et al., 2007), 
and in situ hybridisation has localised expression to the main fluid secreting segment of the 
tubule (Guo, 2007), suggesting a role in fluid secretion. 
 
1.5.4 Dm Cyclic nucleotide gated channels 
Cyclic nucleotide gated channels are tetrameric proteins that bind cyclic nucleotides under 
conditions of increased intracellular cyclic nucleotide concentration, which facilitates the 
permeation of extracellular cations, and thus the depolarisation of the plasma membrane. 
There are at least four CNG channel genes in Drosophila (Littleton and Ganetzky, 2000). 
Cng is expressed in eye and antenna, and forms a cGMP sensitive homomeric channel 
(Baumann  et  al.,  1994). Cng-like  is  expressed  in  neuronal  cells  and  in  the  mushroom 
bodies, and is a homologue of the mammalian CNG channel beta subunit. It does not form 
functional monomeric channels (Miyazu et al., 2000). CG3536, and CG17922 both encode 
CNG channels although very little is known about them.  
cGMP has been shown to stimulate Ca
2+ influx into the tubule, which expresses cng, in a 
verapamil sensitive manner. As verapamil can be used as a CNG channel blocker, this 
suggests  that  cGMP  gated  ion  channels  modulate  fluid  secretion  via  Ca
2+  signalling 
(MacPherson et al., 2001). 
 
1.5.5 Cyclic nucleotide transport in Drosophila 
Drosophila has contributed to the understanding of cyclic nucleotide transport, and the 
Malpighian tubule has been the tissue of choice in this area of study. Cyclic nucleotides are 
transported across the Malpighian tubule (Riegel et al., 1998). PDE6 has been found to 
regulate  cGMP  transport  across  the  Malpighian  tubule  (Day  et  al.,  2006);  targeted 
overexpression  in  tubule  principal  cells  completely  ablates  the  process,  whereas 
knockdown  in  principal  cells  significantly  increases  transport.  This  is  the  first 
demonstration  of  a  direct  role  played  by  a  PDE  in  cyclic  nucleotide  efflux.  White,  a 40 
member of the ATP binding cassette G2 (ABC G2) transporter family, has classically been 
used  as  an  eye  colour  marker  in  Drosophila.  It  was  shown  to  participate  in  vesicular 
transepethilial transport of cGMP in the Malpighian tubule; the same study demonstrated 
that cyclic nucleotide transport is performed by the ABC G2 subfamily in Drosophila, and 
not the ABC C transporter subfamily as in mammals (Evans et al., 2008).  
 
1.5.6 Dm cGKs 
There are two Drosophila cGMP-dependent protein kinase genes; dg1, and dg2 (foraging 
or  for),  which  has  eleven  transcripts,  forRA  -  forRK.  DG2P1  and  DG2P2  are  the 
catalytically  active  isoforms  (MacPherson  et  al.,  2004b).  DG2  shares  64%  sequence 
identity with its nearest homologue in mammals, bovine lung cGK, with 75% sequence 
identity  to  the  catalytic  domain,  and  64%  to  the  cGMP  binding  domain.  cGK  is  a 
holoenzyme, which is active as a homodimer (Gamm et al., 1995), and is maintained in a 
catalytically inactive state by a pseudosubstrate-like regulatory region located in the N 
terminus of the enzyme. At an elevated concentration of cGMP, the regulatory region is 
displaced, and the enzyme becomes enzymatically active. DG1 is a dimer, (Foster et al., 
1996) whilst DG2 purifies as a dimer under gel filtration (MacPherson, 2004). Malpighian 
tubules express dg1, and the four main transcripts of dg2, P1-P4.  cGKs show differential 
localisation in the Malpighian tubule. DG1 is localised to the cytosol and to the basolateral 
membrane. DG2P1 is localised to the apical and basolateral membranes, whereas DG2P2 
is localised to the apical membrane. cGK activity is high in tubules, where the cGKs play 
distinct  roles  in  the  modulation  of  fluid  transport  in  the  Malpighian  tubule.  When 
overexpressed  in  tubule  principal  cells,  DG1  increased  fluid  secretion  in  response  to 
exogenous cGMP, which is transported into the tubule via cyclic nucleotide transporters 
(Riegel, 1998). DG2P2 overexpression, on the other hand, increased the fluid secretion 
response to capa-1 (MacPherson et al., 2004b). A naturally occurring polymorphism in dg2 
has been shown to determine the food search pattern employed by larval Drosophila (de 
Belle et al., 1989), where rovers (for
R) travel further to find food than the sitter (for
S) 
isoform (Pereira and Sokolowski, 1993). It was shown that as well as a 10% reduction in 
catalytic activity, the sitter isoform shows a slight reduction in transcript and protein levels 
(Osborne et al., 1997). The for
S and for
R isoforms were further characterised using the 
Malpighian tubule, where the polymorphism did not affect cGK activity, but rather the 
sitter  polymorphism  was  shown  to  slightly  increase  the  cGMP-PDE  activity  of  an 41 
unidentified PDE, with the result of lowering cGMP content (MacPherson et al., 2004a). 
As capa-1 neuropeptide increases fluid transport via cGMP, it follows that fluid transport 
of the Malpighian tubules from a forS background shows hypersensitivity to exogenously 
applied Capa-1 (MacPherson et al., 2004a) and cGMP (Dow and Davies, 2003b).  
 
1.5.7 Dm PDEs 
A cytogenic analysis of the Drosophila genome for regions that increase cAMP-PDE and 
cGMP-PDE activity when duplicated yielded four such regions; two of which, 3D3 / 3D4 
and 90E-91B, increased cAMP-PDE activity in fly extracts when duplicated; the other two, 
5D-9C  and  88C-91B,  increased  cGMP-PDE  activity  in  fly  extracts  when  duplicated  
(Kiger and Golanty, 1977). Biochemical analysis of Drosophila extracts showed cAMP 
specific/Form II, and dual specificity (cAMP and cGMP) specific/Form I PDE activity 
(Davis and Kiger, 1980). Dunce (dnc) was identified in a screen for mutants in learning 
(Dudai et al., 1976) , and was later characterised as having Form II (cAMP) PDE activity, 
and  mapped  to  3D4  (Byers  et  al.,  1981).  The  form  I  PDE  was  characterised  as  Ca
2+ 
dependent, whereas the form II PDE was shown to be unaffected by Ca
2+, which suggested 
that the neurological defects seen in dnc mutants were linked directly to defects in cAMP-
PDE  activity,  as  opposed  to  cAMP  mediated  Ca
2+  influx  in  presynaptic  transmission 
(Byers et al., 1981). Work on several dnc mutants showed aberrant cAMP metabolism 
(Davis and Kiger, 1981), and molecular analysis of the enzyme verified the dnc gene as 
encoding a cAMP-PDE (Chen et al., 1986). This lead to the identification of mammalian 
PDE4  in  rat  (Colicelli  et  al.,  1989;  Davis  et  al.,  1989;  Swinnen  et  al.,  1989)  and 
subsequently the human PDE4 family  (Conti et al., 2003).  Following the discovery of 
dunce, it took several years for the cloning and characterisation for the other Drosophila 
PDEs to occur. 
There are 11 mammalian PDE families encoded by 21 genes, which in total yields over 
100 novel proteins. These have been grouped into 11 families, to reflect a shared sequence 
similarity,  nucleotide  specificity,  regulatory  properties,  and  inhibitory  profile.  Such  a 
diverse array of proteins all responsible for degrading cyclic nucleotides allows for tight 
control and shaping of these signals, and contributes to the incredible specificity that these 
signalling events display (Beavo and Brunton, 2002). These all share a highly conserved 
catalytic domain, which contain a metal binding motif (HX21-23HX3D/E) (Charbonneau et 
al.,  1986),  the  identification  of  which  allowed  homologous  PDEase  domains  to  be 42 
identified,  and  the  corresponding  11  phosphodiesterase  gene  families  to  be  cloned. 
Mammalian PDE sequences were used to screen the Berkeley Drosophila Genome Project 
database  (http://flybase.net/)  for  Drosophila  PDE  orthologues.  Positive  hits  were  then 
screened  for  the  HX21-23HX3D/E  cyclic  nucleotide  motif.  This  analysis  revealed  that 
Drosophila  contains  orthologues  to  mammalian  PDE1  (CG14940),  PDE4  (CG32498), 
PDE6 (CG8279),  PDE8 (CG5411), PDE9 (CG32648) and PDE11 (CG10231) (Day et al., 
2005). These were also identified in a separate study (Morton and Hudson, 2002). Other 
than Dunce (Qiu, 1991), these PDEs were cloned and verified by Day et al, 2005. PDEs in 
Drosophila  show  widespread  expression  (Chintapalli  et  al.,  2007;  Day  et  al.,  2005), 
underlying their importance. 
 
1.6 Drosophila  PDEs  share  biochemical, 
pharmacological,  and  structural  characteristics  with 
their mammalian orthologues 
Analysis  of  Drosophila  PDEs  reveals  a  high  degree  of  homology  with  respect  to 
specificity, and the presence and arrangement of conserved domains (table 1.1). 
 
Table 1.1: Drosophila contains homologues to PDE1, 4, 6, 8, 9, and 11. Drosophila 
PDEs show a high degree of homology with respect to specificity, and the presence and 
arrangement of conserved domains. From (Day et al., 2005). 
Vertebrate PDEs Specificity Domains Drosophila PDEs Specificity Domains 
(predicted  PDE 1 Dual spec CaM binding PDE 1 Dual spec CaM binding
PDE 4 cA-PDE UCR Dunce cA-PDE -
PDE 6 cG-PDE GAF PDE 6 cG-PDE GAF
PDE 8 cA-PDE REC, PAS PDE 8 unknown REC, PAS
PDE 9 cG-PDE - PDE 9 unknown GAF
PDE 11 Dual spec GAF PDE 11 Dual spec GAF
 
When  compared  to  their  mammalian  homologues,  a  high  level  of  sequence 
similarity/identity was found in the catalytic domains (69 -96%), with generally over 50% 
similarity over the length of the protein (table 1.2). 
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Table  1.2:  A  comparison  of  Drosophila  and  mammalian  PDEs.  Drosophila  PDEs 
display high levels of homology with their mammalian homologues, especially within the 
catalytic domain. Adapted from (Day et al., 2005). 
Percentage amino acid identity (similarity)
Gene  Human homologue  Human homologue  Catalytic domain 
Predicted length 
of polypeptide 
(amino acids) 
CG14940  PDE1  40 (56)  63 (79)  1818
CG8279  PDE6  28 (46)  51 (69)  1131
CG32498 transcript A PDE4 59 (74) 79 (91) 701
CG32498 transcript B PDE4 59 (74) 79 (91) 1209
CG32498 transcript C PDE4 60 (76) 79 (91) 1057
CG32498 transcript D PDE4 59 (74) 79 (91) 1068
CG32498 transcript E PDE4 59 (74) 79 (91) 642
CG32498 transcript F PDE4 60 (76) 79 (91) 662
CG32498 transcript G PDE4 58 (73) 79 (91) 814
CG32498 transcript I PDE4 59 (74) 79 (91) 1070
CG32498 transcript J PDE4 59 (74) 79 (91) 1070
CG32498 transcript L PDE4 61 (76) 79 (91) 521
CG32498 transcript M PDE4 60 (74) 79 (91) 903
CG32498 transcript N PDE4 59 (74) 79 (91) 983
CG5411 transcript A  PDE8  34 (52)   60 (79) 914
CG5411 transcript B  PDE8  35 (53)  60 (79)   904
CG5411 transcript C   PDE8  47 (66)  60 (79)  400
CG5411 transcript D  PDE8  37 (57)  60 (79)   805
CG5411 transcript E   PDE8  34 (52)  60 (79)   914
CG5411 transcript F  PDE8  23 (9 [sic])  60 (79)   400
CG32648     PDE9 26 (34) 63 (76)  2080
CG10231     PDE11 38 (55) 77 (96)  1545
 
1.6.1 DmPDE1 (CG14940) 
CG14940 has an ORF of 1815 nucleotides (nt), which encodes a single polypeptide of 605 
amino  acids  (aa).  DmPDE1  has  been  shown  to  be  a  dual  specificity,  Ca
2+/calmodulin 
dependent  PDE  (Walter  and  Kiger,  1984).  Western  blotting  of  CG14940  transiently 
transfected  S2  cell  lysate  using  an  antipeptide  antibody  to  the  epitope 
EQAVKDAEARALAT confirmed that the gene produces a protein product of 75 kDa. 
Immunoprecipitation of PDE1 using this specific antisera from Drosophila head lysate, 
and subsequent PDE assays confirmed that DmPDE1 is a Ca
2+/calmodulin sensitive dual 
specificity PDE, with a Km for cAMP of 20.5 ﾱ 1.5 μM, and a Km for cGMP of 15.3 ± 1 
μM. DmPDE1 is inhibited by zaprinast at an IC50 of 71 ﾱ 39 μM and by sildenafil at an 
IC50 of 1.3 ﾱ 0.9 μM. Structurally, DmPDE1 is similar to its mammalian orthologue; it 
shares an autoinhibitory domain at the N terminus, although it has one calmodulin binding 
domain, whereas mammalian PDE1 has two (figure 1.4).  
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Figure  1.4:  Protein  structure  of  DmPDE1.  DmPDE1  contains  an  N-terminal 
autoinhibitory motif, and a calmodulin binding site at the N terminus. From (Day et al., 
2005). 
 
 
 
1.6.2 Dunce (CG32498) 
The PDE best understood in Drosophila is dunce (dnc), the mammalian PDE4 orthologue, 
a  cAMP-PDE  which  was  discovered  independently  in  screens  for  mutations  affecting 
olfactory learning and female fecundity (Byers et al., 1981). Dnc expresses predominantly 
in the neuropil of the mushroom bodies (Nighorn et al., 1991), and at lower levels in the 
neuropil of the nervous system, which is in agreement with its role in learning (Dauwalder 
and Davis, 1995). Since the identification of dnc involvement in olfactory learning, cAMP 
and cGMP have both been shown to have a role in learning and memory in mammals 
(Kleppisch  and  Feil,  2009).    Dnc  has  been  shown  to  play  important  roles  in  several 
additional  processes.  Dnc  mutants  have  altered  pacemaker  functioning  (Levine  et  al., 
1994). Analysis of the larval neuromuscular junction in dnc mutants revealed a role in the 
plasticity of synaptic morphology (Zhong et al., 1992) and modulation of synaptic kinetics 
(Corfas and Dudai, 1990; Zhong and Wu, 1991). Dnc is involved in egg chamber and 
ovary development, and some dunce mutants are infertile (Lannutti and Schneider, 2001). 
Interestingly, dnc mutant learning, fertility and synaptic morphology phenotypes can be 
partially rescued by introduction of rutabaga1, an adenylate cyclase hypomorphic mutant, 
and indeed these mutations were identified in a screen for mutations that rescue the dnc 
mutant sterility phenotype (Feany, 1990; Zhong et al., 1992). Dnc has been biochemically 
characterised, with a Km of 2.2 ﾱ 0.5 μM for cAMP (Davis et al., 1989), and is partially 
inhibited by SQ20009 at 140 mM, although the IC50 for the compound is unknown. Dnc 
encodes  12  transcripts,  resulting  in  12  unique  polypeptides  (Qiu  et  al.,  1991), 
(http://flybase.org/reports/FBgn0000479.html)  
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1.6.3 DmPDE6 (CG8279) 
CG8279 has an ORF of 3393 nt, which encodes a single polypeptide of 1131 aa. Western 
blotting of CG8279 transiently transfected S2 cell lysate using an antipeptide antibody to 
the epitope HGSEDSHTPEHQRS confirmed that the gene produces a protein product of 
130 kDa. Immunoprecipitation of DmPDE6 using this specific antisera, and subsequent 
PDE assays confirmed that DmPDE6 is a high Km cG-PDE, with a Km for cGMP of 37 ± 
13 μM. PDE6 shows high sensitivity to both zaprinast and sildenafil, as it is inhibited by 
zaprinast at an IC50 of 0.65 ﾱ 0.15 μM and by sildenafil at an IC50 of 0.025 ﾱ 0.005 μM 
(Day et al., 2005). Interestingly, although CG8279 has been designated as a vertebrate 
PDE6 homologue, it shares functional and structural characteristics with vertebrate PDE5 
and  PDE6,  and  also  has  high  sequence  similarity  to  PDE11  in  the  catalytic  domain, 
although this is a dual specificity PDE. In common with mammalian PDE6, Drosophila 
PDE6 is prenylated via a CAAX-box prenylation motif, resulting in the recruitment of the 
protein to the plasma membrane, where it interacts with a prenyl binding protein (Day et 
al., 2008). As such, it was designated a PDE6 orthologue, although it is commonly referred 
to as a PDE5/6 homologue. DmPDE6 has been implicated in the active transport of cGMP, 
as discussed above (Day et al., 2006). DmPDE6 contains an N-terminal autoinhibitory 
motif,  a  consensus  PKA/cGK  phosphorylation  site  at  each  end  of  the  protein,  and  a 
calmodulin binding site at the N terminus (figure 1.5). 
 
Figure 1.5: Protein structure of DmPDE6. DmPDE6 contains a serine rich region at the 
N terminus, and a polybasic region at the C terminus, both of unknown function. There are 
consensus  PKA/cGK  phosphorylation  sites  at  the  N-  and  C-termini,  and  twin  GAF 
domains N-terminal of the catalytic domain. The protein has a CAAX-box prenylation 
motif at the C terminus. From (Day et al., 2005). 
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1.6.4 DmPDE8 (CG5411) 
CG5411 is a complex gene, with 5 transcripts (A-E) encoding 4 different polypeptides, 
where  the  ORFs  of  transcripts  A  and  E  are  identical.  DmPDE8  has  not  been  well 
characterised, although analysis of the sequence reveals that, in common with mammalian 
PDE8, DmPDE8 contains a REC and a PAS domain to the N terminal of the catalytic 
domain, and an N-terminal myristoylation/palmitoylation motif (figure 1.6) (Day et al., 
2005). 
 
Figure 1.6: Protein structure of DmPDE8. DmPDE8 contains REC and PAS domains N-
terminal of the catalytic domain, and a myristoylation/palmitoylation motif at the extreme 
N-terminus. From (Day et al., 2005).  
 
 
1.6.5 DmPDE9 (CG32648) 
PDE9 has not been well characterised, although the gene encoding DmPDE9 resides within 
an area identified by Kiger and Golanty that resulted in increased cGMP-PDE activity 
when  duplicated  (Kiger  et  al.,  1981).  No  ESTs  are  available;  while  the  predicted 
polypeptide for this gene is 963 aa in length, the gene was designated a homologue of 
mammalian PDE9 based upon homology of 54% within the catalytic domain; outwith this 
region there is little homology (figure 1.7) (Day et al., 2005). As such, future research into 
this gene will require validation of the Flybase prediction of the gene structure. 
 
Figure 1.7: Protein structure of DmPDE9. DmPDE9 contains two consensus PKA/cGK 
phosphorylation sites C-terminal of the catalytic domain. From (Day et al., 2005). 
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1.6.6 DmPDE11 (CG10231) 
CG10231  encodes  a  single  ~5.8  kb  transcript  (DmPDE11  RA)  which  encodes  a 
polypeptide  of  1366  aa.  A  full  length  EST  clone  was  sequenced  in  order  to  verify 
CG10231, and northern blotting confirmed that CG10231 produced a single transcript of 
~5.8  kb.  Western  blotting  of  CG10231  transiently  transfected  S2  cell  lysate  using  an 
antipeptide  antibody  to  the  epitope  PTSTQPSDDDNDAD  confirmed  that  the  gene 
produces a protein product of 100 kDa. Immunoprecipitation of PDE11 using this specific 
antisera  from  Drosophila  head  lysate,  and  subsequent  PDE  assays  confirmed  that 
DmPDE11 is a dual specificity PDE, with a Km for cAMP of 18.5 ﾱ 1.5 μM, and a Km for 
cGMP of 6 ﾱ 2 μM. DmPDE11 shares high sequence identity/similarity with mammalian 
PDE5, PDE6β, and PDE11A. However, the protein has highest sequence identity within 
the catalytic domain to PDE11A (77%), and has twin GAF domains N-terminal of the 
catalytic  domain,  a  characteristic  shared  with  the  HsPDE11A  isoforms  PDE11A3  and 
PDE11A4  (http://www.biochemj.org/bj/388/bj3880333add.htm).  As  the  enzyme  was 
shown to be a dual specificity PDE, DmPDE11 was designated as a PDE11A3/PDE11A4 
orthologue. Interestingly, the Km for cGMP indicates that PDE11 has the highest affinity 
for cGMP of any of the DmPDEs screened. PDE11 is inhibited by zaprinast at an IC50 of 
1.6 ﾱ 0.5 μM and by sildenafil at an IC50 of 0.12 ﾱ 0.06 μM. DmPDE11 has four PKA/cGK 
consensus  phosphorylation  motifs  (http://www.biochemj.org/bj/388/bj3880333addhtm), 
suggesting that it may be a substrate of the enzyme. The enzyme contains glutamine and 
histidine rich regions at the N- and C-termini respectively of unknown significance (figure 
1.8) (Day et al., 2005). 
 
Figure  1.8:  Protein  structure  of  DmPDE11.  DmPDE11  contains  glutamine-  and 
histidine-rich regions of unknown function at the N- and C-termini respectively, and has 
twin GAF domains to the N terminus of the catalytic domain. From (Day et al., 2005). 
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1.7 H. sapiens PDE11A  
The PDE11 family of phosphodiesterases were first characterised in 2000 (Fawcett et al., 
2000; Hetman et al., 2000; Yuasa et al., 2000a). HsPDE11A is a dual specificity cAMP- 
and cGMP-PDE, with four splice variants from a single gene, each containing progressive 
truncations  of  the  N  terminus,  with  a  shared  C  terminus  containing  a  PDE  catalytic 
domain; in the case of HsPDE11A3, the first two exons encode novel N terminal sequence 
of unknown significance. The N terminus of the longest isoform – HsPDE11A4 – has two 
PKA/cGK  phosphorylation  sites  which  reduce  the  EC50  for  cGMP  ~3  fold  when 
phosphorylated (Gross-Langenhoff et al., 2008). The progressively truncated isoforms are 
progressively more sensitive to the inhibitors verdenafil and tadalafil and have a higher 
affinity for substrate. The GAF-A domain has been shown to bind cGMP, but at an EC50 
outside the physiological range (Gross-Langenhoff et al., 2006). Binding of cGMP to the 
GAF-A domain does not stimulate catalytic activity (Matthiesen and Nielsen, 2009). The 
GAF-B domain  is  necessary for oligomerisation;  HsPDE11A1 forms  a  tetramer, while 
HsPDE11A2-4 form dimers (Weeks et al., 2007). The structure of each HsPDE11A is 
summarised in figure 1.9. 
Figure 1.9: Protein structure of HsPDE11A. HsPDE11A isoforms 1-4 share a conserved 
C  terminus  containing  the  catalytic  domain,  and  N  termini  of  varying  lengths,  which 
contain complete or partial GAF domain(s). Modified from (Weeks et al., 2007). 
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Tissue staining utilising a polyclonal antibody which recognises all four human isoforms 
showed expression in epithelial cells, endothelial cells, and smooth muscle cells of every 
tissue screened. The protein localises to the nucleus. The highest expression was found in 
the prostate, testis, kidney, colon, and the epidermis in the skin (D'Andrea et al., 2005). 
Few physiological roles for PDE11A have been identified. PDE11A3 is reported to be 
confined to testis in both rat and human (Yuasa et al., 2001). PDE11A has been shown to 
regulate  spermatozoa  physiology.  Knockout  of  PDE11A  renders  male  mice  infertile 
(Seftel,  2005a;  Seftel,  2005b).  It  has  been  linked  to  erectile  function  and  premature 
ejaculation.  Mutations  to  HsPDE11A  are  frequent  among  patients  with  adrenocortical 
tumours  (Horvath  et  al.,  2006)  and  may  predispose  to  testicular  germ  cell  tumours 
(Horvath et al., 2009). Polymorphisms in HsPDE11A are associated with the diagnosis of 
major depressive disorder (Wong et al., 2006). Taken together, there is a potential role for 
the PDE11A family in the central nervous system.  
 
1.8 The characteristics of PDEs 
1.8.1 Structure of the catalytic domain 
All PDEs share a highly related catalytic domain, which consists of 16 alpha helices that 
form a cleft in which cyclic nucleotides are bound and cleaved. The core contains two 
metal ions, essential for function, which are tightly co-ordinated; a Zn
2+ is bound by an 
aspartate and a histidine, and a Mg 
2+ is held by multiple water molecules.  
1.8.2 Nucleotide specificity 
Specificity to one or both cyclic nucleotides is dictated by an invariant glutamine that is 
proposed to form multiple hydrogen bonds with the purine ring of the cyclic nucleotide; it 
is the orientation of this glutamine that determines PDE specificity. Where this glutamine 
is free to rotate, it will bind both cAMP and cGMP; when it is hindered by its neighbouring 
residues it is able to bind either cGMP or cAMP (Zhang et al., 2004). 
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Figure 1.10: The glutamine switch. Crystal structure of PDE1B (red/C and D), PDE4D 
(blue/A), and PDE5A (green/B). Whereas the conserved glutamine, Q421, of PDE1B is 
unhindered,  and  thus  the  residue  is  free  to  rotate  and  thus  the  catalytic  domain  can 
accommodate both cAMP (C) and cGMP (D), the glutamine of PDE5A (B) and PDE4D 
(A) in both cases is bound in place by hydrogen bonds, and thus the glutamine is unable to 
rotate, resulting in cyclic nucleotide specificity (Zhang et al., 2004). 
 
 
1.8.3 Regulation of PDEs 
PDEs  are  subjected  to  multiple  levels  of  regulation.  Each  phosphodiesterase  family 
contains  differing  regulatory  domains  that  contribute  to  the  unique  properties  of  each 
family (Beavo et al., 2007). To modulate rapid increases in cyclic nucleotide concentration, 
the catalytic activity of PDEs can be rapidly increased or decreased several fold (Conti and 
Beavo,  2007).  To  facilitate  the  localised  nature  of  cyclic  nucleotide  signalling,  post 
translational modifications or association with anchoring proteins may redirect the enzyme, 
for example to the cell membrane (Beavo and Brunton, 2002).  
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1.8.4 Cyclic nucleotide binding 
GAF domains have been identified within a range of different proteins, initially cGMP-
regulated PDEs, Adenylate cyclase, and the Fh1A protein, hence the acronym (Ho et al., 
2000). It is a non-catalytic cyclic nucleotide binding domain, which in PDEs can modulate 
catalytic activity allosterically (Charbonneau et al., 1990). Studies of mammalian PDEs 
have shown that one or both  GAF domains  of PDE2, PDE5, PDE6, and PDE11 bind 
cGMP, and that of PDE10 binds cAMP. This can result in activation of catalytic activity, 
in the case of PDE2 (Martins et al., 1982) and PDE5 (Thomas et al., 1990) (Rybalkin et al., 
2003). In PDE6, it has been shown to aid binding of the inhibitory γ subunit to the catalytic 
domain (Norton et al., 2000). In the case of PDE10 and PDE11, binding does not (directly 
at least) affect catalytic activity (Matthiesen and Nielsen, 2009). The binding of cGMP to 
the GAF domain has also been shown to modulate dimerisation in PDE2 (Martinez et al., 
2002) and PDE6 (Muradov et al., 2003). Interestingly, the four isoforms of PDE11 contain 
four different start sites that represent a progressive truncation of the N terminus; only 
PDE11A4  contains  two  complete  GAF  domains,  with  A3,  A2,  and  A1  each  having 
progressively truncated GAF domains .  
 
1.8.5 Post translational modifications of PDEs 
1.8.5.1  Modulation of PDE activity by other proteins 
The behaviour of phosphodiesterases can be modified through phosphorylation by cyclic 
nucleotide dependent kinases, and other kinases. As detailed above, DG2 has been shown 
to modulate an unidentified cG-PDE in Malpighian tubule (MacPherson et al., 2004a). 
PDE1 is stimulated by Ca/Calmodulin by up to 8 fold in mammals (Cheung, 1970) which 
binds sites either side of the inhibitory domains of the N terminus, likely relieving the 
inhibitory action of this domain (Sonnenburg et al., 1995). Calmodulin stimulates PDE1 
almost 2-fold in Drosophila (Day et al., 2005).  In mammalian systems, PDE3 has been 
shown to be phosphorylated by PKA (Manganiello et al., 1995), which rapidly increases 
catalytic activity.  
The  long  forms  of  PDE4  are  also  known  to  be  rapidly  stimulated  by  PKA  via 
phosphorylation  of  a  crucial  serine  residue  in  the  N-terminal  regulatory  domain 
(MacKenzie  et  al.,  2002),  acting  as  a  feedback  mechanism  to  terminate  hormonal 52 
stimulation. ERK2, a MAP kinase, phosphorylates PDE4B, C and D subfamilies in the 
catalytic domain, where long-form isoforms are inhibited, whereas short-form isoforms are 
stimulated (Baillie et al., 2000). cGK phosphorylates PDE5 when the GAF domains have 
bound cGMP (Thomas et al., 1990; Turko et al., 1998), to increase activity by 50-70%, and 
also increase the cGMP binding capacity of the GAF domain (Corbin et al., 2000). Isoform 
multiplicity, with the resultant sequence changes and changes to the protein‟s interactome 
that brings, may mask or remove putative phosphorylation sites, thus altering the function 
of these proteins.  
1.8.5.2  Addition of lipids  
Lipid kinases play intrinsic roles in many facets of cell signalling, trafficking proteins to 
the cell membrane, possibly resulting in their activation, and association  with membrane 
based proteins or substrates and thus modifying their function (Heath et al., 2003). The 
catalytic subunits of PDE6 are subjected to differential prenylation at the C terminal; PDEʱ 
is  modified  by  farnesylation,  and  PDEβ  by  geranylgeranytion  (Anant  et  al.,  1992),  to 
ensure targeting to rod outer segment membrane (Qin and Baehr, 1994). The differential 
prenylation also controls binding of the inhibitory γ subunit (Cook et al., 2000). PDE8 has 
an  N-terminal  myristoylation  motif,  and  PDE9  has  an  N  terminal 
myristoylation/palmitoylation  motif,  although  neither  has  been  shown  to  occur  in  vivo 
within the published literature. 
1.9 The  use  of  Drosophila  to  investigate  vertebrate 
phosphodiesterase function 
Previously, Drosophila has been used to transgenically express vertebrate PDE genes, and 
these have proved functional in vivo. Bovine PDE5 has been overexpressed in the tubule, 
resulting in an increase in cGMP-PDE activity and conservation of the pharmacological 
characteristics of PDE5 (Broderick et al., 2004).  The transgene could participate in and 
modulate osmoregulation, which was  inhibited by sildenafil  at  substrate concentrations 
which would affect the enzyme in mammalian systems. The enzyme localised to the apical 
membrane,  the  site  of  fluid  transport.  Such  physiologically  relevant  targeting  suggests 
interaction with relevant signalling proteins (Broderick et al., 2004). In another example, 
Rat PDE4A1 increases cAMP-PDE activity in the fly when transgenically over-expressed, 
and can rescue cAMP-PDE levels to normal levels and beyond when expressed in a dunce 53 
mutant  background that displays  46% dnc cAMP-PDE activity. Furthermore, when rat 
PDE4A1 is expressed in this mutant background, it rescues a learning phenotype resulting 
from  the  knockdown  of  dunce  activity  (Dauwalder  and  Davis,  1995).  Such  functional 
conservation  suggests  that  Drosophila  and  vertebrate  genes  originated  from  common 
ancestral genes, and as such a high degree of functional complementation still exists. That 
Drosophila  and  vertebrate  PDE  genes  share  functional  and  structural  homology,  yet 
display key differences, may allow the side by side study of PDE genes, to shed light on 
the function of PDEs in both areas. As such, it was decided to clone the closest orthologue 
to DmPDE11, HsPDE11A3, and to express this in fly, to allow the investigation of human 
PDE11A function in an in vivo context. The results of this investigation are presented in 
chapter eight. 
 
1.10 Compartmentalisation in cyclic nucleotide signalling  
A cell can transduce multiple extracellular cues simultaneously, using cAMP and cGMP as 
second  messengers,  with  specific  activation  of  target  effector  proteins,  and  resulting 
downstream  actions.  To  maintain  specificity,  cyclic  nucleotide  concentration  must  be 
tightly regulated spatiotemporally. As well as the localisation of the cyclase, gene and 
isoform multiplicity of phosphodiesterases, and AKAPs, which modulate PDE localisation, 
allow the placement of PDEs with distinct subcellular localisation, which act as a “sink” to 
generate  multiple,  simultaneous  intracellular  domains  (“pools”)  of  elevated  cyclic 
nucleotide concentration (Baillie, 2009). The signal transduced within these pools depends 
upon the effector proteins within it, and the substrates that they are directed to. 
 
1.10.1  cAMP compartmentalised signalling 
 The idea the cAMP signalling may be compartmentalised was postulated as early as 1980 
(Brunton et  al.,  1981;  Hayes  et  al.,  1980), following the discovery that  within cardiac 
myocytes,  stimulation  of  different  adenylate-stimulatory  GPCRs  lead  to  differing 
physiological outputs. Advances in cAMP reporters revealed that microdomains of cAMP 
exist,  which  have  distinct  subcellular  localisation,  and  show  differing  changes  to  the 
magnitude  and  duration  of  cAMP  concentration,  depending  upon  the  upstream  signal 
(Zaccolo and Pozzan, 2002). It was proposed that PKA is compartmentalised within these 54 
distinct  subcellular  microdomains,  thus  allowing  the  phosphorylation  of  distinct  PKA 
substrates, and so convey a specific signal depending upon the upstream GPCR activated 
(Hayes and Brunton, 1982). It was subsequently shown that PKA type I and type II are 
differentially  tethered  by  A-Kinase  Anchoring  Proteins  (AKAPs)  (Di  Benedetto  et  al., 
2008). Indeed, the formation of AKAP-tethered complexes has been shown to mediate 
compartmentalisation at every level of cAMP signalling. Gene and isoform multiplicity of 
PDEs, cyclases, downstream effector proteins, and AKAPs, and the various associations 
between these, allow the formation of cAMP microdomains. Particular combinations of 
GPCRs,  Gs  proteins,  and  adenylate  cyclases  occupy  distinct  membrane  localisations 
(Rybin  et  al.,  2000).  This  allows  feedback  whereby  PKA  can  phosphorylate  AC  to 
terminate the cAMP signal (Bauman et al., 2006), ensuring rapid transmission of signal, 
while ensuring spatiotemporal control over the cAMP signal. The formation of adenylate 
cyclase-AKAP-PKA complexes allows the tying of PKA-substrate association by AKAPs 
to the site of cAMP generation. AC activity may be modulated by serine/threonine kinases 
and Ca
2+, in addition to Gs. Combined with the subcellular targeting and association with 
AKAPs, this level of control ensures that microdomains may be modulated by multiple 
signals  and  proteins  (Willoughby  and  Cooper,  2007).  The  formation  of  PKA/PDE 
signalling complexes allows crosstalk, where the PDE regulates local cAMP concentration, 
and thus PKA activity, while the kinase can modulate PDE function by phosphorylation, 
thus facilitating feedback. An AKAP18ʴ-PDE4D3/9-PKA signalling complex localised to 
vesicles has been shown to regulate water permeability in human renal principle cells. The 
water  channel  aquaporin  2  (AQP2)  is  recycled  from  the  membrane  in  these  vesicles. 
Arginine vasopressin (AVP) activates PKA, which stimulates the trafficking of vesicles 
containing AQP2 to the plasma membrane; thus water permeability is directly modulated 
by PKA activity. PKA then activates PDE4D, thus reducing local cAMP concentration 
inhibiting PKA activity, and stimulating the endocytosis of the AQP2 bearing vesicles 
(figure 1.11) (McSorley et al., 2006). 
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Figure 1.11: AQP2, PDE4D and PKA form an AKAP18δ mediated complex.  AQP2, 
PDE4D,  and  PKA  are  tethered  to  intracellular  vesicles  by  AKAP18ʴ,  where  PKA 
stimulates  trafficking  of  the  AQP2  bearing  vesicle  to  the  membrane;  when  at  the 
membrane PKA phosphorylates PDE4D3/9, thus reducing localised cAMP and initiating 
vesicle endocytosis. From (Stefan et al., 2007).  
 
 
 
1.10.2  cGMP compartmentalised signalling  
Like cAMP signalling, a cell may receive different signals that initiate a cGMP signalling 
event, such as a natriuretic peptide or nitric oxide, which result in distinct and perhaps 
simultaneous cellular responses. There is a great deal of evidence to suggest that cGMP 
microdomains facilitate the faithful transmission of these signals, and that this is facilitated 
by  compartmentalisation  of  cGMP  signalling  at  every  level.  cGK  is  recruited  to  the 
membrane upon binding of atrial natriuretic peptide, and directly interacts with NPRA, a 
type 1 ANP receptor/rGC. cGK phosphorylates the receptor, increasing the potency of the 
response  to  ANP  (Airhart  et  al.,  2003).  Although  both  soluble  and  receptor  guanylate 
cyclases  exist,  the  terms  are  misleading,  in  that  activated  sGC  translocates  to  the 
membrane  in  a  Ca
2+  concentration-dependent  manner,  where  it  is  sensitised  to  NO 
stimulation (Zabel et al, 2002). NO has a very short half life, and NO is 9 times less 
soluble in water than in hydrophobic environments, suggesting that NO would be present 
in the cell in a concentration gradient highest at the membrane, and reduced in the cytosol. 
Thus, the modulation of sGC localisation by Ca
2+ to bring sGC into close proximity of 
NOS, a membrane bound enzyme, points to a tight spatial control of cGMP signalling. The 
localisation of NOS itself is tightly regulated. Endothelial NOS (eNOS) is doubly acylated, 56 
which  mediates  interactions  with  distinct  caveolin  isoforms  in  various  cell  types,  thus 
dictating the localisation and activity of eNOS, and therefore the site of release of NO. 
These signal transducing microdomains are termed caveolae  (Feron et al., 1998).  In a 
landmark paper using a exogenously expressed CNG channel as a biosensor, by measuring 
cGMP-induced uptake of Ca
2+ and Mn
2+ in HEK cells overexpressing rGC, it was found 
that  the  “pool”  of  cGMP  generated  by  rGC  has  stimulatory  effects  at  the  membrane, 
whereas cGMP generated by sGC is not accessible to membrane-localised cGMP sensing 
proteins (Castro et al., 2006). A similar finding was made in vascular smooth muscle cells; 
while stimulation of sGC led to higher cellular cGMP than stimulation of rGC, it was 
stimulation of rGC that resulted in the stronger CNG channel activation (Piggott et al., 
2006). PDE1C and PDE5 show differing subcellular localisation across multiple cell types, 
and thus sample and modulate distinct pools of cGMP (Dolci et al., 2006).  Inhibition of 
PDE2 and PDE5 has differential effects on cGMP produced by soluble and receptor GCs; 
PDE2 is responsible for modulating cGMP produced by rGC at the membrane, whereas 
PDE5  modulates  cGMP  generated  in  the  cytosol  by  sGC,  and  furthermore  acts  as  a 
physical barrier to prevent this pool from diffusing to the cell membrane (Castro et al., 
2006). Signalling complexes have been identified in cGMP signalling, similar to those 
formed in  cAMP signalling, which facilitate the tight  spatiotemporal  control  of cGMP 
signalling events. Transmembrane conductance in enterocytes is induced by the activation 
of cystic fibrosis transmembrane conductance regulator (CFTR) Cl
- channels. Although 
both cGK type I and II can phosphorylate CFTR in vitro, only cGK type II can induce 
transmembrane  conductance  in  vivo,  due  to  its  localisation  at  the  apical  membrane 
(Vaandrager et al., 1998). In smooth muscle cells, cGK type I forms a dimer with vimentin, 
with the association occurring outside of the catalytic domain at the N-terminus; this dimer 
then targets histone F2b, and other target peptides (MacMillan-Crow and Lincoln, 1994). 
cGMP-dependent protein kinase anchoring proteins (GKAPs) have been identified, which 
bind cGKs in the regulatory domain of the N terminus. GKAP42 serves to localise cGKIʱ 
to the Golgi apparatus of male germ cells. cGK phosphorylates GKAP42, where activation 
of cGKIʱ terminates the interaction (Yuasa et al., 2000b). GKAPs which bind cGK type II 
have been identified in multiple tissues (Vo et al., 1998). One such GKAP, myosin heavy 
chain, may facilitate cGK type II mediated smooth muscle relaxation (Lincoln et al., 1994), 
which  is  still  not  well  understood.  In  platelets,  a  PDE5-cGK1β  signalling  complex  is 
recruited  to  inositol  1,4,5  triphosphate  receptor  type  1  (IP3R1)  enriched  membranes. 
cGK1β  mediates  a  reduction  in  Ca
2+  release  from  the  endoplasmic  reticulum  by 
phosphorylating IP3R1 (Schlossmann et al., 2000). cGK phosphorylates PDE5 at the ER, 57 
causing a localised reduction in cGMP, and a subsequent inhibition of cGK activity, yet 
PKA does not affect PDE5 function in the cytosol (Wilson et al., 2008). Taken together, 
these data suggest that cGMP microdomains play a vital role in shaping signal specificity 
and the spatiotemporal nature of cGMP signalling events. 
Understanding  of  cGMP  signalling  has  been  advanced  by  genetically  encoded  cGMP 
reporters.  The  first  generation  of  FRET  based  cGMP  reporters  were  generated  by 
sandwiching PKG1ʱ, rendered catalytically null, with the dimerisation domains removed, 
with differing emission-shifted green fluorescent protein at either terminus, called CGY 
(Sato et al., 2000) and cygnet-2 (Honda et al., 2001). Cygent-2 was used to investigate 
cGMP signalling in vascular smooth muscle, where natriuretic peptides induce muscular 
relaxation  via  an  NO-cGMP  signalling  cascade.  Cygnet-2  permitted  the  temporal 
characterisation  of  this  cGMP  response;  it  was  shown  that  stimulation  with  NO, 
irrespective of the rate or duration of the NO release, resulted in rapid, transient cGMP 
“peaks”, and that the kinetics  of this  cGMP response are  controlled by the  actions  of 
soluble guanylate cyclase and PDE 5, which are not desensitised during the process, thus 
facilitating continuous response to NO (Cawley et al., 2007). Such a study was previously 
not feasible. This finding was advanced by the use of a novel, non-FRET based cGMP-
indicator, where cGMP-binding domains of cGKIʱ and β were fused to a single GFP, 
named FlincGs. They found a similar, global elevation of cGMP upon application of NO to 
vascular smooth muscle. However, upon the application of natriuretic peptide, elevation of 
cGMP was limited to the sub-membrane, where inhibition of PDE5 saw global elevations 
(Nausch et al., 2008). 
Many such advances in these sensors have been achieved, including the development of 
membrane permeable cynet-2 (Honda et al., 2005), which avoids the issues associated with 
maintaining  cells  in  culture  while  transfecting  the  reporter,  and  the  development  of 
reporters with higher specificity and more rapid responsiveness, where rather than fuse 
whole proteins or truncates with fluorescent proteins, single cGMP-binding domains were 
sandwiched  by  CFP  and  YFP;  constructs  using  cGMP  binding  domains  from  various 
proteins were generated, that of PDE5 was selected based on its selectivity of cGMP over 
cAMP, and its rapid responsiveness, and named cGES-DE5 (Nikolaev et al., 2006). Such 
systematic development of sensors is producing tools of increased quality (Russwurm et 
al., 2007), and will permit a fuller understanding of the tight spatiotemporal control cGMP 
signalling is evidently subjected to. 
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1.10.3  Cyclic nucleotide cross talk 
cAMP and  cGMP cross talk has  been shown to widely occur in  mammalian systems; 
further development of cGMP reporters could be used to answer whether there is overlap 
between cAMP and cGMP microdomains during a signalling event. Phosphorylation of 
PDE5  by  PKA  or  cGK  increases  cG-PDE  activity  by  50-70%,  and  also  increases  the 
cGMP binding capacity of the allosteric cGMP binding sites in vitro (Corbin et al., 2000). 
Cyclic nucleotide cross talk occurs in PDEs; cAMP-PDE activity of PDE2 is allosterically 
increased by cGMP (Martins et al., 1982), whereas for PDE3, cGMP acts as a competitive 
inhibitor against cAMP, thus  reducing cAMP-PDE activity (Shakur  et  al.,  2001).  This 
cGMP regulation of cAMP signalling has been shown to have several regulatory effects in 
cardiac cells, including a reduction in responsiveness to beta-adrenergic agonists, and the 
potentiation of Ca
2+ currents (Zaccolo  and Movsesian, 2007).  Interestingly, cAMP and 
cGMP signalling often have opposing effects on cardiac function, partly due to PKA and 
cGK targets mediating differing physiological outputs (Shah and MacCarthy, 2000).  
 
1.11 Immunity in Drosophila 
Drosophila are presented with immune challenges through septic injury, and through the 
ingestion of infected food, termed natural infection. Whereas mammals use innate and 
acquired  immune  systems,  insects  use  innate  immunity  to  counter  immune  challenges 
(Janeway, 1989). Drosophila has informed a great deal of our knowledge towards insect 
immunity. There are two main types of innate immunity employed by  Drosophila, the 
humeral response and the cellular response. The main humeral response is the systemic 
production of anti microbial peptides (AMPs), which are secreted into the hemolymph, and 
function to kill infectious microorganisms  (Lemaitre et al., 1995). Barrier epithelia are 
presented  with  a  microbial  challenge  when  food  containing  microbes  is  ingested.  The 
generation of ROS eliminates microbes in tissues such as the gut, trachea and Malpighian 
tubules  (Bogdan,  2001;  Ha  et  al.,  2005).  Melanisation  (Nappi  and  Vass,  1993)  and 
coagulation (Muta and Iwanaga, 1996) occur at the wound site to prevent further infection. 
The primary cellular response is performed by the haemocytes, which are responsible for 
phagocytosis  (Meister,  2004)  and  also  produce  AMPs  (Charroux  and  Royet,  2009; 
Dimarcq et al., 1997). As well as systemic production  of AMPs, they are also produced in 
epithelial tissues (Tzou et al., 2000).  59 
The  best  characterised  immune  response  of  Drosophila  is  the  systemic  response 
(Silverman and Maniatis, 2001). Pathogen detection results in the activation of the NFκB-
like Toll or IMD pathways, depending upon the nature of the pathogen. Fungi and gram 
positive bacteria recognition occurs extracellularly, and results in the cleavage of Spaetzle 
by microbe-specific serine protease cascades. Cleaved Spaetzle is recognised by the toll 
receptor, and stimulates the production of the antimicrobial peptide drosomycin through 
activation of the NFκB factors Dif and Dorsal. Gram negative bacteria are recognised by 
peptidoglycan recognition protein (PGRP), and through activation of the NFκB homolog 
Relish,  a  transcription  factor,  stimulate  the  production  of  the  antimicrobial  peptide 
Diptericin. The toll and IMD pathways are summarised in figure 1.12. 
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Figure 1.12: The Toll and IMD pathways. Toll pathway: Gram positive bacteria and 
fungi induce a specific protease cascade, resulting in the proteolytic activation of C-106 
Spaetzle (Spz). Upon binding of Spz, the Toll receptor forms a dimer. MyD88 interacts 
with Toll via TIR domains, and initiates a signalling cascade through Tube and Pelle, 
resulting in the activation of cactus kinase, which phosphorylates cactus, which is then 
targeted for degradation. This frees the transcription factor Dif, which translocates to the 
nucleus and initiates AMP transcription.  
IMD pathway: Gram negative bacteria are recognised by PGRP-LC and –LE isoforms, 
which dimerise and initiate a signalling cascade through IMD, dFADD, and Dredd. Dredd 
can directly activate Relish by cleavage, or can signal through the IKK complex, consisting 
of  Ird5  and  Kenny;  cleaved  Relish  translocates  to  the  nucleus,  whereupon  it  initiates 
transcription of AMPs. Diagram from (Cherry and Silverman, 2006). 
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1.11.1  NO modulates innate immunity in Drosophila 
NO has been shown to activate the IMD pathway, although the mechanism is unclear 
(Foley and O'Farrell, 2003). NO has been assigned an immune role as both an autocrine 
and a paracrine messenger (Silverman, 2003); (Foley and O'Farrell, 2003); where a tissue 
senses an immune challenge, NOS is upregulated, and generates NO, in order to signal to 
other tissues to induce an anticipatory immune reaction in distal tissues, perhaps signalling 
via hemocytes (Basset et al., 2000). Underlying its role in immunity, NOS is upregulated 
following immune challenge to the tubule (McGettigan et al., 2005). 
 
1.11.2  The Malpighian tubule is a critical immune tissue 
cGMP plays an critical role in Malpighian tubule immunity (Aitchison, 2008; Dow et al., 
1994; McGettigan et al., 2005). NO has been shown to activate the IMD pathway in tubule, 
and transgenic upregulation of NOS in only principal cells of the Malpighian tubule leads 
to increased whole organism survival under immune challenge (McGettigan et al., 2005). 
Unpublished  data,  which  will  be  discussed  in  the  relevant  results  chapter,  suggests  a 
possible role for DmPDE11 in immunity. This was further investigated during the course 
of this study, and is discussed in chapter seven.  
 
1.12 Aims  
Phosphodiesterase 11 is not well characterised, but is known to be of importance within a 
number  of  disorders.  PDE11A  regulates  spermatozoa  physiology  through  an  unknown 
mechanism  (Wayman  et  al.,  2005),  where  inhibition  of  PDE11A  impacts  upon  sperm 
quality (Pomara and Morelli, 2005). Certain PDE11A haplotypes are associated with major 
depressive  disorder  and  affect  the  response  to  antidepressant  drugs  (Luo  et  al.,  2009). 
Familial mutations within PDE11A may predispose to Cushing syndrome and testicular 
cancer (Horvath et al., 2009; Libe et al., 2008). Yet the physiological role of HsPDE11 is 
not well understood. 
As the gene model of CG34341 (DmPDE11) is “weakly supported”, the ORF must be 
verified. Following the verification of DmPDE11, the generation of genetic tools will allow 
the  characterisation  of  the  protein  by  expression  in  S2  cells  and  in  Drosophila 62 
melanogaster,  predominantly  focusing  on  the  Malpighian  tubule,  as  this  tissue  utilises 
cAMP and cGMP signalling (Dow and Davies, 2003a), and cGMP signalling modulates 
fluid  secretion  in  the  tubule  (Davies  et  al.,  1995).  Previous  data  have  suggested  that 
DmPDE11 and cGK interact; an aim is to determine the relationship between DmPDE11 
and  the  cGKs  using  co-immunoprecipitation  and  peptide  arrays.  The  interaction  of 
DmPDE11 and cGKs may permit each to regulate the function of the other, as DmPDE11 
can hydrolyse cGMP (Fawcett et al., 2000), and HsPDE11A4 is subject to regulation by 
cGK (Gross-Langenhoff et al., 2008). DmPDE11 has also been implicated in immunity; an 
aim is to acquire further data with regards to how PDE11 might influence the immune 
reaction. HsPDE11A will be subjected to phylogentic analysis, and the closest homologue 
to DmPDE11 will be subject to analysis by transgenic expression in Drosophila, a tool that 
should prove valuable for future research into this important enzyme family. 
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2.1 Drosophila melanogaster 
2.1.1 Drosophila stocks 
The Drosophila melanogaster strains used in this study and their purpose are listed in table 
2.1. Lines in grey boxes were existing lab stocks, and those in darker grey were generated 
during this study. Those in white were supplied by Bloomington stock centre. 
Table 2.1: Drosophila melanogaster lines used in this study 
Strain Genotype Description and use
Oregon R Wild type Protein, DNA, RNA, survival assays
w
1118 (Hazelrigg et al., 1984) w
1118 Microinjection
c42 GAL4 w
-; +/+; c42 tubule principal cell GAL4
c42 Aequorin GAL4 (Rosay 
et al., 1997)
w
- aeq/aeq; +/+; 
c42/c42
Aequorin/GAL4 expression in principal cells; calcium assays
UO (Terhzaz, in prep.) UO; +/+; +/+ tubule principal cell GAL4
Actin GAL4/CyO w-; ActGAL4/Cyo; +/+ Ubiquitous GAL4
Actin GAL4/GFP CyO
w-; ActGAL4/GFP 
Cyo; +/+
Ubiquitous GAL4; non-expressors GFP
UAS-DG1 w-; +/+; UASDG1 UAS DG1 overexpressor
UAS-DG2 P1 UASDG2P1; +/+; +/+ UAS DG2 P1 overexpressor
UAS-DG2 P2 w-; UASDG2P1; +/+ UAS DG2 P2 overexpressor
UAS-PDE11 RNAi
w-; +/+; 
UASPDE11RNAi
UAS PDE11 RNAi
Relish E20 (Hedengren et al, 
1999)
w-; +/+; relish
E20, e
- homozygous relish null with ebony marker; survival assays
TS10
w-; Bristle/CyO; 
TM2/TM6
Balancing
Ato Gal4 w-; +/+; ATO GAL4 paired DC neurons GAL4
D42 Gal4  w-; +/+; D42 GAL4
GAL4: embryogenesis: broad, larvae: 
motorneurons, interneurons, adult: nervous 
system
Appl Gal4 (Torroja et al., 1999) appl GAL4; +/+; +/+ adult and larval neuron specific GAL4
Repo Gal4 
w-; +/+; Repo 
Gal4/Tm3, Sb
glial cell GAL4
Sgs3 Gal4 w-; +/+; sgs3 GAL4 salivary gland GAL4
UAS-HPDE11A3 YFP
w-; Bristle/CyO; 
H11A3/TM6 UAS human PDE11A3 YFP Overexpressor
UAS-HPDE11A3 YFP w-; H11A3YFP/Bristle; 
TM2/TM6  UAS human PDE11A3 YFP Overexpressor
UAS-HPDE11 A3 w-; Bristle/H11A3; 
TM2/TM6 UAS human PDE11A3 Overexpressor
UAS-HPDE11 A3 w-; 8H11/CyO; 
TM2/H11A3 UAS human PDE11A3 Overexpressor
11∆121  w-; 11∆121/CyO ; +/+ PDE11 deletion line; survival assays  65 
 
Strain Genotype Description and use
UAS-Dm RB Long PDE11 YFP w-; B11LYFP/CyO; +/+ UAS-Dm RB long PDE11 YFP overexpressor
UAS-Dm RB Long PDE11 YFP w-; +/+; B11LYFP/Tm5 UAS-Dm RB long PDE11 YFP overexpressor
UAS-Dm RB Short PDE11 YFP w-; +/+ ; B11SYFP/Tm5 UAS-Dm RB short PDE11 YFP overexpressor
UAS-Dm RB Short PDE11 YFP w-; B11S YFP/CyO ; +/+  UAS-Dm RB short PDE11 YFP overexpressor
UAS-Dm RB Short PDE11 YFP  w-; B11S YFP ; +/+ ; +/+ UAS-Dm RB short PDE11 YFP overexpressor
UAS-Dm RC Long PDE11 YFP w-; +/+ ; RCLYFP/TM5 UAS-Dm RC long PDE11 YFP overexpressor
UAS-Dm RC Long PDE11 YFP w-; RCLYFP/CyO; +/+ UAS-Dm RC long PDE11 YFP overexpressor
UAS-Dm RC Short PDE11 YFP w-; RCSYFP/CyO; +/+ UAS-Dm RC long PDE11 YFP overexpressor
UAS-Dm RC Short PDE11 YFP  w-; +/+; RCS/TM5 UAS-Dm RC short PDE11 YFP overexpressor
UAS-Dm RC Short PDE11 YFP w-; RCSYFP; +/+ ; +/+ UAS-Dm RC short PDE11 YFP overexpressor
UAS-Dm RC Short PDE11 w-; +/+; RCS/TM5 UAS-Dm RC short PDE11 overexpressor
UAS-Dm RC Short PDE11 w-; RCS/CyO; +/+ UAS-Dm RC short PDE11  overexpressor  
 
2.1.2 Drosophila rearing 
Drosophila were raised  in  vials  or bottles containing standard  food medium  (recipe in 
appendix), on a 12 hr: 12 hr light: dark cycle at 22-26˚C, or 18˚C when GAL4 activity 
proved developmentally lethal. 
 
2.1.3 Generation of balanced transgenic flies 
In order to localise P-element insertions and generate stable, balanced transgenic fly lines, 
homozygous transgenic flies were crossed to the TS10 balancer line (w
-; Bl/CyO; TM2e
-
/TM6Tb
-), where TM2e
-/TM6b
- is ebony. Red eyed f1 progeny were then back-crossed to 
TS10, and red eyed f2 progeny analysed for markers. Where flies are Bl/CyO and ebony, 
the insertion is on the X chromosome. Where flies are ebony, with the curly phenotype or 
the bristle phenotype, the insertion is on the 2
nd chromosome. Where flies have the curly 
phenotype  and  the  bristle  phenotype,  but  are  not  ebony,  the  insertion  is  on  the  third 
chromosome. Two flies of the same balancer status were backcrossed to generate balanced 
transgenic flies. 
 
2.1.4 Dissection of Drosophila tissues 
Where tissue was required, 5-7 day old flies were anesthetised on ice, before dissection in 
sterile Schneider‟s medium (Invitrogen) using forceps.   66 
2.1.5 Heat shock of Drosophila 
Where  transgenics  were  crossed  to  heat  shock  GAL4  Drosophila,  to  induce  GAL4 
expression and subsequently transgene expression, flies were transferred from food vials 
into screw top 10 ml universals, and were subjected to 3 x 30 min heat shocks in a 37˚C 
incubator on subsequent days. Following heat shock flies were transferred back to food 
vials to room temperature to recover 
 
2.1.6 Fluid secretion assays 
The diagram below shows the experimental setup used for fluid secretion assays. A dish is 
half filled with molten wax, which sets. A number of small depressions are made in the 
wax, and adjacent to these, an array of fine metal pins are arranged a half centimetre away. 
The dish is filled with mineral oil (Sigma), and each small depression has added to it 9 μl 
of a 50:50 solution of Drosophila saline: Schneider‟s solution, with a trace amount of 
amaranth, a red dye that allows visualisation of the bubble formed at the ureter. Drosophila 
Saline is made from a stock solution stored at -20˚C (7.5 mM NaCl, 20 mM KCl, 2 mM 
CaCl2, 8.5 mM MgCl2, 10.2 mM  NaHCO3, 4.3 mM  NaH2PO4, 15 mM  HEPES  (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5) by the addition of 20mM glucose. 
Intact Malpighian tubules are dissected from Drosophila as above, and are picked using a 
fine drawn glass rod; one end is wrapped around the metal pin, and the other is submerged 
in the bubble, with the ureter mid way between. Once it was established that the tubules 
were secreting, the secreted drops were removed from the ureter, and a timer started. Every 
ten  minutes,  the  size  of  the  drops  was  measured  using  a  microscope  graticule.  When 
baseline  secretion  had  been  established,  cGMP  was  added  to  the  9  μl  bubble  at  a 
concentration of 10
-3, for a final concentration of 10
-4. Secreted drops were again measured 
every ten minutes to measure an increase in secretion rate. The process is summarised in 
figure 2.1. 
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Figure 2.1: The fluid secretion assay 
 
2.1.7 Microinjection 
Drosophila  transgenics  were  generated  by  Bestgene  Inc.  using  the  w
1118  stain  of 
Drosophila  melanogaster,  by  co-injection  of  pP{UAST}  and  pP{D2-3}  plasmids  into 
larvae. Transgenic lines were delivered balanced, or were balanced upon arrival using the 
TS10 balancing line. 
2.2 Escherichia coli 
2.2.1 E. coli strains 
Table 2.2 lists the strains of E. coli used in the course of this study, and their genotype. 
Table 2.2: E. coli strains used in this study 
Strain Genotype
DH5a
TM subcloning efficiency 
competent cells (Invitrogen)
F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoAsupE44 thi-1 gyrA96 relA1 λ-
DH5a
TM library efficiency 
competent cells (Invitrogen) hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-
One Shot TOP10 competent 
cells (Invitrogen)
(F- mcrA, D(mrr-hsdRMS-mcrBC), f80lacZ DM15, 
DlacX74, recA1, deoR, araD139, D(ara-leu)7697,galU, 
galK, rpsL, (StrR), endA1,nupG)
BL21 pLysS competent cells 
(Novagen)
hsdS gal (lcIts857 ind1 Sam7 nin5 lacUV5-T7 gene 1)
XL10-gold Kan Ultracompetent 
cells 
Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZΔM15 Tn10 (Tetr) Tn5 (Kanr) Amy]  68 
2.2.2 Plasmids 
Table 2.3 lists the plasmids used in the course of this study, and their purpose. 
 
Table 2.3: Plasmids used in this study 
Plasmids used Purpose
pP{UAST}
germline transformation of coding sequence downstream 
of UAS (Brand and Perrimon, 1993). 
pP{D2-3} co-transformed with pP{UAST} as transposase source
pP{YFP UAST}
germline transformation of coding sequence downstream 
of UAS with a C-terminal YFP tag (Kind gift of John Day)
pCR 2.1 TOPO® TOPO® vector used for sub-cloning
pMT/V5-His-TOPO® (DES) inducable S2 cell TOPO® expression vector
pAC V5 HIS
Constituitive S2 cell expression vector under control of 
actin promoter, C terminal V5 and HIS6, 
pGEX-6P-1 
E. Coli expression vector, fusing ORF to N-terminal GST 
tag
pET-28c 
E. Coli expression vector, fusing ORF to N-terminal 
His6/thrombin/T7 tag, plus optional C-terminal His6 tag 
pcDNA3.1  PDE11A3 Mammalian cell expression vector containing PDE11A3
DES PDE11 RA DES containing PDE11 RA
DES DG1 DES containing DG1
DES DG2 P1 DES containing DG2 P1
DES DG2 P2 DES containing DG2 P2
 
 
2.2.3 Transformation of E. coli 
2.2.3.1  Transformation  of  DH5α™  subcloning/library  efficiency  competent 
cells 
Cells were thawed on ice, and aliquotted into pre-chilled 1.5 ml falcon tubes to a volume of 
50  μl.  50-100  ng  of  plasmid  or  2  μl  of  ligation  reaction  were  added  under  sterile 
conditions, and gently mixed. The cells were incubated on ice for 30 min, and heat shocked 
for 45 s in a 42°C water bath. The tube was immediately transferred to ice, and following a 
2 min recovery step, 250 μl of pre-warmed SOC broth (Invitrogen) was added. The tube 69 
was shaken horizontally at 200 rpm at 37°C for one hour, and spread on a pre-warmed L-
agar  plate  containing  the  appropriate  antibiotic.  The  plates  were  incubated,  inverted, 
overnight at 37°C. 
 
2.2.3.2  Transformation of One Shot TOP10 competent cells 
Vials of cells were thawed on ice. 2 μl of a TOPO® reaction was added under sterile 
conditions, gently mixed, and incubated for 30 min on ice. They were heat shocked in a 
42˚C water bath for 30 s, and left on ice for 2 min. 250 μl of SOC was added, and the cells 
were incubated 37˚C on a flat-bed shaker for 1 hour. In the vicinity of a Bunsen burner, 
cells  were  plated  at  a  variety  of  volumes  on  agar  plates  (appendix)  containing  an 
appropriate concentration and type of selective antibiotic to ensure well spread colonies. 40 
μl  of  a  40  mg/ml  X-GAL  (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) 
dissolved in dimethylformamide (DMF) was added to the selective L-agar plate 30 min 
prior to use where blue/white selection was employed. The plates were incubated, inverted, 
overnight at 37°C. 
 
2.2.3.3  Transformation of XL10-GOLD 
Cells were thawed on ice, and aliquoted into pre-chilled 1.5 ml falcon tubes to a volume of 
50 μl.  To each tube, 2 μl of the β-Mercaptoethanol mix provided was added, and incubated 
on ice for 10 min, swirling gently every two min. 50 ng of plasmid or 2 μl of ligation 
reaction were added, and gently mixed. The cells were incubated on ice for 30 min, and 
heat shocked in a 42°C water bath for 30 s. The tube was immediately transferred to ice, 
and following a 2 min recovery step, 250 μl of pre-warmed SOC broth was added. The 
tube was shaken horizontally at 200 rpm at 37°C for one hour, and spread on a pre-warmed 
agar  plate  containing  the  appropriate  antibiotic.  The  plates  were  incubated,  inverted, 
overnight at 37°C. 
 
2.2.4 Antibiotic usage 
Selection for ampicillin resistance on L-Agar or in L-Broth was performed at 200 g/ml, 
from a 100 mg/ml stock solution (w/v) in 50% H2O, 50% ethanol which was stored at -70 
20C. Selection for kanamycin resistance on L-Agar or in L-Broth was performed at 50 
g/ml from a 50 mg/ml solution (Sigma), which was stored at 4C.  
 
2.2.5 Selection of positive colonies 
Individual colonies (white colonies where blue/white selection was employed) were picked 
under sterile conditions using a sterile toothpick, and  added to  3-5 ml of liquid  broth 
containing  an  appropriate  concentration  and  type  of  selective  antibiotic  (1.2.4),  and 
incubated in a flat bed shaker at 37˚C overnight. Transformants were analysed using PCR 
or restriction digests, detailed below.  
 
2.2.6 Isolation of plasmid DNA 
For plasmid purification, where up to 20 μg of plasmid DNA was required, the QIAprep 
Spin  Miniprep  Kit  was  used;  where  up  to  100 μg  of  plasmid  DNA  was  required,  the 
QIAGEN Midi Kit was used, and where up to 500 μg of plasmid DNA was required, the 
QIAGEN Maxi Kit was used, following manufacturer‟s instructions. 
 
2.2.7 E-Z-Prep 
A 3 ml overnight culture was generated as detailed above; 1.5 ml of cells was spun down 
for 60 s at 13,000 x g to pellet the cells, and resuspended by vortexing in 80 μl of EZ lysis 
buffer (Appendix). After a 10 min incubation, a needle was used to prick a hole in the top 
of the eppendorf, and the sample was boiled for 1 min in a boiling water bath. Following a 
2  min  incubation  on  ice,  the  tube  was  centrifuged  at  17,000  x  g  for  10  min.  5  μl  of 
supernatant was used for a diagnostic digest in a total digest volume of 20 μl, and 2 μl was 
used for a diagnostic PCR. 
 71 
2.2.8 PCR from colony 
Typically one gene specific and one vector specific primers were added at 200 nM to 18 μl 
of ReddyMix MasterMix (Thermoprime) in a sterile PCR tube to a total of 20 μl. A colony 
was picked using a sterile pipette tip, and mixed into the PCR mix by pipetting. The tubes 
were added to a PCR block, set to the following protocol: 
 
92C 2 min 
92C 30 s 
50-65C 30 s             30 cycles               
72C 30 s/kb 
72C 5 min 
 
Samples were held at 4°C until they were run on an agarose gel. 
 
2.2.9 Generation of a Glycerol stock 
For each plasmid, 2 glycerol stocks were generated. 850 μl of overnight culture was added 
to a 1.8 ml Ultra Surity Cryo Vial (Alpha Labs), and 150 μl of glycerol was added. The 
tube was vortexed to mix, and stored at 80°C. To reanimate, the frozen stock was scraped 
with a sterile pipette tip, and streaked on an agar plate containing the appropriate antibiotic. 
A colony from this plate was picked and added to 5ml LB containing selective antibiotic to 
grow overnight. 
 
2.3 Molecular protocols 
2.3.1 Oligonucleotide synthesis 
Oligonucleotides were synthesised by MWG biotech on a 0.01 or 0.05 μmol scale, and 
purified using High Purity Salt Free (HPSF) technology. Primers were assessed for quality 
using  Matrix  Assisted  Laser  Desorption  Ionisation  -  Time  of  Flight  (MALDI-TOF) 72 
analysis. Primers were received as a lyophilised pellet, and were resuspended in distilled 
H2O to generate a 100 μM stock solution, stored at -20˚C. Further dilution in distilled 
water to 10 μM gave working aliquots used for PCR. A list of primers used is given in the 
appendix. 
 
2.3.2 Quantification of nucleic acids  
Nucleic acids were quantified using a NanoDrop™ spectrophotometer ND-1000, where an 
OD260 of 1 equals 50 μg/ml of double stranded DNA, and 40 μg/ml of single stranded 
DNA, or RNA. The spectrophometer was zeroed with the elution buffer used. Purity was 
measured by the ratio of OD260:OD280, where a reading of >1.8 for DNA and >2.0 for RNA 
indicated acceptable levels of purity.     
 
2.3.3 Polymerase Chain Reaction (PCR) 
Where fidelity of amplified DNA was not a critical issue, Taq pol (NEB) was used. The 
reaction mix was set up according to manufacturer‟s instructions; 1x DNA polymerase 
buffer, dNTPs each at 200 M, primers at 200 nM each, 50 ng of cDNA / 10 ng of plasmid 
template, 0.25 U of Taq polymerase, to a final volume of 50 l with H2O. Amounts of 
template DNA varied according to the type of DNA, and the abundance of the desired 
sequence within the DNA. The tubes were flicked to mix, and briefly centrifuged.  Cycling 
was performed in thin walled 0.2 ml PCR tubes in a Hybaid OmnE, Hybaid PCR Sprint or 
Hybaid PCR Express-Gradient thermocycler. Cycling procedures were typically 
 
92C 2 min 
92C 30 s 
50-65C 30 s             25-30 cycles               
72C 30 s/kb 
72C 5 min 
 
Samples were then cooled to 4˚C. 73 
2.3.4 Pfu PCR 
Pfu  DNA  polymerase  (Promega)  is  a  thermostable  enzyme  which  exhibits  3‟5‟ 
exonuclease activity, and was thus used for PCR reactions requiring high fidelity. The 
reaction mix was set up as described in the manufacturer‟s protocol as follows: single 
strength Pfu DNA polymerase buffer, dNTPs each at 300 M, primers at 260 nM each, 
plasmid DNA template up to 10 ng, 1.25 U of Pfu DNA polymerase, final volume of 50 l 
with H2O. Cycling procedures were typically: 
 
94C 2 min 
94C 30 s  
50-65C 30 s             25-30 cycles               
72C 2 min/kb 
72C 10 min 
  
Samples were then cooled to 4˚C. 
 
2.3.5 Herculase II PCR 
Herculase  II  Fusion  DNA  polymerase  (Stratagene)  is  a  thermostable  enzyme  which 
exhibits 3‟5‟ exonuclease activity, and was thus used for PCR reactions requiring high 
fidelity and high yield from “difficult,” e.g., GC rich template, and thus was frequently 
used  for  amplification  from  cDNA.  The  reaction  mix  was  set  up  as  described  in  the 
manufacturer‟s protocol as follows: single strength Herculase II DNA polymerase buffer, 
dNTPs each at 400 M, primers at 250 μM each, 50-500 ng cDNA, 1 μl of Herculase II 
Fusion  DNA  polymerase,  final  volume  of  50  l  with  dH2O.  Cycling  procedures  were 
typically 
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94C 2 min 
94C 30 s 
50-65C 30 s             25-30 cycles               
72C 1 min/kb 
72C 10 min 
 
Samples were then cooled to 4˚C. 
 
For all PCRs, annealing temperatures were primer- and template-dependent; new primers 
were  optimised  by  running  a  gradient  PCR  reaction  across  a  range  of  annealing 
temperatures. The annealing temperature used gave one strong, clear band when subjected 
to agarose gel electrophoresis. 
 
2.3.6 Fusion PCR 
Fusion PCR was performed in three separate PCR steps. Amplification of DS fragments 
overlapping by ~50bp  was  performed with  a  high fidelity DNA polymerase  as  above. 
These  fragments  were  gel  purified,  and  used  in  a  subsequent  fusion  PCR  containing 
equimolar  concentration  at  ≥0.7μg/50μl,  with  no  primers,  with  the  following  PCR 
protocol: 
 
92˚C, 1 min 
92˚C, 30 sec   
50-65˚C, 30 sec            13 cycles                   
72˚C, 1min/kb 
72˚C, 10 min 
 
The product was then PCR purified, and used as a template for full length PCR at 20% of 
PCR volume, with primers for the extreme ends of the target DNA.  75 
 
92˚C, 1 min 
92˚C, 30 sec   
50-65˚C, 30 sec            30 cycles                   
72˚C, 1min/kb 
72˚C, 10 min 
 
PCRs  were  performed  in  a  gradient  PCR  machine,  with  a  spread  of  annealing 
temperatures. 
 
2.3.7 Reverse transcription (RT) PCR 
RT-PCR was performed as per the standard PCR protocol, with cDNA as the template. For 
cloning of an ORF, primers were designed between the ATG encoding the transcription 
start site, and the bases encoding the stop codon. Where the purpose of RT-PCR was to 
establish  the  presence  or  absence  of  a  transcript  within  a  tissue,  primers  spanning 
intron/exon boundaries were used, as a control against genomic contamination. 
 
2.3.8 Quantitative PCR (Q-PCR) 
2.3.8.1  Plate Setup 
To quantify transcription of a gene of interest, Q-PCR was performed using DyNAmo™ 
SYBR® Green (Finnzymes), a 2x master mix that contains  Thermus brockianus DNA 
Polymerase, SYBR Green  I, a double stranded DNA binding dye, PCR buffer, 5 mM 
MgCl2, and a dNTP mix including dUTP. Gene-specific primers were designed to amplify 
<500 bases across an intron-exon boundary of the gene of interest to ensure only processed 
mRNA would be quantified by the Q-PCR. These primers were used in a PCR to amplify a 
band from cDNA; if a single clean band was achieved, this was gel purified, quantified, 
and used as a standard in the Q-PCR. Each plate was set up on ice, using optical grade 
PCR strips (MJ Research, MLL-9651), and sealed with ultra-clear strip caps (MJ Research, 
TCS-0803). Serial 1 in 10 dilutions were performed with the purified band, to generate a 76 
standard curve between 10
-1 to 10
-7 ng of template. Alongside this, two blank reactions 
containing 25 μl SYBR green, 25 μl H20, and two “primer only” reactions, containing 25 
μl SYBR green, 21 μl H20, 2 μl forward primer, 2 μl reverse primer (each 0.3μM final 
concentration). For each cDNA condition, 25 μl SYBR green, 20 μl H20, 2 μl forward 
primer, 2 μl reverse primer (each 0.3 μM final concentration), and 1 μl of cDNA, typically 
500ng total, was set up, each in triplicate.  To facilitate quantification against a reference 
gene, primers were designed against an intron-exon boundary of the ribosomal protein 
rp49, considered to have standard expression across cell types. Three biological replicates 
were performed on three different plates.  
 
2.3.8.2  Q-PCR  
Q-PCR strips were briefly centrifuged in  a technico mini centrifuge, and added to the 
Opticon™ 3 thermal cycler. The following cycling protocol was followed: 
Table 2.4: Q-PCR cycling protocol 
Step Temperature Time Function
Initial Denaturation 95˚C Template denaturation
Denaturation 95˚C 20 s
Annealing 55˚C 20 s
Determined by gradient 
PCR
Extension 72˚C 5 s/100bp
Data aquisition -
Fluorescence recorded 
after every cycle
Final extension 72˚C
Melting curve 65 - 95˚C
Checks specificity of 
primers
40 cycles
10 min
5 min
-
 
The melting curve was analysed; where more than one clear peak was produced, either for 
the gene and rp49, data was discarded. 
Data  was  analysed  using  Opticon™  3  software,  following  manufacturer‟s  instructions. 
Absolute quantification of gene expression was calculated by comparison of the threshold 
cycle C(t) of the gene to that of the standard curve generated by the gene standards of 
known concentration using an excel spreadsheet. Relative quantification was calculated by 
comparing the ratio of target gene DNA concentration to rp49 DNA concentration. Plotted 
in GraphPad prism 4.0, ±SEM  (where control = 1) Statistical significance determined by a 
1-way ANOVA test. 77 
2.3.9 Primer list 
A list of primers used, their sequence, and their applied use are listed in table 2.5. 
 
Table 2.5: Primers used in the course of this study. 
Primer name Sequence Use
PDE11 RAF ATGAAAGTGACACAGAGTGAAGAAAA PCR of full length PDE11 RA
RCfulllengthNSF ATGGCATCATCCCAAATA PCR of full length PDE11
RCfulllengthNSR TTTTTCAACCGCCATAGCG PCR of full length PDE11
RbNtoGAFF ATGGGCCAAGCGGCAA truncation PDE11 cloning
RbNtoGAFR CTCGAGCTCGTTGCAAATGT truncation PDE11 cloning
RCNtoGAFF ATGGCATCATCCCCAAATAA truncation PDE11 cloning
RCNtoGAFR CTCGAGCTCGTTGCAAATG truncation PDE11 cloning
GafF ATGGTGCGCACTTTGTGC truncation PDE11 cloning
GafR AATGGCCTTCTCGTACATGTG truncation PDE11 cloning
CofgaflongF ATGGTGGCAATGGCCAAG truncation PDE11 cloning
CofGAFshortF ATGTGGGCAATGGCCA truncation PDE11 cloning
CofGAFshortR CTGGGCTGGGTGGCTT truncation PDE11 cloning
PDE11spliceBF    CCAAGCGGCAAGTATGTGTC pUAST PDE11 cloning
PDE11spliceR    GGTGTTGTGGCGAGTTGGC pUAST PDE11 cloning
PDE11spliceCF      CCTCAAAGGCGGATAAATACC pUAST PDE11 cloning
dPDE11-RBORF F          ATGGGCCAAGCGGCAAGTAT pUAST PDE11 cloning
dPDE11-RBORF    TTATTTTTCAACCGCCATAGCGG pUAST PDE11 cloning
dPDE11-RC ORF F    ATGGCATCATCCCCAAATAA pUAST PDE11 cloning
dPDE11-RC ORF R     TTATTTTTCAACCGCCATAGC pUAST PDE11 cloning
Pde11ntermRcmyc 
TACAGATCCTCTTCTGAGATGAGTTTTTGTT
CGCAGAAGATGGCGAACGC
pUAST PDE11 cloning
Pde11nterminusR    GCAGAAGATGGCGAACGC pUAST PDE11 cloning
Pde11CtermF   GAGGCGTTCGCCATCTTC pUAST PDE11 cloning
dPDE11cterminusR 
CTACAGATCCTCTTCTGAGATGAGTTTTTGT
TCTTATTTTTCAACCGCCATAGC
pUAST PDE11 cloning
PDE11RBEcoR1F     AAAGAATTCATGGGCCAAGCGGCAAGTAT pUAST PDE11 cloning
PDE11RBkpn1R  TTTGGTACCTTATTTTTCAACCGCCATAGCG pUAST PDE11 cloning
Pde11rbYFPEcoR1F   GAATTCATGGGCCAAGCGGCAAGTAT pUAST PDE11 YFP cloning
Pde11rcYFPNot1Rn     GCGGCCGCTTTTTCAACCGCCATAGCGGT pUAST PDE11 YFP cloning
Pde11RCEcoR1F         GAGGAATTCATGGCATCATCCCCAAATAA pUAST PDE11 cloning
Pde11RCKpn1R   GAGGGTACCTTATTTTTCAACCGCCATAGC pUAST PDE11 cloning
Pde11RCYFPEcoR1F            GAATTCATGGCATCATCCCCAAATAAC pUAST PDE11 YFP cloning
Pde11RCYFPNot1Rn       GCGGCCGCTTTTTCAACCGCCATAGCG pUAST PDE11 YFP cloning
RBF72.47    ATGGGCCAAGCGGCAAGTATGTGTC pUAST PDE11 cloning
RBR72.79     TTATTTTTCAACCGCCATAGCGGTGGC pUAST PDE11 cloning
RCF73.39      ATGGCATCATCCCCAAATAACGCGG pUAST PDE11 cloning
RCR72.79   TTATTTTTCAACCGCCATAGCGGTGGC pUAST PDE11 cloning
RBNT_EcoRIF                        GAATTCATGGGCCAAGCGGCAAGTA pUAST PDE11 cloning
RCNT_EcoRIF     GAATTCATGGCATCATCCCCAAATAACG pUAST PDE11 cloning
11NT_BglIIR   CGATTTCGCCAAAGATCTTCCA pUAST PDE11 cloning
11CT_BglIIF      AGATCTTTGGCGAAATCGAATGC pUAST PDE11 cloning
11CT_Kpn1R    GGTACCTTATTTTTCAACCGCCATAGCGG pUAST PDE11 cloning
11CT_Not1NSR  GCGGCCGCTTTTTCAACCGCCATAGCGG pUAST PDE11 cloning  78 
Primer name Sequence Use
dPDE11xho1F GCTCGAGGTGCGCACTTTG pUAST PDE11 cloning
dPDE11xho1R GTATCTTGTGGCACAAAGTGCGC pUAST PDE11 cloning
dPDE11xho1F GCTCGAGGTGCGCACTTTG pUAST PDE11 cloning
dPDE11xho1R GTATCTTGTGGCACAAAGTGCGC pUAST PDE11 cloning
ShortCtermRevKpn GGTACCTCACTGGGCTGGGTGG pUAST PDE11 cloning
ShortCtermNSRevN GCGGCCGCCTGGGCTGGGTGGCTTG pUAST PDE11 cloning
RBR_3475to3492 GGCAACGTTGGAGCCATT DmPDE11 validation
RBRgap_3475to349 TCATCATCACTGGGCTGG DmPDE11 validation
RCF_45to63 GGCGAGACGTAAAATTGGC DmPDE11 validation
RCR_3350to3368 CTGTTGTTGGCAACGTTGG DmPDE11 validation
RCRgap_3344to336 ATTATCATCATCACTGGGCTG DmPDE11 validation
Forward_3015to30 GAGCATGACTGTCTGTGATTTGT DmPDE11 validation
dg1ntFBamHI GATCCATGCCGCTGGAATGTTGACT Primers for pET cloning
dg1ntFBamHI ACGGATCCATGGCCGCTGGAATGTT Primers for pET cloning
dg1ntRXhoI CTCGAGTTACTTCCTGCTCTCATCGCC Primers for pET cloning
dg1ctFEcoRI CGAATTCGACTAGCCATGAAGCAGGCG Primers for pET cloning
dg1ctFEcoRI CGAATTCCTAGCCATGAAGCAGGCG Primers for pET cloning
dg1ctRSalI ATATATGTCGACTTAGAAATCCGCATCCCAG Primers for pET cloning
dg2ntFEcoRI ATTCGACGTTTCTGCTTTGATCGGC Primers for pET cloning
dg2ntFEcoRI TGAATTCATGCGTTTCTGCTTTGATCG Primers for pET cloning
dg2ntRnotI
GCGGCCGCTTAGATCTGCGTCAGATCCAGAT
TC
Primers for pET cloning
dg2ctFSalI
ATA TAT GTC GAC ACG CGA GAT CGT TGA 
CTG C
Primers for pET cloning
dg2ctFSalI
ATA TAT GTC GAC CGC GAG ATC GTT GAC 
TGC Primers for pET cloning
dg2ctRNotI
GCG GCC GCT TAT TAG AAG TCC TTG TCC 
CAT CCA G
Primers for pET cloning
rbnNotIR
AGT TGG ATC AGC GGC CGC TTA TTG AGA 
TTT CTC ATA CAG CTG TGC Primers for pET cloning
middlexhoR
AGA CCT CGA GTT AAC GAT TAT CGC GCA 
CGC Primers for pET cloning
endxhoR
AGA CCT CGA GTT ATT ATT TTT CAA CCG 
CCA TAG C Primers for pET cloning
rbnEcoRIFET AGA ATT CGA GGC CAA GCG GCA AGT AT Primers for pET cloning
rcnEcoRIFET ATT CGA GCA TCA TCC CCA AAT AAC G Primers for pET cloning
middleBamHIFET
ACG GAT CCG ACT GGA GAT CAA GCG GAA 
TCA
Primers for pET cloning
endBamHIFET
ACG GAT CCG AGA TCT GGC CGA TGT CGT 
G Primers for pET cloning
modpuast_f GAA TTC TGC CTC GAG GTT AGA TC Modify pUAST MCS
500+puast_r CAG GTT CAG GGG GAG GTG Modify pUAST MCS
M13 Reverse  CAGGAAACAGCTATGAC
Sequencing primers for 
TOPO cloning
M13 Forward  GTAAAACGACGGCCAG
Sequencing primers for 
TOPO cloning
 
2.3.10  Automated DNA sequencing 
DNA sequencing was performed at the MBSU sequencing centre of Glasgow University, 
using  a  MegaBACE1000  96  capillary  sequencer,  using  either  Big  Dye  (Applied 
Biosystems) or ET-Dye Terminator (GE Heathcare) chemistries, both based upon Sanger‟s 
dideoxy sequencing method. Construct and primers were supplies at 1 μg and 3.2 pmol 79 
respectively. Constructs were sequenced using primers spaced by 500bp throughout the 
sequence to achieve 100% sequence coverage. Sequencing results were analysed using 
Editview 1.0 (Perkin Elmer) and MacVector software. 
 
2.3.11  RNA extraction 
For  purification  of  RNA,  the  RNeasy  mini  kit  (Qiagen)  was  used,  following 
manufacturer‟s instructions. mRNA was prepared from either 10 whole flies, 15 heads, 30 
brains, 40 Malpighian tubule pairs or 40 hindguts, dissected in Schneider‟s solution. Tissue 
was  transferred  to  a  1.5  ml  eppendorf  containing  350  μl  RLT  buffer  with  1%  β-
mercaptoethanol on ice, and homogenised with a pestle. Following this, the tissues were 
subjected to brief bursts of L2 sonication by a microson™ ultrasonic cell disruptor. Tissues 
other than the tubules were then centrifuged at 4˚C at 16,200 x g for 3 minutes, and the 
supernatant  transferred  to  a  new  1.5ml  eppendorf.  350  μl  70%  ethanol  was  added, 
pippetted to mix, and transferred to an RNeasy spin column. Following this, RNA was 
purified following manufacturer‟s instructions, eluted in 25 μl nuclease free water, and 
quantified using a NanoDrop™ spectrophotometer ND-1000 as described in 1.4.2. 
 
2.3.12  First strand cDNA synthesis  
For each amplification of cDNA performed, a further half-volume reaction was performed 
without superscript, and quantified for ds DNA afterwards to discount contamination. 4 l 
5x First Strand buffer, 2 l DTT (0.1 M), l dNTP mix (each, and 1 μl oligo 
DT12-18 (500 μg/ml) were added to a nuclease-free centrifuge tube, mixed, and incubated in 
a PCR block at 65˚C for 5 min. The tube was chilled on ice and briefly centrifuged. 1 
μl/200  units  of  M-MLV  Superscript  Reverse  Transcriptase,  1  μl/40  U  of  RNase  OUT 
RNase inhibitor, and 1 μg RNA were added, and the mix made up to 20 μl with RNase free 
water.  The  tube  was  incubated  in  a  PCR  block  at  42˚C  for  one  hour;  enzyme  was 
inactivated by a further incubation at 72˚C for 15 min. cDNA was frozen at -20˚C if not 
used immediately. All reagents were purchased from Invitrogen.  
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2.3.13  Restriction digests 
Digests  were  performed  in  a  water  bath  using  NEB  restriction  endonucleases,  at  the 
recommended concentration of enzyme, buffer and BSA. Digests were performed at the 
recommended temperature for that enzyme. When cloning, inserts were cloned using two 
different restriction sites at the 5‟ and 3‟ ends, where possible. Where double digests were 
performed, digests were either performed in a single reaction, or in sequential digests with 
PCR purification in between digests, depending on buffer compatibility. Where plasmid or 
insert was required for a ligation reaction, 2 – 4 μg DNA was added to a total volume of 
typically 80 μl, to facilitate digest loading into two agarose gel wells. Diagnostic digests 
were performed in 20 μl total volume with 200 μg DNA. Where plasmid was required for a 
ligation reaction, 1 U of alkaline phosphatase was added for the final 30 min to make the 
final amount of enzymes no more than 5% of total digest volume. 
 
2.3.14  Agarose gel electrophoresis of DNA 
DNA was separated by running at 100 V in a 1% agarose gel (1% agarose and 0.1 g/ml 
ethidium  bromide  dissolved  in  0.5  x  TBE  (appendix)),  using  0.5x  TBE  as  the 
electrophoresis buffer as described in (Sambrook and Russel, 2001). DNA fragment size 
was determined by comparison with a 1 kb ladder (Invitrogen). 6x loading dye (0.25 % 
(w/v) bromophenol blue, 0.25 % (w/v) xylene cyanol, 30 % (v/v) glycerol in H20) was 
added to DNA samples to a final 1x concentration prior to loading. 
 
2.3.15  Gel extraction of DNA 
DNA was excised from agarose using a sterile scalpel, and purified using the QIAquick 
Gel Extraction Kit (Qiagen) using manufacturer‟s instructions. 
 
2.3.16  PCR purification of DNA 
DNA was purified from enzymatic reactions using the QIAquick PCR Purification Kit 
(Qiagen) using manufacturer‟s instructions. 81 
 
2.3.17  Ligation reaction 
Ligations were performed using the rapid DNA ligation kit (Roche) at a molar ratio of 6:1 
insert: vector, with typically a total of 200 ng of DNA. Volume of DNA was brought to 5 
μl with EB buffer, and 5 μl of T4 DNA ligation buffer was added, and mixed. To this 0.5 
μl  of  DNA  ligase  was  added,  with  thorough  mixing.  This  reaction  was  left  at  room 
temperature for 30 min, and frozen at -20˚C if not used immediately. 
 
2.3.18  TOPO cloning 
Where TOPO® cloning was performed with a PCR product produced with a proofreading 
DNA  polymerase,  the  PCR  product  was  incubated  at  72°C  for  10  min  with  a  non 
proofreading Taq pol to add A overhangs. “Half volume” reactions were used, where 2 μl 
of PCR product had added to it 0.5 μl of salt solution, and 0.5 μl TOPO® vector. The 
reaction  was  mixed,  and  left  at  room  temperature  for  5  to  30  min.  Following 
transformation the reaction was stored at -20°C if not used immediately. 
 
2.3.19  Modification of plasmid multiple cloning site 
Where the restriction sites within a plasmid‟s multiple cloning site were not suitable for the 
insert, a new multiple cloning site was designed. Two sets of primers were designed, which 
represented the new multiple cloning site. These primers overlapped except for 3 bases, 
which were compatible with the terminal restriction sites of the plasmid‟s multiple cloning 
site; upon annealing, the primers form double stranded DNA with sticky ends. Annealing 
was achieved by incubating equimolar amounts of each primer at 92˚C for 2 min, then a 
progressively reduced annealing temperature, 65˚C for 1 min, 60˚C for 1 min, then 55˚C 
for 1 min. The multiple cloning site of the plasmid was removed using the appropriate 
restriction  endonucleases,  and  the  plasmid  was  subsequently  treated  with  calf  alkaline 
phosphatase. The double stranded DNA was then ligated into the plasmid.    82 
2.3.20  Generation and details of DNA constructs 
A list of DNA constructs generated in the course of this study are listed in table 2.6. 
Table 2.6: DNA constructs generated in the course of this study 
Construct Source Cloning method
DmPDE11 RB EcoRI-XhoI 2.1 
TOPO
PCR from cDNA TOPO
DmPDE11 RB XhoI-BglII 2.1 
TOPO
PCR from cDNA TOPO
DmPDE11 RC EcoRI-BglII 2.1 
TOPO
PCR from cDNA TOPO
DmPDE11 long C term Stop 
BglII-KpnI 2.1 TOPO
PCR from cDNA TOPO
DmPDE11 long C term No 
stop BglII-NotI 2.1 TOPO
PCR from cDNA TOPO
DmPDE11 short C term Stop 
BglII-KpnI 2.1 TOPO
PCR from cDNA TOPO
DmPDE11 short C term No 
stop BglII-NotI 2.1 TOPO
PCR from cDNA Digest / ligation
PDE11RBl pP{YFP UAST} 
RB EcoRI-XhoI/RB XhoI-
BglII/Cl NS
Digest / ligation
PDE11RBs pP{YFP UAST} 
RB EcoRI-XhoI/RB XhoI-
BglII/Cs NS
Digest / ligation
PDE11RCl pP{YFP UAST} 
compiled from RCN and 
Cl NS TOPO fragments
Digest / ligation
PDE11RCs pP{YFP UAST} 
compiled from RCN and 
Cs NS TOPO fragments
Digest / ligation
PDE11RCs pP{UAST} 
compiled from RCN and 
Cs S TOPO fragments
Digest / ligation
hPDE11A3 pP{UAST}  pcDNA3.1  PDE11A3
PCR w/restriction sites 
digeted; ligated
hPDE11A3 pP{YFP UAST}  pcDNA3.1  PDE11A3
PCR w/restriction sites 
digeted; ligated
PDE11RBl pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
PDE11RBs pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
PDE11RCl pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
PDE11RBl pAC V5 HIS
ORF from pP{UAST} 
construct
Digest / ligation
pGEX-6P-1 RB N
PDE11RBl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 RC N
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 PDE11 middle
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 long C term
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated  
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Construct Source Cloning method
pGEX-6P-1 DG1 N DES DG1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG1 C DES DG1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P1 N DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P1 C DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P2 N DES DG2 P2
PCR w/restriction sites 
digeted; ligated
pGEX-6P-1 DG2 P2 C DES DG2 P2
PCR w/restriction sites 
digeted; ligated
pET-28c RB N
PDE11RBl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c RC N
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c PDE 11 middle
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c PDE11 long C term
PDE11RCl pP{YFP 
UAST} 
PCR w/restriction sites 
digeted; ligated
pET-28c DG1 N DES DG1
PCR w/restriction sites 
digeted; ligated
pET-28c DG1 C DES DG1
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P1 N DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P1 C DES DG2 P1
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P2 N DES DG2 P2
PCR w/restriction sites 
digeted; ligated
pET-28c DG2 P2 C DES DG2 P2
PCR w/restriction sites 
digeted; ligated
DES DG1-TAP DES DG1
PCR; F primer w/ tap tag 
seq
DES DG2P1-TAP DES DG2 P1
PCR; F primer w/ tap tag 
seq
DES DG2P2-TAP DES DG2 P2
PCR; F primer w/ tap tag 
seq
pP{UAST} DG1-TAP DES DG1
PCR; F primer w/ tap tag 
seq
pP{UAST} DG2P1-TAP DES DG2 P1
PCR; F primer w/ tap tag 
seq
pP{UAST} DG2P2-TAP DES DG2 P2
PCR; F primer w/ tap tag 
seq
pACT2 AD DG2 P1 DES DG2 P1 Digested PCR
pACT2 AD DG2 P2 DES DG2 P2 Digested PCR
pACT2 AD PDE11 RA DES PDE 11 RA Digested PCR
pGBK T7 BD DG2 P1 DES DG2 P1 Digested PCR
pGBK T7 BD DG2 P2 DES DG2 P2 Digested PCR
pGBK T7 BD PDE 11 RA DES PDE 11 RA Digested PCR  84 
2.4 Schneider 2 (S2) cells 
2.4.1 S2 cell maintenance 
S2 cells were stored in a 28˚C incubator, in complete Schneider‟s Drosophila Medium  
with 10% heat inactivated Foetal Calf Serum (FCS), and were split when they reached a 
density of 6 – 20 x 10
6 S2 cells/ml. Transfections were performed in a cell culture hood 
using  sterile  techniques.  Stock  was  split  into  new  flasks  for  general  maintenance; 
transfections and selection were kept in the same flasks or plates. The S2 cells/ml of an S2 
cell stock was calculated using a haemocytometer (Hawksley).  
 
2.4.2 S2 cell transfections 
For each transfection, 3 x 10
6 S2 cells/transfection were spun down in a 15 ml falcon tube 
at 1000 x g for 3 min, and resuspended in 800 μl of Schneider‟s  Drosophila Medium 
(without  serum). 800 μl  of cells  were added to each well  of a 6 well  plate. For  each 
experimental  condition,  a  total  of  2  μg  plasmid  DNA  was  incubated  with  10  μl 
Cellfectin/Cellfectin II (Invitrogen), made up to 200 μl total with Schneider‟s Drosophila 
Medium. This mixture was vortexed briefly, incubated for 30 min, and then added to the 
cells  in  a  dropwise  fashion,  while  swirling  the  plate.  The  plate  was  then  incubated 
overnight (for Cellfectin) or for 4 hours (Cellfectin II). Cells were resuspended using a 
transfer pipette, added to a 1.5ml eppendorf, and spun down for 3 min at 1000 x g. The 
supernatant  was  removed,  and  the  S2  cells  were  resuspended  in  3  ml  Schneider‟s 
Drosophila Medium with 10% FCS. Where DES constructs were used these were induced 
with CuSO4 at a final concentration of 0.7 μM. Time of incubation varied depending on 
expression level of the plasmid, which was assessed by ICC or western blot. 
 
2.4.3 Generation of stable S2 cell lines 
Transfections were performed as above, but with the addition of an equimolar amount of 
pCoHygro selection vector. Stable cells were selected for using 300 μg/ml hygromycin-B, 
where the medium was not changed until the cells showed strong resurgence in growth. 85 
 
2.4.4 Generation of an S2 cell frozen stock 
S2 cells were grown to a density of 1 – 2 x 10
7 S2 cells/ml.  They were centrifuged at 1000 
x g, and resuspended  to a density of 1.1 x 10
7 S2 cells/ml in Freezing Medium (45% 
conditioned complete Schneider‟s Drosophila Medium containing 10% FBS, with 45% 
fresh  complete  Schneider‟s  Drosophila  Medium,  and  10%  DMSO).  1  ml  aliquots  in 
cyrovials  were  placed  in  an  insulated  container,  then  transferred  to  a  -80˚C  freezer 
overnight. The vials were then stored in liquid nitrogen. 
 
2.4.5 Initiation of S2 cell frozen stock 
A frozen S2 cell stock was removed from liquid nitrogen, and thawed in a 30˚C water bath. 
The vial was washed with 70% ethanol, and the cells added to 5 ml room temperature 
complete Schneider‟s Drosophila Medium, and stored at 28˚C for 30 min. The cells were 
resuspended, centrifuged at 1000 x g for 3 min, and transferred to a new flask containing 5 
ml  Schneider‟s  Drosophila  Medium  with  10%  FCS  at  28˚C  until  the  cells  reached  a 
density of 6 x 10
6.   
 
2.5 Immunoprecipitaions (IP) 
2.5.1 Preparation of S2 cell lysates  
For S2 cell transfections, each transfection was viewed under 20x magnification to assess 
cell  membrane  integrity  (as  a  measure  of  survival),  and  resuspended  using  a  transfer 
pipette. Each transfection was split into two 1.5 ml eppendorfs, and spun down for 4 min at 
1000 x g. The supernatant was removed, and the cell pellets were frozen in a -80°C freezer 
(if  there  wasn‟t  time  to  pre-clear  overnight).  When  needed,  these  cell  pellets  were 
resuspended in a suitable volume of ice cold 3T3 lysis buffer (25mM HEPES pH 7.4, 
50mM NaCl, 10% glycerol, 1% Triton X-100) containing protease inhibitor cocktail. The 
lysate was then sonicated on ice. Where background was apparent the buffer could be 
modified. 3 million S2 cells yielded ~150μg of soluble protein. 86 
 
2.5.2 Preparation of Malpighian tubule lysates  
For each genotype, 200 tubule pairs were dissected, and transferred to a suitable volume of 
ice-cold 3T3 lysis buffer with 1% (v/v) protease inhibitor cocktail. Tubules were lysed on 
ice, using a hand held pestle, then by brief L3 sonication. Insoluble material was pelleted 
by centrifugation at 18,000 x g for 10 min at 4˚C, and the supernatant transferred to a new 
eppendorf tube. Total protein recovered was ~30μg.  
 
2.5.3 Preparation of whole fly lysate 
For each genotype, 10 flies were anesthetized using CO2, and transferred to a suitable 
volume of ice-cold 3T3 lysis buffer with 1% (v/v) protease inhibitor cocktail. Flies were 
lysed on ice, using a hand held pestle, then by three five second bursts of L3 sonication. 
Insoluble material was pelleted by centrifugation at 18,000 x g for 10 min at 4˚C, and the 
supernatant  transferred  to  a  new  eppendorf  tube.  Total  soluble  protein  recovered  was 
~30μg. 
 
2.5.4 IP with rabbit serum 
Where the IP was performed with a Rabbit polyclonal antibody, 50μl of pre-immune rabbit 
serum per ml (ideally from a pre-immune sample from the immunized rabbit) was added to 
each lysate, and incubated at 4°C on a rotator for ≥30 min. During this preclearing step, 
10-20μl Protein A-Sepharose 4B Fast flow, from Staphylococcus aureus (Sigma)/IP was 
washed 3x in ice cold lysis buffer, and added to each lysate. The samples were incubated at 
4°C on a rotator for ≥1 hour, and then spun down at 8000g. The lysate was removed and 
transferred to a new tube, where 20-50μl serum was added to each sample, and incubated 
at 4°C on a rotator for 1 hour. Pre-washed Protein A beads were added as before, and 
incubated at 4°C on a rotator for 1 hour. The beads were washed 3x in 750μl 3T3 lysis 
buffer with protease inhibitor, with the wash buffer removed as completely as possible 
without disturbing the pellet. The pellet was then used immediately if possible, or frozen at 
-80°C. 87 
 
2.5.5 With Fixed state proteinA beads 
Where the IP was performed with EZview Red ʱc-Myc Affinity Gel (Sigma), EZ View 
Red Protein A Affinity Gel (Sigma) was used to preclear in place of Protein A-Sepharose 
4B Fast flow; serum was still used because the ʱc-Myc antibody is Rabbit polyclonal. 
Where ʱV5 Agarose conjugate (Sigma) was used for the IP, Protein A Agarose conjugate 
(Sigma) was used to preclear as above, but with no addition of serum, as the ʱV5 antibody 
is a monoclonal.  
 
2.5.6 IP with monoclonal antibodies 
Where monoclonal antibodies were used, amounts used was dictated by the recommended 
concentration in the accompanying protocol. A pool of monoclonal antibodies was used 
wherever possible, and the concentrations of each were lowered as appropriate. Antibody 
was  added  to  each  sample,  and  incubated  at  4°C  on  a  rotator  for  1  hour.  Pre-washed 
Protein A beads were added as before, and incubated at 4°C on a rotator for 1 hour. The 
beads were washed 3x in 750 μl 3T3 lysis buffer with 1:100 protease inhibitor, with the 
wash buffer removed as completely as possible without disturbing the pellet. The pellets 
were then used immediately if possible, or frozen at -80°C. 
 
2.5.7 IP with antibody conjugate 
Where antibody-agarose conjugates were used, the IP was performed as before, except 
there was no antibody incubation before the addition of the antibody-agarose conjugate. 
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2.6 Western blotting 
2.6.1 Preparation of sample 
2.6.1.1  Preparation of S2 cell lysates  
For S2 cell transfections, each transfection was viewed under 20 x magnification to assess 
cell membrane integrity at every stage (as a measure of survival), and resuspended using a 
transfer pipette. Each transfection was split into two 1.5 ml eppendorfs, and spun down 
spun down for 4 min at 2000 rpm in a Thermo Heraeus centrifuge. The supernatant was 
removed, and the cell pellets were frozen in a -80°C freezer. When needed, the pellets were 
resuspended  in  IGEPAL  buffer  (150mM  NaCl,  50mM  Tris,  1%  IGEPAL)  containing 
protease inhibitor cocktail. The lysate was  then sonicated on ice. An  equal  volume of 
Laemmli 2 x buffer (4% SDS, 5% β-Mercaptoethanol, 20% glycerol, 0.004% bromophenol 
blue, 0.125M Tris-HCl) was then added, and the samples boiled in a boiling water bath for 
3 min.    
 
2.6.2 Bradford assay 
The Bradford assay was performed on a 96 well plate. Standards from 0-5 μg (typically 0 
μg, 0.5 μg, 1 μg, 1.5 μg, 2 μg, 3 μg, 4 μg, 5 μg) were generated in triplicate using Bovine 
Serum Albumin (BSA), Fraction V (Roche) in a volume of 50 μl distilled H20. For each 
protein sample, 1 μl of sample was added to 49 μl H20 in triplicate. To each well, 200μl of 
a well mixed 1 in 5 dilution of Bio-rad protein assay dye reaction concentrate (Biorad) in 
H20  was  added.  Absorbance  at  590  nm  was  read  using  a  plate  reader;  Quanta  smart 
software was used to generate a standard curve, and from this ascertain the concentration 
of each protein sample. 
 
2.6.3 Sodium  Dodecyl  Sulfate  PolyAcrylamide  Gel 
Electrophoresis 
10 or 15 well resolving gels between 6-20% were prepared according to the size of the 
protein  of  interest,  as  according  to  (Joseph  Sambrook  2001).  Electrophoresis  was 89 
performed in a Biorad Miniprotean 3 Cell electrophoresis system. Samples were run at 50 
V until the dye front had settled at the bottom of the stacking gel, and then at 130 V for 1 
hour.  Prestained  Benchmark  Ladder  (Invitrogen)  was  used  to  determine  the  size  of 
proteins. 
 
2.6.4 Coomassie staining of PAGE gels 
PAGE gels were fixed by brief treatment with 40% distilled H20, 10% acetic acid, 50% 
methanol on a horizontal shaker. The gel was then added to the same mix but with the 
addition of 0.25% by weight Coomassie Brilliant Blue R-250, and incubated for 4 hours to 
overnight.  The  gel  was  then  washed  in  67.5%  distilled  H20,  7.5%  acetic  acid,  25% 
methanol on a horizontal shaker, the solution changed until excess dye was removed, and 
the protein bands were clear. 
 
2.6.5 Transfer 
Hybond P was incubated in methanol for 5 min, and then rinsed in distilled H20. Western 
blotting was carried out according to Novex Xcell II Blot Module (Invitrogen) instructions. 
Transfer was carried out at 60 V for 1 hour, with ice packs to prevent overheating. 
 
2.6.6 Ponceau S Staining 
To visualise protein on the membrane, the membrane was rinsed in methanol, then washed 
in PBST. The membrane was then incubated for 5 min in PBST-10% (v/v) Ponceau with 
rocking, scanned, rinsed in methanol to remove the stain, and then washed in PBST.   
 
2.6.7 Western blotting 
The membrane was  briefly  rinsed  with  PBS with 0.1 % (v/v) Tween  20 (PBST),  and 
blocking was performed with PBST containing 5% Marvel Milk (w/v), for three hours, or 
overnight at 4°C. The membrane was then rinsed in PBST. Incubation with a primary 90 
antibody was performed in block with a suitable amount of primary antibody, for one hour.  
The membrane was then extensively washed for an hour with frequent changes of PBST. 
The membrane was then incubated with a HRP-conjugated secondary antibody in block for 
one hour. The membrane was then extensively washed for an hour with frequent changes 
of PBST. All steps were performed on a flat bed shaker. 
 
2.6.8 Signal detection 
Chemiluminescence detection was performed using the ECL Western Blotting analysis 
system (Amersham Pharmacia) following manufacturer‟s instructions. Equal volumes of 
reagent 1 and reagent 2 were mixed, and added to a sheet of Saran wrap. The filter was 
added protein side down, and incubated for 1 min. The membrane was then wrapped in 
Saran Wrap, added to a cassette, and exposed to ECL film (Amersham Pharmacia), before 
development in an X-OMAT film processor. 
 
2.7 Antibody design and purification 
2.7.1 Antibody design 
Polyclonal antibody epitopes were designed by analysing protein sequence with Abie Pro 
3.0: Peptide Antibody Design and Macvector software. 14mers showing high antigenicity 
were selected, and a cysteine added at the C terminal to facilitate conjugation. Putative 
sites were blasted against the Drosophila proteome, and any showing 5 consecutive amino 
acids  with  identity  against  other  proteins  were  rejected.  Antibodies  were  generated  by 
PickCell Laboratories, using the Express Rabbit 28 day protocol, and subjected to ELISA 
testing  on  peptides  attached  to  Polysorb  plates.  Serial  dilutions  of  rabbit  serum  were 
applied for 2 h at rt. Specific IgGs were detected using gamma-chain specific anti-rabbit 
IgG-HPRO conjugate. 
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2.7.2 Isolation of IgG fraction from immune-serum 
Antibody  was  purified  as  detailed  in  Day,  2005.  A  „HiTrap  Protein  A  HP‟  column 
(Amersham) was flushed with 5 ml 0.1 M glycine pH 2.5, passed through at ~2ml/min, 
then equilibrated with 30 ml of PBS. 5 ml of immune-serum was filtered through a 0.45 
M filter, and then syringed through the column to bind.  The column was washed with 30 
ml of PBS, and the IgG fraction was eluted with 17 ml of 0.1 M glycine, pH 3.0. The first 
2 ml were discarded, and the subsequent 15 ml flow-through was collected in a 50 ml 
Falcon tube containing 1.5 ml 1 M Tris-HCl pH 8.0. The column was then washed with 5 
ml 0.1 M glycine pH 2.5, and stored, sealed, containing ethanol, at 4˚C.  The absorbance at 
280 nm was read to confirm IgG elution, and the IgG eluate was dialysed overnight against 
a large volume of PBS in a Slide-A-Lyzer dialysis cassette (Pierce). 
 
2.7.3 Preparation of affinity columns 
The bottom cap was fitted to a 10 ml polypropylene column (Pierce) and the column filled 
with deionised water. A frit was pushed to the bottom of the column using the plunger 
from a disposable syringe. The water was drained by removing the end cap and 5 ml of 
Sulfolink slurry (Pierce) was added. When the slurry had sedimented, the slurry buffer was 
removed down to the surface of the gel and 2 x 25 ml of 50 mM Tris-HCl, 5 mM Na-
EDTA pH 8.5 was run through the column, with the end cap replaced when the buffer 
reached the slurry. 1 mg of antibody-specific peptide was dissolved in 4 ml of 50 mM Tris-
HCl, 5 mM Na-EDTA, and added to the column. The top cap was added, and the column 
subjected to rotation for 15 min at 4˚C. The column was left upright for 45 min, following 
which the column was drained. 15 ml of 50 mM cysteine in 50 mM Tris-HCl, 5 mM Na-
EDTA was  added to the column, and rotated for 15 min at 4˚C. The column was set 
upright and allowed to settle for 45 min.  The top cap was removed and the top frit fitted 
just above the level of the gel.  The end cap was removed and the column drained. 60 ml of 
1 M NaCl was then run through the column, followed by 50 ml of PBS and then 40 ml of 
0.05 % (w/v) sodium azide in PBS keeping the level above the gel. The end caps were 
fitted and the column stored at 4 
oC until use. 
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2.7.4 Affinity purification of antibodies 
The affinity column was brought to room temperature and the sodium azide was drained. 
The column was equilibrated by passing through 30 ml of PBS and the IgG fraction was 
passed through in 5ml batches.  Next followed a wash with 30 ml of PBS and finally the 
antibody was eluted with 0.1 M glycine, pH 3.0. 12 x 1 ml fractions were collected into 12 
x 1.5 ml  Eppendorfs  containing 100  l  Tris-HCl  pH 8.0.  To determine the  yield  the 
absorbance at 280 nm of each fraction was measured and fractions with readings greater 
than 0.05 were pooled and dialysed overnight  against PBS with 0.01 % (w/v) sodium 
azide.  The absorbance at 280 nm was again taken in order to ascertain the final yield using 
the equation: 
 
Antibody concentration (mg/ml) = O.D 280 x 1.35 mg/ml 
 
Aliquots of the antibodies were made and frozen at -20 
oC until use. 
 
2.7.5 Antibodies generated 
The rabbit polyclonal antibodies generated during the course of this study, the epitope 
chosen, and any additional remarks are listed in table 2.7. 
 
Table 2.7. Antibodies generated during the course of this study, the epitopes used.  
Antibody generated Epitope chosen Remarks
αDG1 PKYEKDFSDKQQIKD
αDG2 FDDYPPDPEGPPPDD Recognises all isoforms
αPDE11 KTKTSQDQEPEEEQQ Recognises all isoforms
αhPDE11Aa QRQTKTKDRRFNDE Recognises DmPDE11-A3 and -A4
αhPDE11Ab SKGEYDWNIKNHRD PDE11-A1, -A2, -A3, -A4, -006, -202, -203, -204
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2.7.6 Antibodies used in this study 
A list of the antibodies used during the course of this study are shown alongside their 
dilution and use in table 2.8.  
 
Table 2.8: Antibodies used in this study 
Antibody used Dilution and use
PDE11-1 rabbit polyclonal 
(αPQNGHGLPFGSYQH)
1: 500 (IP)
PDE11-2 rabbit polyclonal 
(αPTSTQPSDDDNDAD)
1: 500 (IP)
DG1 rabbit polyclonal 1: 500 (IP)
DG2 rabbit polyclonal 1: 500 (IP)
Anti-V5 (mouse monoclonal, Invitrogen)
1:1000 (immunocytochemistry), 1:5000 
(western)
Anti-cMyc (mouse monoclonal, 
Invitrogen)
1:5000 (western)
Anti-GFP (mouse monoclonal, ZYMED) 1:1000 (western)
Alexa FluorÒ568-labelled anti-rabbit IgG 
H & L (goat polyclonal, Molecular 
Probes)
1:500 (immunocytochemistry)
Alexa FluorÒ568-labelled anti-mouse IgG 
H & L (goat polyclonal, Molecular 
Probes)
1:500 (immunocytochemistry)
HRP labelled anti-rabbit IgG H & L 
(donkey polyclonal, Amersham)
1:5000 (western)
HRP labelled anti-mouse IgG H & L 
(sheep polyclonal, Amersham)
1:5000 (western)
Anti-HIS4 HRP-conjugated 1° antibody 
(mouse monoclonal, Biorad)
1:5000 (peptide array)
 
 
2.8 Immunocytochemistry on tubules 
Protocol from {MacPherson, 2001}. Malpighian tubules from 10 flies were dissected in 
Schneider‟s medium and transferred to a 1.5 ml eppendorf containing 100 l of PBS. This 
was aspirated with care taken not to disturb the tubules. 200 l of fixation solution (4 % 
(w/v) paraformaldehyde in PBS) was then added for 30 min. The fixation solution was 
removed, and the tubules were washed three times in PBS for 30 min each wash, following 94 
a single quick wash.  The tubules were then permeabalised for 30 min with PBS, 0.5% 
triton (v/v), 0.15M NaH2PO4, 0.1% Sodium Azide (PBTA) (w/v), changing every 10 min. 
The tubules were then incubated in PBS, 0.3 % (v/v) Triton X-100, 0.5 % (w/v) BSA 
(PAT) for 3 h at RT. Hybridisation in 1° antibody (at an appropriate concentration in PAT) 
was carried out overnight at 4°C. Tubues were then washed 4 x in PAT for 2 h, and then 
blocked with PAT for 3 h. Incubation with 2° antibody was performed in PAT for 1 h to 
overnight. The tubules were washed three times with PBTA for 30 min each wash. Where 
nuclei staining was required, the tubules were incubated with DAPI (500 ng/ml in PBS) for 
2 min, and washed three times with PBTA for 30 min each wash. Finally, the tubules were 
then washed 2 x 10 min in PBS. All solutions were filter sterilised using a 0.22 μm filter. 
 
2.8.1 Mounting 
Tubules were mounted in glycerol mounting medium. The tubules were incubated in 20 % 
glycerol in PBS for 15 min. Around 2mm of a 1ml pipette tip was cut off, and the tubules 
were then pippetted into a dish with 50% glycerol. Slides or glass-bottomed dishes had 
80% glycerol added, and the tubules transferred to these. Where coverslips were required, 
they were sealed with glycerol/gelatin (Sigma). 
 
2.9 Survival assays 
2.9.1 Septic challenge with a needle 
A  single  pellet  of  freeze-dried  pellet  of  E.  coli  (Selectrol  freeze-dried  pellets,  TCS 
biosciences) was added to 5 ml LB-broth, and grown overnight at 37˚C with shaking to 
stationary phase. E. coli was harvested by centrifugation, the LB-broth removed, and the 
pellet resuspended in a small volume of B broth. 5-7 day old flies were separated into vials 
containing 30 flies each. These were anaesthetised on the gas pad. A thin-bore needle (BD 
Microlance ™ 3, 26 G x ⅝) was dipped into the bacterial culture; the flies were stabbed 
just below the first abdominal turgite. Control stabbing with a sterile needle was carried 
out on an equal number of flies to monitor stabbing-induced death. Survival was monitored 
at least daily. Flies were tipped into fresh vials daily. 
 95 
2.9.2 Septic challenge with microinjection 
A  single  pellet  of  freeze-dried  pellet  of  E.  coli  (Selectrol  freeze-dried  pellets,  TCS 
Biosciences) was added to 5 ml LB-broth, and grown at 37˚C with shaking to an OD600 of 
2.0. The E. coli was harvested by centrifugation, and resuspended in an equal volume of 
PBS. Flies were injected with 69 nl bacteria using a Nanoject II (Drummond Scientific) 
mounted to a micromanipulator. Microinjection needles (N-51-A glass capillaries) were 
pulled using a moving coil microelectrode puller (Campden Instruments limited). The tip 
of the needle was broken by touching to the flat plane of a pair of forceps, and the needle 
was backfilled with mineral oil prior to the uptake of bacteria. Where possible, the same 
needle was used for every fly. The site of injection was just below the first abdominal 
turgite. 30 flies/genotype were used, and transferred daily to fresh vials. 
 
2.10 Enzymatic assays 
2.10.1  [Ca
2+
]i measurements in aequorin expressing tubules 
Measurement  of  [Ca
2+]i  in  the  Malpighian  tubules  was  performed  using  transgenically 
expressed  aequorin,  following  the  method  detailed  in  {Rosay,  1997}.  To  reconstitute 
intracellular aequorin, 30 tubules from 5-7 day old adults were dissected in Schneider's 
medium and placed in 160 l of Schneider‟s solution with coelenterazine added to a final 
concentration of 2.5 M.  Samples were then incubated in a rack wrapped in tin foil for 3 
h. Bioluminescence recordings were carried out using an LB9507 luminometer (Berthold 
Wallace).  To monitor tubule condition and control for transients initiated by the injection 
process itself, samples were 'mock' injected with 25 l of Schneider's, before injection with 
the appropriate agonist at the desired concentration, and bioluminescence recorded for 20 
min.  Tubules were then disrupted with 300 l lysis solution (1% (v/v) Triton X-100, 100 
mM CaCl2); integration of total counts allowed the calculation of total aequorin levels. 
Ca
2+ concentrations for each time point in an experiment were calculated by backward 
integration,  using  a  program  written  in  Perl  based  on  work  previously  described  by 
{Button, 1996}, and plotted using Excel or GraphPad prism. 
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2.10.2  PDE assays 
PDE assays were performed as per the protocol detailed in {Day, 2005}.Samples were 
prepared as above, in KHEM buffer (50 mM KCl, 10 mM EGTA, 1.92 mM MgCl2, and 50 
mM HEPES), containing protease inhibitor cocktail (Sigma) at a 1:100 dilution. Protein 
samples were added at equal concentrations to 1.5 ml eppendorfs in a total of 50 μl on ice, 
with two control tubes containing 50 μl KHEM buffer for each substrate concentration. A 
2  x  stock  solution  was  generated  by  adding  the  appropriate  amount  of  3‟,  5‟-cyclic 
adenosine monophosphate, or 3‟, 5‟-cyclic guanosine monophosphate (sigma) to 20 mM 
Tris-Hcl, 10 mM MgCl2 pH 7.4. To this solution, [
3H] cGMP or [
3H] cAMP was added at 
3 μCi/ml. 50 μl of substrate was added to the protein samples, and mixed by flicking the 
tubes. Phosphodiesterase activity was stimulated by incubation in a 30˚C water bath for 20 
min. Samples were transferred to a boiling water bath for 2 min to denature the enzyme, 
and were then cooled on ice. 25 μl of snake venom (diluted 1:10 from a 10 mg/ml stock 
solution (Sigma)) was added to each sample, the tubes flicked to mix, and transferred to 
the 30˚C water bath for a further 10 minutes, to remove phosphate groups from AMP or 
GMP. Dowex ion exchange resin (Sigma) diluted 1:1 in water was further diluted 1:2 with 
ethanol, and 400 μl was added to each sample. Tubes were vortexed, incubated on ice for 
15 min, and vortexed again. Tubes were then subjected to centrifugation at 13,000 x g, 4˚C 
for 2 min, and 150 μl of supernatant was removed from each sample, and added to a fresh 
eppendorf containing 1 ml Ecoscint ORIGINAL scintillation fluid (National Diagnostics), 
with a further two “substrate” eppendorfs generated by adding 50μl substrate. Each tube 
was vortexed to homogeneity, and added to a beta scintillation counter set to record 
3H 
counts for 1 min / sample. Counts should not exceed 18,000 counts / min after subtraction 
of blanks to represent less than 20% of substrate hydrolysed. 
 
2.10.3  Calculation of PDE activity and kinetic parameters 
Specific PDE activity was calculated using the following formula: 
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Where  
A = specific PDE activity (pmol cGMP or cAMP/mg/min) 
C = sample value (CPM) 
B = blank value (CPM) 
S = substrate value (CPM) 
N = cAMP or cGMP in substrate (moles) 
P = protein (g) 
t = time (min) 
 
2.24 Cyclic GMP-dependent protein kinase assay 
 
The cyclic GMP-dependent protein kinase activity of Malpighian tubules was determined 
by  direct  measurement  of  radiolabelled  phospho-transfer  to  a  short  peptide  sequence 
substrate,  homologous  to  sequence  of  a  bovine  PDE  5  cGK  phosphorylation  site,  as 
detailed in {MacPherson, 2004}.  Approximately 400 tubules per sample were dissected 
and homogenised on ice in 20 l of homogenisation buffer (20 mM Tris (pH 7.5), 250 mM 
sucrose,  2  mM  EDTA,  100  mM  NaCl,  50  mM  -mercaptoethanol,  1:100  dilution  of 
protease  inhibitor  cocktail  (Sigma)).  The  protein  concentration  of  each  sample  was 
measured by Bradford assay, and standardised by addition of homogenisation buffer.  Two 
stock solutions of kinase assay buffer were prepared fresh, with and without 1 M cGMP. 
This comprised 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2 mM EGTA, 10 mM magnesium 
acetate,  1  nM  PKA  inhibitor  (TYADFIASGRTGRRNAI-NH2),  20  M  ATP,  1  mM 
zaprinast, 1 M sildenafil, 1 mM DTT, 0.2 g/ml GLASS-tide (RKRSRAE, Calbiochem), 
0.5-2  l  of  [-
32P]  ATP  (370  MBq/ml,  to  an  approximate  specific  activity  of  4000 
cpm/pmol ATP). 
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Reaction samples were generated by the addition of 40  l kinase assay buffer to 5  l 
(approximately 30 mg of protein) homogenised tubule sample in 500 μl eppendorfs. Two 
sets were generated, one with and one without cGMP in the reaction buffer. Sample blanks 
consisted of 40 μl reaction buffer and 5 μl homogenisation buffer.  Kinase activity was 
stimulated by incubation for 30 min in a 30˚C block, after which 35 μl of each sample was 
spotted onto individual squares of P81 paper (Whatman, Maidstone, Kent) labelled with 
pencil, and allowed to dry on a tray with benchtop paper, facing absorbent side up under a 
plastic shield for 45 min. To calculate specific activity of the radiolabelled ATP at the end 
of the reaction, 5 μl of several random samples (representative of 1/9 total count) were 
spotted onto individual squares of P81 paper („total count‟), and allowed to dry as above. 
 
The reaction samples were washed for 3 x 5 min in 75 mM phosphoric acid, then washed 
once for 15-20 s in ethanol and allowed to dry.  All squares of paper, including the total 
count  samples,  were  then  transferred  to  scintillation  vials,  with  the  addition  of  3  ml 
scintillation fluid and counted in a scintillation counter (Beckman, High Wycombe, UK) 
set to record 
32P for 60 s. 
 
Specific  activity  of  [-
32P]  ATP  was  calculated  (9  x  mean  c.p.m.  of  total  count 
squares/[ATP] in reaction) and used to calculate protein kinase activity (pmol ATP min
-1 
g
-1 protein) as follows: 
kinase activity = γ-
32P cpm (total) x 45/5)  (45 initial radiation mix put in; 5 amount of                                     
                  (usually 20) μM moles ATP            radiation mix added to substrate paper)                         
0.37 mBq usually used. 
= 1μL / ml 
 ½ life 14 days; double this amount/14 days 
Activity =           (γ-
32P cpm – blank cpm x 35) 
               Specific activity x total protein x time x 45 (assay buffer amount)  
 
Where  99 
C = sample counts per minute 
B = blank counts per minute 
V = sample volume on filter  
R = reaction time in minutes 
P = protein amount in g 
S = specific activity  
 
2.11 Peptide arrays 
The peptide array protocol given is based upon {Bolger, 2006}. 
2.11.1  SPOT synthesis of peptides 
Peptide libraries comprising amino acid 25mers were generated on a Whatman 50 cellulose 
membrane  support  by  automatic  SPOT  synthesis  using  Fmoc  (9-
fluorenylmethyloxycorbonyl)  chemistry  with  the  Autospot  Robot  ASS  222  (Intavis 
Bioanalytical Instuments).  
 
2.11.2  Expression of HIS6 tagged proteins 
HIS6  tagged proteins  were  generated by  transfection of the expression vector pET-28c 
(cloned  with  appropriate  ORF)  into  BL21  (DE3)  pLysS  competent  cells  following 
manufacturer‟s instructions. Cells were thawed on ice, mixed, and 100 μl aliquots were 
generated in pre-chilled 1.5 ml culture tubes. To each tube, 1.7 μl of β-mercaptoethanol 
was added and mixed. 50ng of DNA was then added to each tube, and flicked to mix. 
Tubes were stored on ice for 10 min, and heat-shocked in a 42°C water bath for 45–50 s in 
a water bath. Tubes were then transferred to ice for 2 min. 900μl of (4°C) SOC medium 
was added to each transformation reaction, and the tubes were incubated for 60 minutes at 
37°C on a horizontal shaker at 225rpm. Cells were plated on antibiotic plates, and left, 
inverted, at 37˚C overnight. 100 
2.11.3  Analytical-scale growth 
 Individual cultures were added to 3 ml  L. Broth, and grown to an OD600 of ≥0.6 – ≤1.0. 
From this 3 ml, 1 ml was removed, from which 100 μl was centrifuged at 18,000 g for 3 
min and the pellet used as a non-induced control, and 900 μl were used to generate a 
glycerol  stock  as  detailed  in  materials  and  methods.  The  remaining  2  ml  culture  was 
induced by the addition of IPTG (typically 0.1 mM) and incubated for a further 2 h with 
shaking at 37˚C. Two 1 ml aliquots were centrifuged at 18,000 g. One of these pelltets was 
lysed in IEPAL lysis buffer, and one lysed in native lysis buffer using L3 sonication, both 
with protease inhibitor, and lysed on ice. These were run alongside the non induced control 
(also lysed in IGEPAL with an identical dilution factor) on an SDS page gel, and western 
blotting was performed with the appropriate antibody. All conditions were individually 
optimised for each fusion protein. 
2.11.4  Purification-scale growth 
Following optimisation of the growth and induction protocol, growth was performed on a 
large scale to facilitate protein purification. Growth was performed as above, except the 3 
ml culture was used a starter culture. From this, 100 μl was added to 50 ml L. Broth 
containing the appropriate antibiotic, and was incubated at 37˚C with shaking to an OD600 
of ≥0.6 – ≤1.0. The culture was induced by the addition of IPTG (typically 0.1 mM) and 
incubated for a further 2 h with shaking at 37˚C. Cells were harvested by centrifugation at 
3,000 x g for 5 min at 4˚C. 
 
2.11.5  Native cell lysis 
The 50 ml cell pellet was resuspended in 8 ml native lysis buffer. 8 mg lysozyme was 
added to the cell pellet, and incubated on ice for 30 min. Cells were lysed by L3 sonication 
on ice. To reduce viscosity, 10 μg/ml RNase A and 5 μg/ml DNase I (Invitrogen) were 
added, and mixed. Insoluble material was pelleted by centrifugation at 3,000 x g for 15 
min, at 4˚C, and the supernatant used for protein purification. 
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2.11.6  Preparation of Ni
2+/NTA columns 
HIS6 tagged peptides were purified using 2 ml Ni
2+/NTA agarose (Invitrogen) immobilised 
in a disposable chromatography column, under native conditions, following manufacturer‟s 
instructions. 10 ml Ni
2+//NTA Columns were prepared by pipetting 1.5 ml of well-mixed 
resin into a 10-ml Purification Column with a frit at the bottom. The resin was allowed to 
settle, and the supernatant was aspirated.  6 ml distilled water was added to the column, 
and the resin resuspended by tapping the column. The resin was allowed to settle, and the 
supernatant again removed. 6 ml Native Binding Buffer (50 mM NaH2PO4, pH 8.0, 0.5 M 
NaCl) was then added to the column, and the resin resuspended by tapping the column. 
When the resin had settled, the supernatant was removed and the column stored at 4˚C 
until use.  
 
2.11.7  Purification of HIS6 tagged peptides 
8 ml lysate was added. The column was rotated at 4˚C for 30–60 min. The resin was 
allowed to settle, and the supernatant aspirated, and stored for SDS-PAGE analysis. The 
resin was then washed with 8 ml Native Wash Buffer (50 mM NaH2PO4, pH 8.0, 0.5 M 
NaCl, 10 mM Imidazole), and allowed to settle. The supernatant was aspirated and again 
saved for SDS-PAGE analysis. This wash was repeated three times. The column was then 
clamped in a vertical position, and the bottom cap of the column was removed. The protein 
was eluted with 8–12 ml Native Elution Buffer (50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 
250 mM Imidazole), which was collected in 1 ml fractions. These were analysed by SDS-
PAGE, and stored at 4˚C with protease inhibitors until use. 
 
2.11.8  Overlay experiments 
The array was bathed in ethanol for 5-10 min, and equilibrated in TBST (50mM Tris, 150 
mM NaCl 0.1% Tween-20 (v/v),pH 7.5) in a 10 min wash on a flat bed shaker. The array 
was then blocked in 5% Marvel-TBST (w/v), 0.1% Tween-20 (v/v) for two hours. After a 
brief rinse with TBST, recombinant HIS6 tagged proteins were diluted at 10 μg/ml in 1% 
Marvel-TBST  (w/v)  0.1%  Tween-20  (v/v),  applied  to  the  array  in  a  sealed  bag,  and 
incubated overnight with shaking at 4°C. Following 3 x 15 min washes with TBST, an 102 
anti-HIS4 HRP-conjugated 1° antibody (Biorad) was applied to the array, diluted 1:5000 in 
1% block. This was incubated in a sealed bag at 4°C for two hours. Following 3x15 min 
washes  in  TBST,  the  array  was  treated  with  ECL  as  in  an  Immunoblot,  and  several 
different exposures were obtained.  
 
2.11.9  Stripping arrays 
Stripping buffer (0.31g DTT 2g SDS 0.75g Tris-HCl in 100ml H20, pH 6.8) was pre-heated 
to 70°C and applied to the array, face up in a hybridisation tube.  The arrays were bathed 
with rotation in a hybridisation oven set to 70°C for 30 min. The stripping buffer was 
removed, and the array was briefly rinsed twice, then for 2 x 10 min, in TBST. The array 
was then removed, dried on blue roll on the non-protein side, and stored, sealed, at 4°C; 
arrays  were  stripped  and  reused  a  maximum  of  4  times.  When  needed  for  reuse,  the 
membranes were bathed in ethanol and incubated in TBST as before. 
 
2.12 Phylogenetic analysis 
Phlogentic  analysis  was  performed  using  ClustalW  alignment  in  MacVector,  using  a 
Gonnet matrix with the default settings (open gap penalty = 10, extend gap penalty 0.1, 
delay divergent 40%, using end gap separation, residue specific penalties and hydrophilic 
penalties). A best tree phylogram was generated using neighbour joining tree building, and 
uncorrected “p” distance calculation. As a control bootstrap analysis (1000 repetitions) was 
performed. 
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3.1 Summary 
This chapter describes the work done on the  Drosophila melanogaster dual specificity 
phosphodiesterase PDE11RA. The PDE11 family was discovered in 2000. It is  a dual 
specificity phosphodiesterase, but the in vivo function of the enzyme is currently not well 
understood.  Drosophila  melanogaster  utilises  cAMP  and  cGMP  signalling  to  control 
numerous vital processes, which are well studied in the organism. As such, Drosophila 
should prove a useful tool to reveal the function in vivo function of PDE11. 
Difficulties were encountered in proving that DmPDE11RA was in fact a bona fide PDE, 
which was likely explained by Flybase release 5.2 (http://flybase.org/), which replaced the 
RA transcript with two newly predicted transcripts, RB and RC, as detailed in chapter four. 
The aims of my PhD when this enzyme was shown to be falsely predicted did not change, 
save the need to clone the newly predicted RB and RC isoforms, and from these repeat any 
necessary subcloning in order to perform subsequent experiments. As such this chapter 
essentially serves as a blueprint for the work done on the RB and RC transcripts, although 
limited time dictated that some experiments be prioritised, and other experiments were 
replaced  because  they  did  not  appear  to  work,  or  had  been  superseded  by  alternative 
techniques. 
3.2 Introduction  
Phosphodiesterases  are  the  only  known  enzyme  responsible  for  cyclic  nucleotide 
hydrolysis, and as such are of great importance in the modulation of cyclic nucleotide 
signalling. The PDE11 phosphodiesterase family is the most recently discovered of the 
PDEs.  Discovered  in  2000  (Fawcett  et  al.,  2000a;  Hetman  et  al.,  2000;  Yuasa  et  al., 
2000b),  its  function  is  not  well  understood.  It  is  a  dual  specificity  enzyme,  with  four 
isoforms in human, and one in Drosophila melanogaster.  
Drosophila  has  been  used  to  great  effect  in  the  study  of  PDE4,  known  as  dunce  in 
Drosophila.  Furthermore,  many  phenotypes  in  Drosophila  have  been  linked  to  both 
cAMP-, and cGMP-dependent processes and enzymes. Yet until 2005, only two PDEs had 
been identified in Drosophila, PDE1, a Ca
2+/Calmodulin sensitive, dual specificity PDE 
(Walter  and  Kiger,  1984),  and  PDE  4,  dunce,  a  cA-PDE  (Davis  et  al.,  1989).  Work 
undertaken  in  the  Dow/Davies  lab  revealed  that  Drosophila  expresses  six  of  the  PDE 105 
families; PDE 1, PDE 4, PDE6 (cG-PDE), PDE 8 (predicted cA-PDE), PDE 9 (predicted 
cG-PDE), and PDE11 (dual specificity PDE) (Day et al., 2005). These genes showed high 
sequence similarity with their mammalian counterparts, with amino acid identity ranging 
from 26 – 47% (34 – 66% similarity). However sequence identity in the catalytic domain 
was higher at 51 – 77% sequence identity (69 – 96% similarity). The lower number of PDE 
genes in Drosophila should result in lower redundancy than mammalian systems, and thus 
make  the  elucidation  of  function  easier.  These  genes  show  widespread  expression 
(http://www.flyatlas.org/), underlying their importance (table 3.1). 
Table 3.1: Tissue expression profiles of the Drosophila phosphodiesterases. Data from 
(Chintapalli et al., 2007)   
PDE1 dunce PDE6 PDE8 PDE9 PDE11
Tissue Enrichment
Brain 0 4.1 7.3 5.4 8.9 2.5
Head 0.4 1.3 2.5 1.9 4.6 1.2
Eye 0.23 1.83 0.91 1.79 6.55 3.09
Thoracicoabdominal ganglion 0 3.3 8.9 3.3 13 1.5
Salivary gland 0.06 6.07 2.23 1.45 2.96 2.53
Crop 0 0.9 0.8 2.4 2.9 1.7
Midgut 6 0.8 0.5 1.9 0.6 1.8
Tubule 1 1.5 2.1 3.7 2 1.5
Hindgut 1.8 0.7 2.1 3.5 0.8 2.7
Heart 0.9 2.37 1.34 2.36 6.21 3.14
Fat body 1.36 0.79 3.08 2.2 5.15 0.92
Ovary 0 1 0.1 0.5 0.4 1.8
Testis 0 0.2 0.1 2.9 1.8 0.4
Male accessory glands 0.5 0.8 1.4 1.5 1.6 0.7
Virgin spermatheca 1.56 0.79 4.55 0.69 7.17 0.99
Mated spermatheca 1.49 0.9 3.9 0.75 4 1.04
Adult carcass 0.6 1.6 1.3 2.3 3.9 1
Larval CNS 0.01 1.87 1.82 2.46 2.43 0.75
Larval Salivary gland 1.12 0.8 0.28 0.47 4.21 1.66
Larval midgut 6.81 0.86 0.11 1.79 2.4 0.86
Larval tubule 1.1 0.7 0.3 3.1 3.8 1.7
Larval hindgut 2.15 0.89 0.49 2.31 1.89 1.63
Larval fat body 0.2 0.5 0.3 1.1 4.5 0.7
Larval trachea 0.05 1.75 0.14 3.48 5.35 1.48
Larval carcass 0.01 3.49 2.58 3.25 0.99 0.73
S2 cells (growing) 0 1.05 0.01 6.78 3.67 2.31
Whole fly 1 1 1 1 1 1  
The number of cG-PDEs represented above is reflected in the numerous processes that are 
modulated by cGMP in Drosophila. These include fluid secretion of the Malpighian tubule 106 
(Davies et al., 1995), feeding behaviour (Osborne et al., 1997), immunity (McGettigan et 
al., 2005), hypoxia (Dijkers and O'Farrell, 2009), and nervous system signalling (Bicker, 
1998). 
3.3 DmPDE11RA 
CG34341 encodes DmPDE11RA, a gene spanning 9kb at position 37A1 on chromosome 2 
(Figure 3.1).  
Figure  3.1:  Ensemble  CG34341/DmPDE11RA  gene  model. 
http://www.ensembl.org/Drosophila_melanogaster/geneview?gene=CG34341.  Accessed 
04.03.2008.  
 
The expression profile of DmPDE11 is shown in table 3.2. 
 
 
 
 
 
 
 
 107 
Table 3.2: PDE11 expression in Drosophila melanogaster. Table showing enrichment of 
DmPDE11 expression in each tissue when compared to whole fly (Chintapalli et al., 2007). 
PDE11
Tissue
Brain 2.5
Head 1.2
Eye 3.09
Thoracicoabdominal ganglion 1.5
Salivary gland 2.53
Crop 1.7
Midgut 1.8
Tubule 1.5
Hindgut 2.7
Heart 3.14
Fat body 0.92
Ovary 1.8
Testis 0.4
Male accessory glands 0.7
Virgin spermatheca 0.99
Mated spermatheca 1.04
Adult carcass 1
Larval CNS 0.75
Larval Salivary gland 1.66
Larval midgut 0.86
Larval tubule 1.7
Larval hindgut 1.63
Larval fat body 0.7
Larval trachea 1.48
Larval carcass 0.73
S2 cells (growing) 2.31
Whole fly 1 
 
Drosophila PDE11 shows widespread expression in the fly, with enrichment in brain, eye, 
salivary  gland,  heart,  gut  tissues,  and  Malpighian  tubules  (Chintapalli  et  al.,  2007). 
Likewise, H. sapiens PDE11 shows widespread expression, and is enriched in the pituitary 
gland, the salivary gland, testis, liver and kidney (D'Andrea et al., 2005; Fawcett et al., 
2000b). 
 
3.3.1 The Expressed Sequence Tag SD13096 encodes the entire 
PDE11RA ORF 
When attempts to clone the full length ORF of PDE11RA were undertaken (Day, 2005), 
two incomplete Expressed Sequence Tags (ESTs) were available that included sequence 
extending from approximately half way through the ORF through to the poly-A tail and 108 
3‟UTR. Attempts to clone the 5‟ end of the gene using Reverse Transcriptase-Polymerase 
Chain Reaction (RT-PCR) and Rapid amplification of 5' complementary DNA ends (5‟ 
RACE) on the available ESTs failed. The EST SD 10396 was released by the BDGP EST 
sequencing program concurrently with these efforts. SD 10396 is a 5.8Kb EST, containing 
sequence  present  in  the  previously  released,  incomplete  DmPDE11RA  ESTs,  but  also 
incorporating  a  5‟  UTR,  and  an  in-frame  start  codon  within  two  novel  5‟  exons.  A 
Northern  blot  of  PDE11RA  produced  one  band  of  approximately  5.8kb;  as  the  sizes 
matched it was accepted that SD13096 encodes the entire DmPDE11RA ORF. However, 
expression of full-length protein in S2 cells was not achieved (Day et al., 2005).  
 
3.3.2 DmPDE11RA encodes a protein of the predicted size 
DmPDE11RA  was  sub-cloned  from  the  full  length  EST  SD13096  into  Drosophila 
Expression System (DES) pMT/V5-His-TOPO vector in-frame with the C-terminal V5 and 
His tags (primers used listed in materials and methods table 2.5). Two constructs were 
generated;  one  full  length  and  one  N  terminal  construct  extending  to  the  end  of  the 
catalytic  domain.  These  constructs  were  expressed  in  Drosophila  S2  cells  to  verify 
expression (figure 3.2).  
 
Figure 3.2: Western analysis of pMT/V5-His DmPDE11RA transfected S2 cells. Lanes 
1 + 2: N terminal half of DmPDE11RA-V5 (expected size 95kDa) Lanes 3 + 4: Full length 
DmPDE11RA-V5 (expected size: 173kDa). Antibody used anti-V-5 mouse monoclonal.  
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When S2 cell lysate was subjected to western analysis, the full length protein (lanes three 
and four), predicted to be 173kDa, showed one faint band at approximately the correct 
size, and an equally faint band around 60KDa, which potentially represents a breakdown 
product.  The  faintness  of  the  band  can  be  attributed  to  an  extremely  low  transfection 
efficiency  of  less  than  5%,  determined  by  immunocytochemistry  of  anti-V5  antibody-
probed  transiently  transfected  S2  cells,  where  ≥95%  of  DAPI-stained  cells  showed  no 
fluorescence. The N terminal construct was predicted to yield a protein of 95kDa. One 
band was produced at approximately this size, with two additional bands, one over 100kDa 
and  one  around  80kDa.  The  larger  band  may  be  explained  by  post  translational 
modification,  such  as  phosphorylation.  The  smaller  band  may  be  explained  by  an 
alternative in-frame start codon, 267bp into the ORF. Alternatively, as PDEs usually run to 
a larger size than that predicted under SDS-PAGE analysis, bands other that the largest 
may again represent breakdown products.  
 
3.3.3 DmPDE11RA shows cytoplasmic localisation 
Full length DmPDE11RA tagged with a V5 epitope tag was transiently transfected into S2 
cells.  These  were  subjected  to  immunocytochemistry  in  order  to  determine  protein 
localisation (figure 3.3).  
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Figure  3.3:  Subcellular  localisation  of  DmPDE11A-V5  in  S2  cells.  S2  cells  were 
transiently  transfected  with  pMT/V5-His  DmPDE11RA.  Subcellular  localisation  of  the 
protein was ascertained by staining with anti-V5 monoclonal antibody, TRITC secondary 
(Red). Nuclei were stained with DAPI (blue). Two examples of transfected cells are shown 
(A and B), and an untransfected cell is shown in C, where immunocytochemical techniques 
used were identical. 
A 
 
B 
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The protein showed cytosolic localisation in S2 cells. Levels of expression were judged to 
be low, both in terms of cellular protein level, and transfection efficiency. Untransfected 
cells showed no visible background expression; one such example is shown in figure 3.3C. 
 
3.3.4 Analysis of full length DmPDE11RA 
Previous attempts to express full length DmPDE11RA in S2 cells had not produced protein 
on western blots (Day et al., 2005). The catalytic domain of DmPDE11 was expressed in 
S2 cells, and showed no cG-PDE activity above basal, and cA-PDE activity at 1, 2, and 
4μM of substrate, but this activity fell at higher concentrations (Day, 2005). Following 
this, DmPDE11 was verified as a bona fide dual specificity PDE by cA- and cG-PDE 
assays  performed  on  immunoprecipitated  DmPDE11  from  head  lysate,  using  specific 
antisera (Day et al., 2005). This data is summarised in appendix 2. As shown above, in my 
hands the construct yielded expressed protein in western blots and ICC. As such, cAMP 
and cGMP PDE assays were performed on transiently transfected S2 cells with the full 
length pMT/V5-His DmPDE11RA construct. Initial experiments to ascertain an effective 
concentration  of  cAMP  and  cGMP  for  use  in  PDE  assays  on  DmPDE11RA,  and  a 
construct expressing a truncation of DmPDE11RA, from the N terminus to the end of the 
catalytic  domain,  were  performed.  When  compared  to  control,  DmPDE11RA 
overexpressing S2 cells showed no significant increase in either cA-, or cG-PDE activity 
(data not shown). 112 
 
Following this, I surmised that S2 cells may lack factors required for either the activation 
or stabilisation of DmPDE11RA. DmPDE11RA contains 4 putative cGK phosphorylation 
motifs.  To  identify  whether  DG2P1  or  DG2P2  would  either  phosphorylate,  thereby 
modulating  DmPDE11  function,  or  stabilise  DmPDE11  by  association,  I  co-expressed 
these with DmPDE11 in S2 cells, and performed cA- and cG-PDE assays (figure 3.4). 
 
Figure  3.4:  DmPDE11A  does  not  show  cG-  or  cA-PDE  activity  when  transiently 
transfected in S2 cells, and is not stimulated by DG2. cG- (A) and cA- (B) PDE assay 
on transiently transfected S2 cell lysate using 1μM substrate in each case. In order to aid 
comparison, data is expressed as % cN-PDE activity of mock transfected S2 cell, where 
(A) mock = 23.8 pmol cGMP/mg/min, and (B) mock = 32.4 pmol cAMP/mg/min. N=1 
       A                                                             B 
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When compared to control, DmPDE11RA overexpressing S2 cells showed no significant 
increase in either cA-, or cG-PDE activity, as found previously. Co-expression of either 
DG2P1 or DG2P2 with DmPDE11 drastically reduced both cA- and cG-PDE activity. This 
data  should  be  considered  preliminary,  as  only  one  replicate  was  performed  in  either 
experiment,  and  cGK-only  transfected  S2  cells  were  not  assayed.  As  these  were  only 
transient transfections, a large number of cells would have unaltered PDE activity. This 
suggests that in those cells which do express cGK, endogenous PDE activity is massively 
reduced,  in  turn  suggesting  that  the  over-expressed  cGK  modulates  phosphodiesterase 
activity or protein levels. The experiment was not repeated, as it mirrors a finding in flies 
overexpressing  DG2P1  and  DG2P2  in  tubule  principal  cells,  which  show  a  drastic 
reduction in endogenous PDE activity (Macpherson and Day, 2004). 113 
3.4 C42  driven  DmPDE11  RNAi  does  not  significantly 
affect cA-PDE activity in tubule  
In order to measure the effect on cA-PDE activity in the tubule, DmUAS-PDE11 RNAi 
(line 9), c 42, and DmUAS-PDE11 RNAi (line 9)/c42 progeny were aged upon eclosion to 
5-7 days, and the tubules were excised and homogenised. A cA-PDE assay was performed 
with 3 biological replicates, using 2 uM cAMP, and 3 μCi/ml [
3H] cAMP (figure 3.5).  
 
Figure 3.5: C42 driven DmPDE11 RNAi does not significantly affect cA-PDE activity 
in  the  tubule.  50  Malpighian  tubules  from  DmUAS-PDE11  RNAi  (line  9),  c42,  and 
c42/DmUAS-PDE11 RNAi (line 9) progeny were assayed for cA-PDE activity at 2M 
cAMP  in  biological  triplicate.  Specific  cA-PDE  activity  given  in  pmol  cAMP/mg 
protein/min. 
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There  was  no  significant  change  in  cA-PDE  activity  between  parents  and  progeny. 
Reasons for this are unknown, although 2μM is below the Km of 18.5 ± 5.5M ascertained 
from IP of head lysate. However the catalytic domain, expressed in S2 cells, only yielded 
cAMP-specific PDE activity at concentrations of between 1 M and 4 M of cAMP, hence 
the use of 2M. Counts were around 15000, close to the 18000 maximum acceptable in 114 
this  assay.  Repeat  with  higher  substrate  concentration  (with  a  shorter  30
◦C  incubation 
period  to  reduce  activity  and  thus  counts)  may  yield  different  results,  and  would  be 
desirable. The complementary cG-PDE assays were not performed, as replicates of the cA-
PDE assay were carried out instead with available tissue lysate. 
A PDE11 deletion line (DmPDE11∆121) in our possession also gave no significant change 
in  cA-PDE  activity  when  midgut  was  excised  and  assayed.  However  cG-PDE  assays 
revealed a large reduction when head lysate was assayed (Sebastian, 2009).  
 
3.4.1 Transgenic tools for the study of DmPDE11 
3.4.1.1  Q-PCR to validate the knockdown of DmPDE11 by RNAi 
Two DmPDE11 RNAi stocks were generated by Day, 2005, labelled DmPDE11 RNAi line 
1 and DmPDE11 RNAi line 9. These were targeted against the same sequence, but differed 
in the insertion point of the pWIZ PDE11 transgene. When DmPDE11 RNAi were crossed 
to the ubiquitous driver line Act5cGAL4, crosses were ~90% lethal at room temperature. 
As such knock down was validated by crossing DmPDE11 RNAi with the principal cell 
driver c42. c42/DmPDE11 RNAi line 1 progeny tubule cDNA and parental strains were 
subjected to Q-PCR analysis. Progeny showed a knockdown of 69% compared to parental 
controls (Aitcheson, 2006). However, the melting curve showed two distinct peaks, and 
thus two products were produced. New primers were designed, and Q-PCR was performed 
using c42/PDE11 RNAi (line 9) and parental strain tubule cDNA; this Q-PCR showed a 
knockdown of 34%, and gave a single product of the predicted size (figure 3.6 A and B). 
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Figure 3.6: Q-PCR to determine knock down of PDE11 RNAi (line 9). (A) Q-PCR 
performed on cDNA from excised tubules, using primers specific to the C-terminal of 
DmPDE11.  cDNA  biological  triplicate  from  PDE11  RNAi  (line  9)  parent,  c42  GAL4 
parent (drives expression in the principal cell of the Malpighian tubule,) and c42/PDE11 
RNAi (line 9) progeny. Significance to a P value of <0.01. Analysis performed using 1-
way ANOVA. (B) Melting curve for a single well/product for PDE11RNAi q-PCR: Upper 
melting curve (Aitcheson) shows two distinct peaks; lower melting curve relating to this 
Q-PCR shows a single peak and thus a single product. 
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Q-PCR  using  the  new  primers  for  line  1  has  yet  to  be  repeated.  c42  drives  GAL4 
expression  in  principal  cells,  yet  Q-PCR  of  tubule  cDNA  will  amplify  DmPDE11 
transcripts from all cell types in the tubule. In order to determine total knockdown, Q-PCR 
would have to be performed on cDNA using a high level ubiquitous driver crossed to 
DmPDE11 RNAi. 
 
3.4.2 Phenotype screen 
As mentioned above, ubiquitous knock down of DmPDE11 using the pWIZ RNAi line 9 
results in ~90% lethality at the larval stage when crossed to the ubiquitous driver Actin 
GAL4,  consistent  with  widespread  expression  pattern  of  DmPDE11.  Additionally,  the 
larvae show delayed eclosion by a day. Upon eclosion males display a green abdomen 
usually present in 10 day plus males. However upon dissection organs appeared normal in 
colour. 
 
Following this result, PDE11 RNAi (line 9) was crossed to several tissue-specific GAL4 
drivers, in order to screen for phenotypes (table 3.3). 
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Table 3.3: Screen for phenotypes in the progeny of PDE11 RNAi (line 9) crossed to 
various GAL4 driver lines. All tissue-specific Gal4 crosses did not show any obvious 
phenotypes  
 
Driver Expression pattern Phenotype?
Ato Gal4 paired DC neurons x
D42 Gal4  embryogenesis: broad, larvae: motorneurons,  x
interneurons, adult: nervous system
 Appl Gal4 neuron specific x
Repo Gal4  glial cell expression x
Sgs3 Gal4 salivary gland expression x  
 
None of these crosses yielded visible phenotypes, and all eclosed normally.  
 
3.5 DmPDE11 doesn’t affect osmoregulation 
DmUAS-PDE11 RNAi (line 9) flies were crossed with c42 GAL4, and Malpighian tubules 
from  DmUAS-PDE11  RNAi  (line  9)  parents,  and  c42/DmUAS-PDE11  RNAi  (line  9) 
progeny were assayed for secretion induced by a final concentration of 10
-5 M exogenous 
cGMP, as detailed in materials and methods. No change was seen between either the basal 
or  stimulated  fluid  secretion  rate  of  Malpighian  tubules  from  c42  and  c42/DmUAS-
PDE11RNAi (line 9) flies (figure 3.7). The data represents the pooling of three datasets. 
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Figure 3.7: Fluid secretion assay. The basal fluid secretion rate of intact Malpighian 
tubules was measured for 30 minutes, whereupon the tubules were stimulated with 10
-5 
cGMP (final concentration, time point of addition represented by arrow), and the secretion 
rate  measured  for  a  further  30  minutes.  Tubules  from  DmUAS-PDE11  RNAi  (line  9) 
parental line, and from c42/DmUAS-PDE11 RNAi (line 9) progeny showed no difference 
in fluid secretion. Error bars represent SEM. 
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3.6 Calcium signalling 
The Malpighian tubule utilises cGMP, cAMP and calcium signalling, (Davies and Day, 
2006)  and  there  is  cross  talk  between  these  signalling  pathways  (Arnold  et  al.,  1977; 
Valeyev et al., 2009; Walter and Kiger, 1984). The nitrigergic peptide capa-1 induces a rise 
in [Ca
2+]i, and stimulates NO production and thus cGMP production in the Malpighian 
tubule, when applied exogenously (Kean et al., 2002). To determine whether DmPDE11 
affects  this  process  in  the  tubule,  DmUAS-PDE11  RNAi  flies  were  crossed  with  c42 
GAL4-aequorin flies, which express a luminescent calcium reporting transgene in tubule 
principal  cells.  The  Malpighian  tubules  of  these  flies  were  excised,  and  the  calcium 
transients  induced  by  capa-1  peptide  were  measured  in  a  luminometer  (figure  3.8),  as 
described in materials and methods.  
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Figure  3.8:  Capa-1  induced  [Ca
2+]
i  transients  are  not  affected  by  a  reduction  in 
DmPDE11 levels. A: In order to measure capa-1-induced [Ca
2+]
i transients, 30 tubule pairs 
from  c42  aequorin  (c42  aeq)  and  c42  aequorin/DmPDE11  RNAi  (line  9)  (c42 
aeq/DmUAS-PDE11 RNAi (line 9) flies were treated with 10
-7 M capa-1 peptide (arrow). 
Each  trace  represents  the  average  of  four  replicates.  B:  Basal  [Ca
2+]  levels  for  each 
genotype  were  calculated  from  the  data  point  1  min  pre-stimulation  with  capa-1. 
Measurement  of  the  secondary  peak  was  taken  from  the  data  point  four  min  post-
stimulation  with  capa-1.  Results  expressed  as  mean  nM  [Ca
2+]i,  where  N=4  for  each 
genotype. Basal [Ca
2+]i, the primary response peak, and the secondary response peak were 
not significantly different when analysed with an unpaired T-Test. 
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The basal [Ca
2+]i, primary response peak, and secondary response peak of c42 aequorin 
and c42 aequorin/DmPDE11 RNAi (line 9) Malpighian tubules were compared using an 
unpaired T-test. There was no significant difference between any of these. This suggests 
that  DmPDE11 does  not  modulate capa-1 induced [Ca
2+]i  transients  in  the Malpighian 
tubule. 
3.7 DmPDE11A and DG2 colocalise in S2 cells 
3.7.1 Individual transfections 
In order to determine subcellular localisation, S2 cells were transiently transfected with 
DmPDE11RA tagged with a V5 epitope, or one of the cGKs DG2P1 or DG2P2, tagged 
with a c-Myc epitope. Subcellular localisation was determined for DmPDE11RA with an 
anti-V5  antibody  (red)  (figure  3.9),  and  for  DG2P1  and  DG2P2,  where  anti-c-Myc 
antibody was used (green) (figure 3.10). Nuclei were stained with DAPI (blue). 
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Figure  3.9:  Confocal  image  of  S2  cells  transfected  with  V5-DmPDE11  (red). 
Subcellular localisation ascertained by staining with anti-V5 monoclonal antibody, TRITC 
secondary Nuclei were stained with DAPI (blue). 
 
Figure 3.10: Confocal images of S2 cells transfected with c-Myc-DG2P1 (green), and 
c-Myc-DG2P2 (green). Subcellular localisation ascertained by staining with anti-c-Myc 
monoclonal antibody, TRITC secondary (green). Nuclei were stained with DAPI (blue). 
Untransfected cells showed no background immunofluorescence; nuclei of untransfected 
cells are visible in both pictures. 
                   c-Myc-DG2P1                               c-Myc-DG2P2 
 
            
In agreement with published data  (MacPherson et al., 2004b), c-Myc-DG2P1 localised 
predominantly to the membrane in S2 cells. Published images of DG2P2 are of V5-tagged 
DG2P2,  stained  with  anti-V5  monoclonal  antibody  and  also  a  vertebrate  anti-cGK 
antibody,  anti-cGKI,  from  (Markert  et  al.,  1995).  Images  with  anti-V5  antibody  show 
solely localisation to the membrane, while those stained with anti-cGKI rabbit polyclonal 
antibody also showed localisation within the cytosol, stronger towards the membrane. The 
DG2P2 construct in my possession was tagged with c-Myc. Staining with an anti-c-Myc 
antibody  produced  similar  staining  to  the  published  anti-cGKI  stained  images, 122 
predominantly showing localisation to the membrane, with staining in the cytosol, stronger 
towards  the  membrane.  This  may  be  a  characteristic  of  the  antibody;  however, 
untransfected  cells  show  no  background  staining.  The  c-Myc  tag  may  alter  protein 
localisation;  however  the  tag  is  one  amino  acid  smaller  than  the  V5  tag  used  in 
Macpherson et al, 2004, and so this is doubtful. A third alternative, and perhaps the most 
likely, is that conditions in those images using anti-c-Myc and anti-cGKI antibodies were 
more sensitive, and so fluorescence was detected that was not detected in anti-V5 images. 
Polyclonal antibodies designed against a novel epitope were unfortunately not delivered on 
time to test untagged DG2P2. 
 
3.7.2 Co-transfections 
It was reasoned that as DmPDE11 will affect cGK activity, the proteins may colocalise so 
that DmPDE11 samples the same pools of cGMP. S2 cells were transiently co-transfected 
with DmPDE11RA tagged with a V5 epitope, and either DG2P1 or DG2P2, tagged with a 
c-Myc epitope. 
 
3.7.2.1  PDE11RA and DG2P1 colocalise in S2 cells 
In  order  to  screen  for  co-localisation,  V5-DmPDE11RA  and  c-Myc-DG2P1  were 
transiently  transfected  in  S2  cells,  and  the  subcellular  localisation  of  the  proteins 
determined by immunohistochemistry (figure 3.11).  
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Figure  3.11:  An  S2  cell  expressing  c-Myc-DG2P1  and  V5-DmPDE11A.  Confocal 
images  of  V5-DmPDE11A  (red)  co-transfected  with  c-Myc-DG2P1  (green).  V5-
DmPDE11A  subcellular  localisation  ascertained  by  staining  with  anti-V5  monoclonal 
antibody, TRITC secondary. c-Myc-DG2P1 subcellular localisation ascertained with anti-
c-Myc  monoclonal  antibody,  FITC  secondary  (green).  Nuclei  were  stained  with  DAPI 
(blue) 
           c-Myc-DG2P1           V5-DmPDE11RA                    Merge 
 
 
 
 
 
 
 
When co-transfected, V5-DmPDE11RA and c-Myc-DG2P1 show a large degree of co-
localisation  in  S2  cells.  The  distribution  of  each  changes;  V5-DmPDE11A  shows  an 
association  with  the  membrane,  and  c-Myc-DG2P1  shows  an  increase  in  cytoplasmic 
localisation compared to the single transfections in figure 3.12. 
3.7.2.2  DmPDE11A and DG2P2 colocalise in S2 cells 
In  order  to  screen  for  co-localisation,  V5-DmPDE11RA  and  c-Myc-DG2P2  were 
transiently  transfected  in  S2  cells,  and  the  subcellular  localisation  of  the  proteins 
determined by immunohistochemistry (figure 3.12).  
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Figure  3.12:  An  S2  cell  expressing  c-Myc-DG2P2  and  V5-DmPDE11A.  Confocal 
images  of  V5-DmPDE11A  (red)  co-transfected  with  c-Myc-DG2P2  (green).  V5-
DmPDE11A  subcellular  localisation  ascertained  by  staining  with  anti-V5  monoclonal 
antibody, TRITC secondary. c-Myc-DG2P2 subcellular localisation ascertained with anti-
c-Myc  monoclonal  antibody,  FITC  secondary  (green).  Nuclei  were  stained  with  DAPI 
(blue). Merge shows two additional nuclei from untransfected cells. 
      c-Myc-DG2P2               V5-DmPDE11RA                   Merge 
 
 
 
 
 
Figure 3.14 shows that V5-DmPDE11RA and c-Myc-DG2P2 show a large degree of co-
localisation in S2 cells. There are multiple areas in the cytosol where both proteins are 
excluded. These could be an unknown form of vesicle, or endosomes. As both proteins 
show  a  cytoplasmic  localisation,  however,  this  does  not  suggest  that  either  protein 
modulates the localisation of the other. 
 
3.8 Projects undertaken that were halted when the new 
DmPDE11 sequence predictions were released 
As  the  DmPDE11RA  gene  model  was  replaced  with  two  newly  predicted  isoforms  in 
Flybase release 5.2, several constructs and projects were postponed until the gene model 
could be investigated and postponed. Subsequently, the data presented in chapter 4 led to 
the verification of the new gene model, and the cancelation of these projects. Details of 
these are found in appendix 1.  125 
3.9 Generation of transgenic DmPDE11RA flies 
In order to generate DmPDE11RA overexpressing Drosophila, the ORF was sub-cloned 
into the pP{UAST} vector. Two constructs were generated, one with a stop codon, and one 
with  without,  in  order  to  fuse  DmPDE11RA  in-frame  with  YFP.  The  inserts  were 
sequenced  for  fidelity  (data  not  shown);  generation  of  the  flies  was  postponed  until 
DmPDE11RA could be validated as a bona fide PDE. In the same week Flybase 5.2 was 
released;  as  above,  the  data  presented  in  chapter  4  verified  the  new  gene  model  and 
rendered the constructs invalid. 
 
3.10 Discussion 
The 5.8 kb expressed sequence tag (EST) SD13096 had previously been shown to contain 
sequence present in the incomplete PDE11RA ESTs previously released by Flybase, but 
also incorporating a 5‟ UTR, and an in-frame start codon within two novel 5‟ exons. A 
Northern blot of DmPDE11RA produced one band of approximately 5.8kb; as this matches 
the  size  of  the  DmPDE11RA  ORF,  was  accepted  that  SD13096  encodes  the  entire 
PDE11RA ORF  (Day).  Expression of this  EST in  S2 cells  revealed that  the construct 
produced a protein of the accepted size, and that the protein localised to the cytoplasm, as 
is the case for several cA- and cG-PDEs (Omori and Kotera, 2007).  
 
A screen for phenotypes, whereby UAS-DmPDE11 RNAi (line 9) flies were crossed to 
various  GAL4  driver  lines,  and  the  progeny  screened  for  phenotypes.  Eclosed  flies 
appeared normal, other than flies crossed to Act-5c GAL4, which had a green tint to their 
abdomen. The flies were dissected, but the tissue responsible was not identified. 
Calcium signalling is modulated by cGMP (Schlossmann et al., 2000), and in Malpighian 
tubules  capa-1  and  capa-2  stimulate  fluid  transport  via  calcium  and  cGMP  signalling 
pathways (Davies et al., 1995; Kean et al., 2002), where the entry of extracellular calcium 
is  permitted by the  activation of a cyclic nucleotide gated  channel,  cng, where  cGMP 
enhances cytosolic calcium and increases fluid transport (MacPherson et al., 2001). cAMP 
and calcium signalling networks display extensive crosstalk in non-excitable cells, where 
each modulates the spatiotemporal dynamics of the other (Bruce et al., 2003; Valeyev et 
al., 2009). As DmPDE11 is a dual specificity PDE, it was hypothesised that the protein 126 
may exert a modulatory effect on tubule calcium signalling in response to capa-1. Thus, the 
protein‟s role in calcium signalling was investigated by stimulating aequorin expressing 
Malpighian tubules from c42 aequorin, and c42 aequorin/DmUAS-PDE11 RNAi (line 9) 
flies  with  capa-1,  and  measuring  the  calcium  response  to  the  neuropeptide.  The  basal 
[Ca
2+]i, primary response peak, and secondary response peak were compared between the 
two  genotypes  using  an  unpaired  T-test,  where  neither  were  found  to  be  significantly 
different. This suggests that DmPDE11 does not modulate the [Ca
2+]i response to capa-1 in 
the Malpighian tubule. 
PDEs are responsible for the hydrolysis of cyclic nucleotides, which subsequently affects 
the activity of cyclic nucleotide-responsive effector proteins (Beavo et al., 2007). cGKs, in 
turn, have been shown to modulate the catalytic activity of PDE11A4 and PDE5A, two 
PDEs capable of hydrolysing cGMP, through phosphorylation (Corbin et al., 2000; Gross-
Langenhoff et al., 2008; Turko et al., 1998; Yuasa et al., 2000a), thus providing a feedback 
loop facilitating a reduction in the activity of the activated cGKs. The co-localisation of 
PDE5 and PKG1β has previously been shown to play an important physiological role, 
where  PDE5  has  been  shown  to  localise  to  the  ER  in  a  PKG1β  signalling  complex 
responsible for the cGMP mediated inhibition of IP3R dependent Ca
2+ release in platelets, 
where PKG1β phosphorylates and activates PDE5, thus initiating a negative feedback loop. 
This co-localisation appears to result from both proteins interacting with IP3R and not a 
direct interaction (Wilson et al., 2008). Thus, the subcellular localisation of DmPDE11 and 
DG2 were characterised and compared in S2 cells. Co-expression of V5 tagged DmPDE11, 
and  c-Myc  tagged  DG2  P1  and  P2  showed  that  the  two  co-localise.  DG2P1  shows  a 
stronger presence in the cytosol when co-expressed with DmPDE11A, which shows an 
association with the membrane in doubly transfected cells. 
Attempts to identify DmPDE11RA as a bona-fide PDE were made using two methods; cA- 
and cG-PDE assays on S2 cell transiently transfected with DmPDE11RA, and a cA-PDE 
assay of the parents  and progeny of a  DmUAS-PDE11 RNAi  (line 9) x c42 cross, as 
DmPDE11 is upregulated in the Malpighian tubule 1.5 times (http://www.flyatlas.org/). 
DmPDE11A did not yield any cA- or cG-PDE activity when expressed in S2 cells. With 
the  rationale  that  DG2  has  been  shown  to  modulate  cG-PDE  activity  in  the  tubule 
(MacPherson et al., 2004a), and that DG2 may therefore modulate DmPDE11 activity, 
DmPDE11 was co-expressed in S2 cells with DG2P1 or DG2P2, and the lysate use to 
perform cA- and cG-PDE assays. Although these were only performed as N=1, again, no 
increase in cA- or cG-PDE activity was seen in DmPDE11 transfected cells. Furthermore, 127 
where DmPDE11 was co-transfected with DG2P1 and DG2P2, a reduction in PDE activity 
was seen. This mirrors an unpublished observation by MacPherson and Day.  
In order to determine if a knock-down in DmPDE11 transcript levels and therefore protein 
levels affected PDE activity in the tubule, DmUAS-PDE11 RNAi (line 9) were crossed to 
c42, and the Malpighian tubules of parent and progeny subjected to a cA-PDE assay. No 
difference in cA-PDE activity was seen. However, it may be that the concentration of 
cAMP used was such that other cA-PDEs expressed in the tubule may have dwarfed the 
contribution of DmPDE11 to total PDE activity, and so no difference was seen. As such, it 
is desirable that this assay be repeated at higher cAMP concentration, and also that the 
assay be performed for cG-PDE activity. 
The significance of the Flybase 5.2 release is discussed in chapter four. 
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Chapter 4 
Identification and cloning of DmPDE11RB long, 
DmPDE11RB short, DmPDE11RC long, and 
DmPDE11RC short 
4  Chapter 4 
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4.1 Summary 
The DmPDE11RA isoform was replaced in the Flybase 5.2 release by two newly predicted 
isoforms;  DmPDE11RB  and  DmPDE11RC 
(http://fb2007_01.flybase.org/reports/FBgn0085370.html).  Both  are  similar,  but  not 
identical  isoforms  to  the  RA  transcript.  There  are  two  key  differences  between 
DmPDE11RA  and  the  two  newly  predicted  isoforms.  Firstly,  the  first  two  exons  of 
DmPDE11RA were predicted to be incorrect, and these exons were newly predicted to be 
5‟ UTR within the DmPDE11RB transcript. DmPDE11 RB and RC each have novel N 
termini  encoded  by  alternate  first  exons,  and  share  a  second  exon  not  present  in 
DmPDE11RA. Secondly, exon 11 within the DmPDE11RA transcript was also predicted 
as false, and is not present in the DmPDE11RB or DmPDE11RC isoforms. Analysis of 
transiently transfected S2 cells expressing V5-tagged DmPDE11RA had shown that the 
protein  displayed  no  discernable  cA-  or  c-PDE  activity,  and  showed  low  levels  of 
expression. As such, it was probable that DmPDE11RA was not a bona fide PDE.   
The evidence rank supporting DmPDE11 RB and RC on Flybase is “weakly supported”; 
i.e., they are predictions backed by sequencing of end sequenced cDNA clones (or ESTs) 
around  500  bases  long,  and  computational  prediction.  The  length  of  supporting  ESTs 
prohibit their use in cloning. As both DmPDE11 RB and RC were still rated as “weakly 
predicted”, updating the RA ORF by cloning the novel N-termini, and the region around 
exon  11,  and  sub-cloning  these  into  the  DmPDE11RA  transcript  using  endogenous 
restriction sites was not pursued, as only PCR of the entire ORF would guarantee that the 
isoforms  were  bona  fide,  and  the  Flybase  predictions  correct.  Prior  to  cloning  these 
isoforms,  they  were  confirmed  as  being  transcribed  by  three  methods;  comparison  of 
predicted exons with a head and Malpighian tubule EST database not used in the Flybase 
sequence  analysis,  sequencing  of  RT-PCRs  from  cDNA  from  multiple  tissues,  and 
diagnostic RT-PCRs, where multiple exons were amplified, and analysed by agarose gel 
electrophoresis and sequencing. 
Each  isoform  was  amplified  in  fragments  using  a  high-fidelity  DNA  polymerase  from 
brain or hindgut cDNA, sequenced for fidelity, and ligated together utilising endogenous 
restriction sites to yield a full length open reading frame. Sequencing of RT-PCR amplified 
ORF fragments revealed a novel exon/exon splice site in the C-terminus not predicted by 
Flybase; the novel exon encodes 4 amino acids followed by a stop codon 1kb from the stop 
codon of the “long” C terminus, and thus a truncated protein. RT-PCR analysis revealed 130 
that both the B and C isoforms have both a long and a short isoform, thus yielding two 
additional  novel  ORFs.  Polyclonal  antibodies  previously  raised  against  sequence  from 
DmPDE11RA target the long isoforms only, in an area with no sequence changes. The 
pWIZ RNAi construct targeted against DmPDE11RA utilises sequence from an unchanged 
region, shared by all four isoforms.  
Transgenic Drosophila expressing the four DmPDE11 isoforms were generated, and the 
proteins verified by western blotting. The B and C isoforms showed differential subcellular 
localisation in the Malpighian tubule, where the long and short isoforms of DmPDE11B 
localised to  the apical  and basolateral  membranes,  and the long and short  isoforms  of 
DmPDE11C localised to unidentified organelles or vesicles. 
Over-expression of DmPDE11 C long or short in S2 cells failed to yield an increase in cA- 
or  cG-PDE  activity.  However,  when  ubiquitously  overexpressed  in  fly, 
immunoprecipitated, and subjected to PDE assays, YFP tagged DmPDE11B long and short 
and  C  long  and  short  display  cA-  and  cG-PDE  activity,  and  thus  are  bona  fide  dual 
specificity phosphodiesterases. 
 
4.2 Introduction 
Previous attempts to transiently transfect S2 cells with DmPDE11RA failed to generate 
expressed protein (Day). Although further attempts to express V5 tagged DmPDE11RA 
yielded expression of a protein of the expected size, the protein was expressed at low 
levels,  and  displayed  unusually  low  transfection  efficiency.  Attempts  to  verify  that 
DmPDE11RA was a bona fide phosphodiesterase through PDE assays yielded no cA- or 
cG-PDE activity above background (as detailed in chapter 3). Previously, PDE assays on 
the sub-cloned catalytic domain yielded slight cA-PDE activity (Day).  
It was thought that perhaps DmPDE11 needed some unknown binding partner to facilitate 
PDE activity; thus S2 cells co-transfected with PDE11 and DG2 were subjected to PDE 
assays;  again,  these  yielded  no  significant  activity,  and  indeed  cGK/PDE11RA  co-
transfected  S2  cell  lysate  demonstrated  lower  PDE  activity  than  untransfected  cells 
(summarised in chapter three).  
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4.2.1 Flybase  5.2  replaces  DmPDE11RA  with  DmPDE11RB  and 
DmPDE11RC 
In  the  Flybase  5.2  genome  annotation  release  of  August  of  2007,  DmPDE11RA  was 
replaced  with  two  newly  predicted  transcripts,  DmPDE11  RB  and  RC  (figure  4.1). 
Ensemble was updated accordingly in March 2008. 
 
Figure 4.1: DmPDE11 RB and RC. Diagram representing the initial transcript, mRNA, 
and  cDNAs  of  the  DmPDE11  isoforms.  From 
http://flybase.bio.indiana.edu/reports/FBgn0085370.html. 
 
 
The Flybase 5.2 predictions for DmPDE11 RB and RC were still based on computational 
prediction, and a number of incomplete cDNAs (or ESTs). The prediction was still classed 
as “very weak”. This may explain why Ensemble kept their prediction as RA until March 
2008. However, several aspects of the research detailed in chapter 3 led me to believe that 
DmPDE11RA was incorrectly predicted. The enzyme provided no PDE activity  above 
baseline when expressed in S2 cells. Whereas transient expression of the N terminus of 
PDE11RA in S2 cells gave robust expression, expression levels of transiently transfected 
full length protein were much lower. Furthermore, the protein showed a classical “non-
specific” cytoplasmic localisation. Thus, validation of the newly predicted isoforms was 
undertaken. The 5639 bp DmPDE11RB transcript contains 17 exons, and encodes a protein 
product of 1451 residues. The 5238 bp DmPDE11RC transcript contains 17 exons, and 
encodes a protein product of 1407 residues. Both encode similar, but not identical protein 
products to the RA transcript. 
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4.2.2 Comparison between DmPDE11RB and DmPDE11RA 
The predicted first two exons of DmPDE11RA were predicted to be incorrect, and replaced 
in the RB transcript, which contains two alternate exons at the 5‟ end (figure 4.2).  
 
Figure 4.2: Transcript structure of DmPDE11RA and DmPDE11RB. Kb figure refers 
to the breadth of sequence localisation within chromosome 2L. White = UTR, Red = exon. 
RA 
 
RB  
 
 
A further difference between RB and RA is the omission of the 78 bp exon 11 of RA from 
the RB transcript. The RB ORF remains in-frame so that 26 amino acids are removed from 
this site but the amino acids following this are unaffected (figure 4.3).  
 
Figure  4.3:  ClustalW  alignment  of  DmPDE11RA  and  DmPDE11RB.  Sequences  of 
DmPDE11RA and DmPDE11RB were aligned using ClustalW, which revealed a 78bp 
deletion within the RB ORF present in the predicted RA ORF.  
 
 
This deletion corresponds to exon 11 of RA. This sequence is located between the GAF 
domains and the catalytic domain. This deletion aside, the C termini of the two isoforms 133 
are identical. As such, DmPDE11B still contains twin GAF domains, and a dual specificity 
PDase domain. 
 
4.2.3 Comparison between DmPDE11RC and DmPDE11RA 
DmPDE11RC  has  a  unique  N-terminus,  consisting  of  two  novel  exons  not  present  in 
DmPDE11RA, the second of which is shared with DmPDE11RB (figure 4.4).  
 
Figure 4.4: Transcript structure of DmPDE11RA and DmPDE11RC. Kb figure refers 
to the breadth of sequence localisation within chromosome 2L. White = UTR, Red = exon. 
RA 
 
RC 
 
Exon 11 of DmPDE11RA is also not present in DmPDE11RC. As such, the only difference 
between DmPDE11RB and DmPDE11RC is the first exon.   
 
4.2.4 Verification of the newly predicted isoforms 
4.2.4.1  Analysis of Expressed Sequence Tag traces 
The RB and RC transcripts were predicted through a combination of EST sequencing and 
computational prediction. I analysed Solexa Illumina EST sequencing runs from poly-A 
primed mRNA generated from head and Malpighian tubule RNA (Dow and Wang, 2009), 
using  a  CLC  genomics  workbench  suite  (CLC  Genomics  Workbench  3.7.,  CLC  Bio) 
which allowed the further screening of predicted exons in the EST library. These ESTs 
were not used in the Flybase sequence analysis. EST sequencing traces of 50 base pairs, 
unless representative of repeat genomic sequence over-represented in the genome, should 134 
only be found in one genomic location. The genomic region of CG34341 was “overlaid” 
with the EST traces using a CLC genomics workbench suite, and the putative start sites 
and exons of the transcripts were validated by comparison with EST coverage. Tubule EST 
reads are shown. 
The sequence originally designated as RA exons 1 and 2 and is now designated as RB 5‟ 
UTR. Within this region there are four ESTs, and significant areas are not represented 
(figure 4.5).  
 
Figure  4.5:  50bp  reads  representing  the  5’  UTR  of  the  PDE11  transcript 
DmPDE11RB.  Yellow  band  represents  translated  region.  Green  band  represents  UTR.  
Purple highlighted sequence shows previously predicted start site for DmPDE11RA. 
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Of  prime  importance  was  the  verification  of  the  newly  predicted  DmPDE11RB  and 
DmPDE11RC N termini. These are represented in the ESTs gathered (figure 4.6 and 4.7). 
 
Figure  4.6:  50bp  read  representing  first  exon  of  DmPDE11RB  with  start  codon 
(ATGGGCCAAGCGGCA...).  Yellow  band  represents  translated  region.  Green  band 
represents 5‟ UTR.   
 
 
Figure  4.7:  50bp  read  representing  first  exon  of  DmPDE11RC  with  start  codon 
(ATGGCATCATCCCCA...).  Yellow  band  represents  translated  region.  Green  band 
represents 5‟ UTR.   
 
 
The  presence  of  these  novel  N  termini  in  these  sequencing  runs  supports  the  Flybase 
prediction. The second, shared exon is also represented within the EST database (figure 
4.8). 
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Figure 4.8: 50bp read representing second exon of  DmPDE11RB and RC. Yellow 
band represents translated region. 
 
 
The coverage of these exons in the Solexa Illumina EST sequencing runs, as well as those 
used in the Flybase prediction, suggests strongly that the newly predicted N termini of the 
RB and RC isoforms are correct. 
 
4.3 Amplification and further verification of DmPDE11 RB 
and RC 
4.3.1 Amplifying DmPDE11 RB and RC from cDNA 
Flyatlas, a database of whole fly and tissue specific expression levels  of every known 
Drosophila gene (Chintapalli et al., 2007), shows the highest enrichment for DmPDE11 
transcript compared to whole fly in brain and hindgut (table 4.1) 
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Table  4.1:  Tissue  expression  profile  of  DmPDE11.  mRNA  signal:  abundance  of 
transcript in each tissue. Enrichment: compared to whole fly (Chintapalli et al., 2007). 
Tissue mRNA Signal Enrichment
Brain 268 ± 9 2.5
Head 132 ± 10 1.2
Eye 327 ± 37 3.09
Thoracicoabdominal ganglion 154 ± 11 1.5
Salivary gland 268 ± 1 2.53
Crop 176 ± 7 1.7
Midgut 188 ± 8 1.8
Tubule 161 ± 7 1.5
Hindgut 285 ± 11 2.7
Heart 332 ± 13 3.14
Fat body 98 ± 7 0.92
Ovary 192 ± 2 1.8
Testis 39 ± 2 0.4
Male accessory glands 77 ± 4 0.7
Virgin spermatheca 105 ± 10 0.99
Mated spermatheca 110 ± 7 1.04
Adult carcass 102 ± 8 1
Larval CNS 79 ± 2 0.75
Larval Salivary gland 176 ± 13 1.66
Larval midgut 91 ± 8 0.86
Larval tubule 180 ± 7 1.7
Larval hindgut 172 ± 9 1.63
Larval fat body 73 ± 4 0.7
Larval trachea 156 ± 16 1.48
Larval carcass 77 ± 9 0.73
S2 cells (growing) 245 ± 9 2.31
Whole fly 106 ± 11  
The probes used in the Drosophila Fly Atlas did not differentiate between RB and RC. It 
was shown by Day and Sebastian that both isoforms are expressed in hindgut and head, as 
shown  in  appendix  3.  As  both  isoforms  are  expressed  in  these  tissues,  cDNA  was 
generated from dissected brain (as this showed enrichment over head) and hindgut, and this 
cDNA used to clone the ORFs, as full length ESTs were not available. 
 
4.4 Cloning of DmPDE11RB and RC 
4.4.1 PCR of full length ORFs 
The newly predicted DmPDE11 RB and RC mRNA coding regions (ORFs) are 4365bp 
and 4224bp in size respectively. Attempts to clone the entire ORFs failed, despite attempts 138 
with non-proofreading DNA polymerase, and with Platinum Taq DNA polymerase high 
fidelity  (Invitrogen),  an  enzyme  supposedly  capable  of  amplifying  up  to  20kb,  adding 
weight to Sambrook‟s description of manufacturer‟s claims towards their proprietary Taq 
polymerases  as  “indefatigably  optimistic”  (Sambrook  and  Russell,  2001).  As  with  all 
cloning from  cDNA in  this  chapter, a  gradient PCR,  with  a wide spread of annealing 
temperatures,  was  used.  Every  variable;  primer  concentration,  MgCl
2+  concentration, 
cDNA type and concentration, and cycle number, were altered, but to no avail.  
 
4.4.2 Fusion PCR 
Fusion PCR is a method of amplifying two or more fragments of DNA, and subsequently 
fusing these fragments into one long DNA molecule (Shevchuk et al., 2004). This involves 
three PCR steps. The first amplifies the fragments, using primers that result in two (or 
more)  products  with  a  21  bp  “overlap”  homologous  region;  these  fragments  are  gel 
purified. The subsequent two steps fuse these fragments. An initial 13 cycles are performed 
without primers, during which the region of homology essentially acts as a primer, and 
generates a full length dsDNA template from the newly fused fragments. Following this, 
the product of the previous fusion step is DNA purified and used as a template; a PCR with 
primers for the extreme 5‟ and 3‟ ends of the gene, (PCRs were performed with two sets of 
primers, either with incorporated restriction sites to facilitate cloning, or without), and an 
extended extension step (to reflect the increase in size of the template) should yield full-
length fusion product. 
 
The N termini of RB and RC, and the conserved C terminus, were amplified with a 21bp 
overlap, as one clean band in each case. Equimolar amounts of these were used in the 
fusion PCR. When the products were separated by gel electrophoresis, strong, non-specific 
bands were obtained, and when a combined annealing/extension PCR program still yielded 
these bands the approach was abandoned (data not shown).   
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4.4.3 Sub  cloning  of  DmPDE11  using  endogenous  restriction 
sites 
As amplification of the full length ORF failed, a multi-step cloning strategy was planned. 
Analysis of DmPDE11 RB and RC sequence for endogenous restriction sites showed a 
BglII site around midway through the two ORFs.  
This pointed towards a two stage cloning strategy; amplify the two unique N termini of RB 
and RC, and the single shared C terminus with these incorporating the endogenous BglII 
site, adding unique restriction sites at the N and C terminals, and clone these sequentially 
into a compatible multiple cloning site. As RB and RC have unique N termini, differing 
forward  primers  were  designed  to  amplify  these.  Reverse  primers  for  the  common  C 
terminal were designed with and without a stop codon. These fragments could then be 
ligated  together  to  yield  a  full-length  ORF,  both  YFP-tagged  and  untagged,  following 
verification by sequencing (figure 4.9). 
Figure 4.9: Cloning strategy for DmPDE11 
Step 1: Primers  are designed to  amplify the N and C terminal  halves of RB and RC, 
extending just past the endogenous BglII site. The C terminal half of RB and RC are 
identical. Restriction sites, not present within the ORF, corresponding to sites in pUAST 
MCS are incorporated at the N and C terminal ends of RB and RC. The C terminal was 
amplified with and without a stop codon to facilitate in frame fusion with a YFP tag. 
 
Step 2: TOPO clone the fragments, and sequence them to screen for fidelity 
 
 
 
    C terminal      N terminal 
pCR 2.1 TOPO  pCR 2.1 TOPO 140 
Step 3: Digest the N and C terminal ends, and ligate sequentially into digested, MCS-
modified pUAST 
 
 
 
Step  4:  Screen  colonies  for  full  length  PDE11  RB  and  RC  inserted  into  pUAST  and 
pUAST-YFP. 
 
All PCRs were performed with Herculase II DNA polymerase, following manufacturer‟s 
instructions. For all PCRs at least three TOPO cloned inserts were sent for sequencing.  
 
4.4.3.1  Amplification of DmPDE11RB N terminus 
The BglII site is 2654bp into the RB ORF. Although the fragment would amplify with 
standard DNA polymerase, using proofreading DNA polymerase, the N terminus of RB 
did  not  amplify  despite  extensive  attempts  to  optimise  the  protocol,  including  primer 
redesign without a 5‟ EcoRI addition. Fortuitously, a Xho I site exists half way through 
this N terminal fragment, and so the N terminus was amplified in two fragments. These 
fragments overlapped so that the primers did not contain a Xho I site, as a control. The 
EcoRI – XhoI fragment, and the XhoI to BglII fragment were amplified, sub-cloned into 
pCR  TOPO  2.1  vector,  and  verified  by  PCR  and  restriction  analysis.  They  were  then 
sequenced for fidelity.  
 
    C terminal      N terminal 
       pP{UAST} / pP{YFP UAST} 141 
4.4.3.2  Amplification of DmPDE11RC N terminus 
Using proofreading DNA polymerase, the N terminus  of  DmPDE11RC amplified as  a 
single clean band of the predicted size. This band was sub  cloned into the TOPO 2.1 
vector, verified by PCR and restriction analysis, and sequenced for fidelity.  
 
4.4.3.3  Amplification of the conserved DmPDE11 C terminus 
The C terminus was amplified using two different reverse primers, one with a stop codon, 
incorporating a KpnI restriction site, and one without a stop codon, with a NotI restriction 
site, to facilitate in-frame fusion to a YFP tag. With either reverse primer, PCR of the C 
terminus of DmPDE11 yielded two fragments, one of the predicted size, and one that ran 
approximately 50bp smaller (figure 4.10).  Both were  gel  purified,  TOPO-cloned using 
pCR TOPO 2.1 vector, verified by PCR and restriction analysis, and sent for sequencing. 
 
Figure 4.10: The DmPDE11 C terminus amplifies as a doublet. Two PCR fragments of 
the DmPDE11 C terminus, produced using proofreading PCR polymerase, BglII C term 
forward  and  KpnI  reverse  primers,  and  tubule  cDNA.  Fragments  were  separated  by 
agarose gel electrophoresis. Band size identified using 1kb ladder.  
 
 
 
 
 
 
 
 
 
 
3 Kb 
1.6 Kb 
1 Kb 
DmPDE11 C terminus     
2 Kb 142 
Sequencing of these fragments showed that the smaller band contained a novel exon/exon 
boundary, not predicted by Flybase, which results in 4 novel amino acids followed by a 
novel stop codon 1kb from the C-terminus, and thus a truncated protein (figure 4.11). 
Figure 4.11: Truncated DmPDE11 transcript. Sequencing of two DmPDE11 C terminal 
PCRs from cDNA, showing a novel intron/exon boundary. * denotes matching sequence 
 
When the C terminal, amplified with no stop codon, was TOPO cloned in-frame with a V5 
tag, and expressed in S2 cells, western blot of cell lysate gave bands of the predicted size. 
The transfer was “dirty,” and so although bands were visible on the exposed film, when 
scanned the bands were no longer visible, and so the data is not shown. 
4.4.4 RT-PCR to verify long and short isoforms 
With two possible N termini, and two C termini, the question of how many isoforms exist 
in vivo arose. RT-PCR was performed in order to determine which combinations of N 
termini and C termini were represented in transcripts. Primers were designed in the unique 
B  and  C  termini,  as  close  to  the  novel  exon/exon  boundary  as  possible.  Two  reverse 
primers were generated, one within the originally predicted exon/exon boundary, and one 
within the novel exon/exon boundary within the short C terminus (figure 4.12). These 
primers were designed to generate products of ~3.5 kb. 
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Figure  4.12:  DmPDE11  transcript  verification  strategy.  Primers  were  designed  to 
confirm  the  presence  of  long  and  short  full  length  isoforms.  Forward  primers  were 
designed in regions of sequence specific to the B and C isoforms, and reverse primers were 
designed  to  either  represent  the  originally  predicted  exon/exon  boundary  of  the  long 
isoform, or to represent the newly discovered exon/exon boundary of the short isoform. 
 
These primers were used in PCRs of hindgut cDNA, and the PCRs run on an agarose gel 
(figure 4.13). 
Figure 4.13: Verification of DmPDE11RB and RC. Forward primers specific to the N-
termini  of  DmPDE11-RB  and  –RC  isoforms  (RBF  and  RCF  respectively)  were  used 
alongside reverse primers designed to amplify the originally predicted exon/exon boundary 
of the long isoform (REV), or to amplify the newly discovered exon/exon boundary of the 
short isoform (GAP) from hindgut cDNA. Band size identified using 1kb ladder. 
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Primers: 144 
Bands of the expected size (~3.5kb) were produced for both DmPDE11 RB and RC using 
both the reverse primer within the originally predicted exon/exon boundary, and one within 
the novel exon/exon boundary within the short C terminus. Thus, both DmPDE11-RB and 
-RC were found to have a full length and a truncated isoform, and as such these were 
designated  DmPDE11RB  long,  DmPDE11RB  short,  DmPDE11RC  long,  and 
DmPDE11RC short. The features of these proteins are summarised in figure 4.14.  
Figure 4.14: The four DmPDE11 isoforms. Antibody epitope refers to the polyclonal 
rabbit antibody generated for DmPDE11RA. 
PKA/PKG 
Phosphorylation 
motif
GAF: cGMP-binding phosphodiesterase, Anabaena adenylyl cyclase,
and Escherichia coli FhlA domain
GAF GAF Catalytic domain
GAF GAF Catalytic domain
GAF GAF Catalytic domain
GAF GAF Catalytic domain
RNAi target
Antibody Epitope
Unique N-terminus
DmPDE11 RC long
DmPDE11 RB short
DmPDE11 RB long
DmPDE11 RC short
Coiled coil motif
 
These isoforms share a “core” area containing twin GAF domains, and a dual specificity 
PDEase domain (Attwood et al., 2003; Bateman et al., 2004; Letunic et al., 2006). The 
novel N termini are of low homology when compared to HsPDE11A, as is the long C 
terminus. The novel N terminus of DmPDE11B is predicted to contain a coiled coil motif 
when analysed with the COILS program (Lupas, 1997; Lupas et al., 1991). 
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4.5 Generation of DmPDE11 transgenic flies 
Due to time constraints, it was reasoned that I should generate the four verified DmPDE11 
transgenic flies while concurrently assaying for cA- or cG-PDE activity in S2 cells. As 
PDE assays  on S2 cell  over-expressed PDE11RA and  catalytic domain had shown no 
significant PDE activity, but anti-DmPDE11 immunoprecipitate of whole fly lysate yields 
significant cA- and cG-PDE activity, it was reasoned that expression in whole fly may be 
needed to verify one way or the other, as the catalytic domain remains unchanged in terms 
of  sequence.  As  such,  if  the  S2  cell  PDE  assays  were  unsuccessful,  PDE  assays  on 
DmPDE11 overexpressing whole fly could be performed. 
4.5.1 Cloning of DmPDE11 ORFs into pUAST 
4.5.1.1  Cloning of DmPDE11RC long and short 
Attempts to ligate the N and C termini of RC into pUAST simultaneously failed, and as 
such these were cloned sequentially. The long and short C terminals (with a stop codon) 
were cloned into pUAST first. pUAST-YFP was a kind gift from John Day; the long and 
short C terminals (without a stop codon) were cloned into this construct in frame with the 
C-terminal YFP tag.  The N terminus of RC was then cloned into these constructs in order 
to generate full length ORFs. pUAST-DmPDE11RC-YFP long and short, and pUAST-
DmPDE11RC short were generated, however, despite numerous attempts, the N terminus 
did not sub-clone into pUAST-Cterm long, and so pUAST-DmPDE11RC long could not 
be generated. Were untagged DmPDE11RC long required, it could be generated by PCR 
using pUAST-DmPDE11-YFP long as a template, with a stop codon incorporated into the 
reverse primer. 
4.5.1.2  Generation of modpUAST 
The order of restriction sites of DmPDE11RB, 5‟  3‟, is EcoRI-XhoI-BglII-NotI/KpnI. 
Numerous vectors were checked for an EcoRI-XhoI-BglII order in the MCS to facilitate 
sequential  cloning,  but  none  were  found.  The  multiple  cloning  site  of  pUAST  has 
restriction sites in the order of EcoRI-BglII-NotI-EagI-XhoI-KpnI-XbaI. As this would not 
permit sequential sub-cloning of the EcoRI-XhoI, XhoI-BglII, and BglII–KpnI/NotI TOPO 
cloned fragments, the MCS of pUAST was modified. This was achieved by the generation 
of two overlapping primers representing the sequence of the desired MCS; the overlap 146 
facilitated the formation of “sticky ends” when then two were incubated together, and 
ligated into doubly digested pUAST (materials and methods 1.3.19). The forward primer 
was coupled to a reverse primer 500bp into pP{UAST}, and this primer set was used to 
screen for successful recombinants (figure 4.15).  
Figure 4.15: Screen for successful mod pP{UAST} recombinants. PCR screening of 
modified pP{UAST} yielded a successful recombinant (lane 10, indicated by an arrow). 
                     1     2     3     4     5     6      7     8     9    10 
 
 
 
When this recombinant pP{UAST} was identified (lane 10), DmPDE11RB was subcloned 
into it in the order BglII–KpnI/NotI, XhoI-BglII, then EcoRI-XhoI. However, the EcoRI 
site was found to be mutated, and so the EcoRI-XhoI fragment was sub-cloned into the N 
terminus  of  pP{UAST}  PDE11RC.  However,  frustratingly  the  EcoRI-XhoI  fragment 
would  not  ligate  into  the  untagged  PDE11  RC  long  or  short  constructs,  and  so  only 
DmPDE11RB long-YFP and DmPDE11RB short-YFP could be generated. Were untagged 
constructs required, these could be generated by PCR of the entire ORF, with a stop codon 
incorporated into the reverse primer. 
4.5.2 Cloning of ORFs into pAc5.1/V5-HIS C 
The above ORFs were sub-cloned into pAc5.1/V5-HIS C, an S2 expression system that 
does not require induction with CuSO4, as it was considered a possibility that CuSO4 may 
displace the Zn ion at the active site of the PDE, rendering it catalytically null, or resulting 
in the mis-folding of the protein. An experiment to check this, where untransfected S2 
cells, one treated with the concentration of CuSO4 used to induce expression using DES 
vectors, and an “uninduced” control,  showed a marked reduction (~13%) in PDE activity 
where the cells were exposed to CuSO4 , although this was N=1 and would need to be 
repeated at N=3 to verify the finding. 
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4.6 Verification of protein size 
YFP  tagged  DmPDE11  flies  were  crossed  to  the  GAL4  driver  line  heat  shock  GAL4 
(HSG4), which drives GAL4 expression ubiquitously in response to a 37˚C heat shock. Fly 
lysate was subjected to western blot analysis. Protein size was verified by western blotting 
using an anti-GFP antibody which recognised YFP. YFP tagged DmPDE11B long and B 
short  were  immunoprecipitated  from  whole  fly  lysate  alongside  HSG4  control,  and 
subjected to western blot analysis (figure 4.16). 
                            
Figure  4.16:  Analysis  of  YFP-tagged  DmPDE11B.  YFP-DmPDE11B  long  and  YFP-
DmPDE11B  short  flies  were  crossed  to  the  ubiquitous  driver  line  heat  shock  GAL4 
(HSG4),  and  gene  expression  induced  by  3  x  20  min  heat  shocks.  Protein  sizes  were 
identified by western blot analysis, where YFP-tagged proteins were identified using ʱGFP 
monoclonal (that recognises YFP) primary, ʱmouse Cy3-coupled secondary, and band size 
was calculated using ImageQuantTL software (GE Healthcare).shown is the. Lane 1. Fly 
lysate  HSG4  2:  Fly  lysate  YFP-DmPDE11RBL/HSG4  3.  Fly  lysate  YFP-
DmPDE11RBS/HSG4.  Expected  sizes  YFP-DmPDE11B  long:  187.9,  YFP-DmPDE11B 
short: 157.0 kDa.          
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Expected band sizes for YFP-tagged DmPDE11B long and short are 187.9 kDa and 157.0 
kDa  respectively.  Analysis  of  band  sizes  for  YFP-tagged  DmPDE11B  long  using 
ImageQuantTL software identifies a novel band at 186.2 kDa, in close agreement with the 
predicted protein size of 187.9 kDa, and a band at 164.6 kDa. Analysis of band sizes for 
YFP-tagged  DmPDE11B  short  identifies  a  novel  band  at  159.2  kDa,  again  in  close 
agreement with the predicted protein size of 157.0 kDa, and two further novel bands at 
121.0 kDa and 55 kDa.  Three bands were present in the HSG4 negative control lane (one 
~85 kDa and two ≤30kDa), and so were identified as non-specific bands. 
Fly lysate from YFP tagged DmPDE11C long and Canton S control were subjected to 
western blot analysis (figure 4.17). 
 
Figure  4.17:  Analysis  of  YFP-tagged  DmPDE11C  long.  YFP-DmPDE11C  long  and 
YFP-DmPDE11C short flies were crossed to the ubiquitous driver line heat shock GAL4 
(HSG4),  and  gene  expression  induced  by  3  x  20  min  heat  shocks.  Protein  sizes  were 
identified by western blot analysis, where YFP-tagged proteins were identified using ʱGFP 
monoclonal (that recognises YFP) primary, ʱmouse HRP-coupled secondary, and band 
size was calculated by comparison with Benchmark prestained protein ladder. Intervening 
lanes deleted in Paint program, and lanes moved together. Lane 1. Fly lysate Canton S 2: 
Fly  lysate  YFP-DmPDE11RCL/HSG4.  Expected  protein  size  YFP-DmPDE11C  long: 
182.6 kDa. 
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YFP-tagged DmPDE11C long is predicted to be 182.6 kDa. When expressed in fly, the 
protein runs to ~180 kDa, in close agreement with the predicted protein size of 182.6 kDa. 
A  band  of  ~70  kDa  was  present  in  the  Canton  S  negative  control  lane,  and  so  was 
identified as a non-specific band. 
YFP tagged DmPDE11C short was immunoprecipitated from whole fly lysate alongside 
HSG4 control, and subjected to western blot analysis (figure 4.18). 
 
Figure 4.18:  Analysis of  YFP-tagged  DmPDE11C short. YFP-DmPDE11C long and 
YFP-DmPDE11C short flies were crossed to the ubiquitous driver line heat shock GAL4 
(HSG4),  and  gene  expression  induced  by  3  x  20  min  heat  shocks.  Protein  sizes  were 
identified by western blot analysis, where YFP-tagged proteins were identified using ʱGFP 
monoclonal  (that  recognises YFP),  and band size was calculated using  ImageQuantTL 
software  (GE  Healthcare).  Lane  1.  Fly  lysate  HSG4  2:  Fly  lysate  YFP-
DmPDE11RBL/HSG4  3.  Fly  lysate  YFP-DmPDE11RBS/HSG4.  Expected  protein  size                                
DmPDE11C short 151.7 kDa. 
 
 
 
 
 
 
 
 
YFP-tagged DmPDE11C short is predicted to be 151.7 kDa. Analysis of the two novel 
bands in the DmPDE11C short lane identifies one band of 149.0 kDa, in close agreement 
with the predicted protein size, and two further bands of 112.7 kDa and 54.2 kDa. Two 
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bands were present in the HSG4 negative control lane of ≤30kDa, and so were identified as 
non-specific bands. 
 
4.7 Verification of phosphodiesterase activity 
S2 cells were transfected with DmPDE11RC long (untagged and YFP tagged) and RC 
short (untagged, V5 tagged, and YFP tagged). cA-PDE assays were performed on S2 cell 
lysate, with concentrations of 5 μM  and 10 μM cAMP. None of these constructs gave a 
significant increase in PDE activity at either concentration (figure 4.19). 
 
Figure 4.19: DmPDE11RC does not yield cA-PDE activity when expressed in S2 cells.  
cA-PDE assay on transiently transfected S2 cell lysate using 5 μM substrate (A) and 10 
μM substrate (B). In order to aid comparison, data is expressed as % cA-PDE activity of 
mock transfected S2 cell, where for A, mock = 142.1 pmol cAMP/mg/min (SEM ±14.61), 
and for B mock = 90.23 pmol cAMP/mg/min (SEM ﾱ10.12). N=≤3 biological replicates, 
except for DmPDE11RCs V5 and DmPDE11RCs stop, where N=2 biological replicates. 
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Indeed, where DmPDE11RC constructs were transfected this resulted in a significantly 
(analysis with one-way anova) lower level of cA-PDE activity compared to untransfected 
control.  Reasons  for  this  are  unknown;  perhaps  the  protein  acts  as  a  catalytically  null 
dominant negative in S2 cells. A smaller cAMP/min/mg value for the 10μM assay mock 
control  may  have  been  due  to  unusually  high  blank  readings.  PDE  assays  using 151 
immunoprecipitate  (IP)  with  an  anti-DmPDE11  polyclonal  antibody  against  whole-fly 
yields a Km of 6ﾱ2μM for cGMP, and 18.5ﾱ5.5μM for cAMP, as published in Day et al, 
2005. Thus, DmPDE11 is a dual specificity cAMP- and cGMP-PDE. It is notable that 
DmPDE8, when transiently expressed in S2 cells and subjected to PDE assays, also fails to 
yield measurable PDE activity (Day, 2005). Furthermore, when aligned with the catalytic 
domain of other Drosophila PDEs, the sequence showed a very high sequence similarity, 
with only one amino acid change within this region, with the same change in DmPDE6 
catalytic domain (figure 4.20). A cG-PDE, this has been shown to display cG-PDE activity 
in S2 cells. 
 
Figure  4.20:  ClustalW  alignment  of  Drosophila  PDE  catalytic  domains  with  their 
human homologues. This region is invariant between the RA, and RB/RC isoforms of 
DmPDE 11 (From Day et al, 2005) 
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As  such  it  was  decided  to  send  the  pP{UAST}  constructs  for  injection,  and  with  the 
generated transgenic flies to perform PDE assays on fly lysate. Indeed, analysis of the 
protein  by  western  blot  does  suggest  that  the  enzyme  may  be  subjected  to  a  post-
translational modification when expressed in fly, which may affect its activity. As such, 
YFP-tagged DmPDE11RB and RC expressing flies were crossed to heat shock GAL4 flies 
to ubiquitously induce expression of the transgene. The protein was immunoprecipitated, 
and the immunoprecipitate used to assay cA- and cG-PDE activity of the protein (figures 
4.21 and 4.22). 
Figure 4.21: YFP tagged DmPDE11RB long, RB short, RC long, and RC short yield 
significant  cA-PDE  activity  when  transgenically  expressed  in  Drosophila.  cA-PDE 
assay on ʱYFP immunoprecipitated PDE from transgenic whole fly lysate using 10 μM 
substrate.  Data  expressed  as  pmol  cAMP  hydrolysed/IP/min.  Assay  performed  in 
biological  triplicate.  Data  statistically  significant  between  parental  control  and  PDE-
expressing progeny to P<0.0001 (Student‟s unpaired T test). Error bars show SEM. 
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Figure 4.22: YFP tagged DmPDE11RB long, RB short, RC long, and RC short yield 
cG-PDE activity when transgenically expressed in Drosophila. cG-PDE assay on ʱYFP 
immunoprecipitated PDE from transgenic whole fly lysate using 10 μM substrate. Data 
expressed  as  pmol  cGMP  hydrolysed/IP/min.  Assay  performed  in  biological  duplicate. 
Error bars show SEM. 
hsGAL4
hsGAL4/YFP-DmPDE11RB long
hsGAL4/YFP-DmPDE11RB short
hsGAL4/YFP-DmPDE11RC long
hsGAL4/YFP-DmPDE11RC short
0
5
10
15
p
m
o
l
 
c
G
M
P
/
I
P
/
m
i
n
 
 
Each YFP tagged PDE11 isoform showed a significant increase in cAMP-PDE activity 
compared to heat shock GAL4 parental control (figure 4.21). As the cGMP-PDE assays 
were performed in biological duplicate, statistics cannot be performed, however B long, B 
short, and C short gave an increase in cGMP-PDE activity compared to heat shock GAL4 
control. 
 
4.8 Implications of the DmPDE11 sequence change 
A concern was that tools designed around the sequence of DmPDE11RA would become 
redundant with the prediction of the RB and RC isoforms. The epitope used to raise anti-
DmPDE11  polyclonal  rabbit  antibodies  is  unchanged  in  the  long  isoforms,  but  is  not 
present in the short isoforms. The published western blot shows one clear band (Day, 154 
2005);  it  may  be  that  the  RB  and  RC  long  isoforms  run  so  close  together  as  to  be 
indistinguishable on a western blot. 
The  RNAi  (pWIZ)  construct  was  targeted  against  an  area  conserved  between  all  4 
isoforms, which remains unchanged between RA, and RB and RC. Thus it should knock-
down  all  four  isoforms.  Furthermore  the  primers  used  in  the  PDE11RA  Q-PCR  also 
amplified a region present in all 4 isoforms, and as such, remains valid, as no single region 
would allow Q-PCR against a single isoform, as Q-PCR with primers designed against 
sequence specific to DmPDE11RB or RC would amplify sequence from both long and 
short isoforms. 
Flyatlas was produced using the Drosophila genome 2 array, which contains 14 probes 
against  DmPDE11-RA  (Affymetrix  nettafx  analysis  center).  These  probes  hybridised 
between 4529 and 5049bp of the ORF. Again, this range of sequence remains unchanged 
between DmPDE11RA and both RB and RC transcripts, and thus these probes hybridise 
to, but do not differentiate between, RB long, RB short, RC long and RC short.  
 
4.9 Confocal microscopy of DmPDE11 
Transgenic Drosophila were crossed to heat shock GAL4 flies, the tubules dissected and 
fixed, and images obtained by immunocytochemistry (figures 4.23-4.27).  
  
Figure 4.23: RB long YFP single plane. Tubules from DmPDE11RB long/HSG4 flies 
were fixed and visualised by confocal microscopy. 
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Figure 4.24: RB short YFP single plane. Tubules from DmPDE11RB short/HSG4 flies 
were fixed and visualised by confocal microscopy. 
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Figure 4.25: DmPDE11 B long YFP projection. Tubules from DmPDE11 B long/HSG4 
flies were fixed, and a Z-stack obtained by confocal microscopy. Shown is a projection of 
this Z-stack. 
 
 
Confocal images of both DmPDE11B long and short show that both proteins show similar 
localisation,  both  localising  primarily  to  the  apical  and  basolateral  membranes  of  the 
Malpighian tubule, with lesser staining in the cytosol. 
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Figure  4.26:  DmPDE11  C  long  YFP  single  plane.  Tubules  from  DmPDE11  C 
long/HSG4 flies were fixed, DAPI stained, and visualised by confocal microscopy. Shown 
is a single cell from the main segment. DmPDE11 C long YFP = green, DAPI = blue. 
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Figure  4.27:  DmPDE11  C  short  YFP  single  plane.  Tubules  from  DmPDE11  C 
short/HSG4  flies  were  fixed,  DAPI  stained,  and  visualised  by  confocal  microscopy. 
DmPDE11 C long YFP = green, DAPI = blue. 
 
 
RC  long  and  short  isoforms  showed  indistinguishable  localisation  to  an  unidentified 
organelle, or perhaps vesicles. It shows no nuclear localisation.  
 
4.10 Discussion 
DmPDE11RA  was  replaced  in  the  Flybase  5.2  release  with  two  novel  isoforms, 
DmPDE11RB and RC. In this chapter, these isoforms were verified as being expressed. 
The ORFs of these genes were cloned into S2 cell expression vectors, and pP{UAST}. 
Overexpression of YFP tagged DmPDE11 in fly yielded proteins of the predicted size. cA-
PDE assays on S2 cells transfected with DmPDE11RC at 5 μM and 10 μM did not yield 159 
cA-PDE activity above that of untransfected S2 cell control, and indeed, as PDE activity 
was reduced compared to control, it may be that in S2 cells transgenically expressed YFP 
tagged  DmPDE11  acts  as  a  dominant  negative,  reducing  endogenous  PDE  activity. 
However, when transgenically overexpressed in fly, the enzymes yield cA- and cG-PDE 
activity, and are thus bona fide dual specificity PDEs. No direct comparison can be made 
with PDE assays performed on ʱPDE11 IPs from head lysate published in (Day et al., 
2005),  where  values  were  ~2.5  pmol/min/IP  for  cGMP,  and  ~6  pmol/min/IP,  as  the 
protocols of that paper and this work differ markedly; Day used 20 heads instead of 10 
whole flies as starting lysate, and used the ʱPDE11 polyclonal antibody which targets an 
epitope  shared  by  all  4  isoforms  of  PDE11  referred  to  in  chapter  3  to  pull  down 
endogenous (untagged) PDE11, instead of ʱGFP monoclonal antibody to pull down YFP 
tagged  overexpressors.  As  PDE  assays  on  immunoprecipitate  cannot  give  specific 
activity/min/mg  protein,  the  data  of  figures  4.21  and  4.22  do  not  show  whether  the 
isoforms differ in affinity for their substrates. A dose response curve would need to be 
generated using overexpressed protein, in a format that allowed quantification of protein. 
As for the reasons that the enzymes displayed no cAMP- or cGMP-PDE activity in S2 
cells, while these same enzymes displayed cAMP- and cGMP activity when transgenically 
overexpressed  in  Drosophila,  they  are  unknown.  It  may  be  that  a  post  translational 
modification occurs in Drosophila but not in S2 cells, which may be necessary to confer 
enzymatic activity on the protein. cNMP-PDE assays were previously performed in S2 
cells on transiently transfected full length PDE1 and PDE8 (transcript A), and the catalytic 
domain of PDE6, 9, and 11 (Day, 2005). Of these, PDE 6 showed cGMP-PDE activity, and 
the  catalytic  domain  of  PDE11  showed  cAMP-PDE  activity,  but  only  at  substrate 
concentrations of between 1 - 4 μM, and did not show cGMP-PDE activity, as was the case 
for IP from fly head lysate. Thus, S2 cells do not appear to be a good cell choice for the 
heterologous study of PDE catalytic function. 
The subcellular localisation of each isoform was determined by immunocytochemistry on 
fixed YFP tagged-DmPDE11 expressing Malpighian tubules. The long and short isoforms 
of YFP-DmPDE11B localised to the apical and basolateral membranes, with lower levels 
of protein in the cytosol. The unique N-terminus of DmPDE11B is 64 amino acids in 
length, and is not predicted to be a transmembrane domain when analysed with Argos or 
von Heijne tests using MacVector software. It contains a polyglutamine region that falls 
within a region predicted to form a coiled coil structure when analysed with the Ncoils test 
of the protein analysis toolkit (Lupas, 1997). Coiled coils are known to reversibly mediate 
homo-  and  heteromeric  protein-protein  interaction  (Strauss  and  Keller,  2008),  and  can 160 
facilitate the formation of protein complexes (Langosch and Heringa, 1998). Therefore this 
region  may  facilitate  the  interaction  of  DmPDE11B  with  an  unidentified  protein  that 
tethers the PDE to the membrane. PDEs from several other families have been shown to 
localise to the membrane due to interaction with other proteins. PDE3 contains N-terminal 
hydrophobic  membrane  association  domain,  which  either  mediate  localisation  by 
interaction  with  unidentified  proteins,  or  by  functioning  as  a  transmembrane  domain 
(Wechsler et al., 2002). PDE4 isoforms contain differing N-termini that encode unique 
subcellular targeting motifs and direct  novel  protein-protein interactions  that tether the 
enzymes to particular subcellular localisations. PDE4A1 contains a motif called tryptophan 
anchoring phosphatidic acid selective-binding domain (TAPAS-1), which permits a Ca
2+ 
sensitive  association  with  the  membrane  via  phosphatidic  acid  binding  (Baillie  et  al., 
2002). PDE4D5 is recruited to the membrane due to the presence of a β-arrestin binding 
site in the N terminus (Bolger et al., 2006). PDE6 localises to the membrane due to its 
interaction with glutamic acid-rich proteins (GARPs) (Körschen et al., 1999), as well as 
lipid modifications to the C terminus of the catalytic subunits (Anant et al., 1992). 
 The long and short isoforms of YFP-DmPDE11C localised to foci within the cytosol, 
likely within unidentified organelles, or to vesicles. As DmPDE11B and C show markedly 
different localisation, and the only difference between these isoforms is the first exon, this 
sequence must encode a targeting motif. As the long and short isoforms of DmPDE11B or 
C do not show any discernable differences in localisation, the long C terminal must have 
some other, unknown function, perhaps pertaining to the predicted PKA/PKG consensus 
phosphorylation  site.  The  C  terminus  is  of  low  homology  to  that  of  HsPDE11A.  As 
DmPDE11C is YFP tagged, the identification of the unknown organelle could be identified 
by either co-staining of each organelle using specific antibodies, or by the crossing of these 
flies to proteins tagged with a different marker such as Venus or GFP that are known to 
localise  to  a  particular  organelle,  and  screening  for  co-localisation.  YFP-DmPDE11C 
localise to organelles similar in appearance to peroxisomes in S2 cells as reported in (Ally 
et al., 2009), a pattern that does not match that reported in (Southall et al., 2006) where the 
peroxisomes are fewer in number and larger. Regardless, the number of peroxisomes per 
cell in the Malpighian tubule is clearly far higher than the number of organelles per cell 
containing DmPDE11C  in  the tubule, thus  discounting the peroxisomes  as  a candidate 
organelle. The localisation is distinct to the staining pattern seen in Malpighian tubules 
when using antibodies against proteins localised to the sarcoplasmic reticulum, endoplamic 
reticulum, Golgi (Southall et al., 2006), and vesicles (Evans et al., 2008), and is distinct to 
that of lysosomes in S2 cells (Tsruya et al., 2002). Thus a survey of the literature does not 161 
identify a candidate organelle. The localisation of other PDEs to organelles is dictated by 
association  with  anchoring  proteins.  PDE4A  localises  to  numerous  organella  via 
interaction with AKAPs, for example AKAP95 (perinucleus), AKAP149 (mitochondria), 
AKAP 450 (Golgi) (Dodge-Kafka et al., 2008), and myeloid translocation gene (Golgi), 
which  also  confers  Golgi  localisation  to  PDE7A  (Asirvatham  et  al.,  2004).  PDE4D 
localises to the Golgi via association with Myomegalin (Verde et al., 2001). PDE5A is 
localised to vesicles and also the centrosome in human myometrical cells (Dolci et al., 
2006) 
That the N termini of DmPDE11B and C affect subcellular localisation, likely by affecting 
the interaction of these proteins with the proteasome, immunoprecipitation of each isoform 
(i.e., using specific antisera or pulling down tagged PDE) and identification of interacting 
proteins using mass spectrometry specific to each isoform, and subsequent characterisation 
of these would perhaps identify proteins showing overlapping subcellular localisation that 
were worthy of investigation as putative anchoring proteins.  
 As  the  short  and  long  isoforms  of  DmPDE11  B  and  C  show  identical  subcellular 
localisation,  the  extended  C-terminal  of  the  protein  does  not  contain  a  subcellular 
localisation sequence. 
The subcellular localisation of Drosophila PDEs has not been widely studied. GFP tagged 
DmPDE6 localises predominantly to the apical membrane of the Malpighian tubule, with 
lower intensity fluorescence at the basolateral membrane (Day et al., 2006). When bovine 
PDE5, a close homologue of DmPDE6, is transgenically overexpressed in tubule, it too 
predominantly  localises  to  the  apical  membrane  (Broderick  et  al.,  2004).  DmPDE11B 
localises to the basolateral and apical membranes. The presence of two DmPDEs capable 
of  hydrolysing  cGMP  to  the  membranes  suggests  that  cGMP  signalling  is  under  tight 
control in the Malpighian tubule, befitting the prominent role of cGMP signalling in the 
tubule. 
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A study of DmPDE11/cGK interaction 
5  Chapter 5 
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5.1 Summary 
Previously  obtained  data  (Day  and  Sebastian)  suggested  that  DmPDE11,  and  other 
DmPDEs capable of hydrolysing cGMP, interact directly or indirectly with cGKs. The Dm 
cG-PDEs  PDE1,  PDE6,  and  PDE11  co-immunoprecipitate  with  significant  amounts  of 
cGK  activity  when  immunoprecipitated  using  specific  antisera  from  Drosophila  head 
lysate. Likewise, the cGKs DG1 and DG2 co-immunoprecipitate with significant amounts 
of  cG-PDE  activity  when  immunoprecipitated  using  specific  antisera  from  Drosophila 
head lysate. 
Co-transfection in S2 cells of DmPDE11 RB long and the cGKs shows that DmPDE11B 
long shows a high degree of co-localisation with DG1, DG2P1, and DG2P2. Furthermore, 
DG1 appears to mediate DmPDE11B long internalisation from the membrane. DmPDE11 
long appears to internalise membrane-tethered DG2P1, so that DG2P1 shows increased 
cytosolic localisation, and localises to foci within the cytosol, mostly coinciding with those 
of PDE11B long.  
Co-immunoprecipitation experiments were performed in S2 cells, between the long and 
short isoforms of DmPDE11, tagged with YFP, and the cGKs, tagged with c-Myc, where 
cGK was immunoprecipitated with anti-c-Myc-conjugated beads, the immunoprecipitate 
resolved by SDS-PAGE, and immunoblotted with anti-GFP antibody which recognised 
YFP. YFP-tagged DmPDE11C long and short was shown to co-immunoprecipitate with c-
Myc tagged DG1, DG2P1, and DG2P2, where bands of the expected size were present in 
doubly  transfected  anti-c-Myc  immunoprecipitates,  but  not  for  anti-c-Myc 
immunoprecipitates of singly-transfected YFP-tagged DmPDE11C long or short, or mock 
transfected  S2  cell  lysate.  No  data  is  presented  for  DmPDE11B-cGK  interactions,  as 
negative controls showed background staining, although this was of lower intensity that 
doubly-transfected S2 cells. This provides direct evidence of DmPDE11 interacting with 
each of the cGKs,  directly or indirectly, and suggests the prospect  of  potential cGMP 
signalling compartmentalisation in Drosophila. 
5.2 Introduction 
Previously obtained data summarised in appendix 4 (Day and Sebastian, unpublished data) 
suggested  that  DmPDE11,  and  other  DmPDEs  capable  of  hydrolysing  cGMP,  interact 
directly  or  indirectly  with  cGKs.  This  demands  further  investigation,  as  interactions 
between numerous cA-PDEs and PKA isoforms (mediated by AKAPs) have been shown to 164 
dictate the specificity of cAMP signalling events, and facilitate the formation of a feedback 
loop where each protein may modulate the function of the other (Wong and Scott, 2004), 
as  detailed  in  the  introduction.  Differential  localisation  of  cGK  and  PDE  proteins, 
facilitated  by  gene  and  isoform  multiplicity,  permits  the  transmission  of  multiple, 
simultaneous signalling events. Interaction of cGKs and cG-PDEs would allow cG-PDEs 
to  modulate  interacting  cGK  function  by  affecting  local  cGMP  concentration.  It  has 
previously been shown that DG2 modulates cG-PDE activity in the Malpighian tubule 
(MacPherson et al., 2004a). This modulation may occur by one of several methods; by 
modulation of cG-PDE function through phosphorylation, by direct, non catalytic binding, 
either of which would be facilitated by protein-protein interaction, or by reduction of PDE 
transcription.  Furthermore, association of cG-PDEs with the main effectors of the cGMP 
signalling  pathway  could  modulate  PDE  and  cGK  localisation,  thus  facilitating  the 
formation of cGMP microdomains, and altering cGK substrate specificity. 
5.3 DmPDE11B long and cGK co-localise in S2 cells 
DmPDE11 RA and DG2 displayed a large degree of co-localisation when co-transfected in 
S2  cells  and  visualised  by  staining  with  anti-tag  antibodies  and  subsequent  confocal 
microscopy, as detailed in chapter 3. The above immunoprecipitation data suggests that the 
two  proteins  interact,  directly  or  indirectly.  However,  to  interact,  proteins  must 
demonstrate subcellular localisations that at least partially overlap. Thus, S2 cells were 
transiently transfected with DmPDE11 RB long tagged with C-terminal YFP, and one of 
the  cGKs  DG1,  DG2P1,  or  DG2P2,  each  tagged  with  C-terminal  c-Myc,  and 
immunocytochemistry performed to ascertain subcellular localisation. To assay whether 
the localisation of cGK or DmPDE11 is affected by the presence or absence of the other, 
each construct was also transfected individually. 
5.3.1 Individually transfected constructs 
Constructs were transfected individually to ascertain the subcellular localisation of each 
protein. An S2 cell expressing YFP tagged DmPDE11B long is shown in figure 5.1. 
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Figure  5.1:  Confocal  image  of  S2  cells  transfected  with  YFP-DmPDE11  RB  long 
(green). Nuclei were stained with DAPI (blue).  
 
YFP tagged  DmPDE11B long predominantly localises to the membrane, with foci-like 
regions  within  the  cytosol  showing  strong  fluorescence,  and  lighter  fluorescence 
throughout the cytosol.  
Individual  S2  cells  expressing  c-Myc  tagged  DG1,  DG2P1,  and  DG2P1  are  shown  in 
figure 5.2. 
Figure 5.2: Confocal images of individual S2 cells transiently transfected with c-Myc-
DG1  (A),  c-Myc-DG2P1  (B),  and  c-Myc-DG2P2  (C).  Subcellular  localisation  was 
ascertained  by  staining  with  anti-c-Myc  monoclonal  antibody,  TRITC  secondary  (red). 
Nuclei  were  stained  with  DAPI  (blue).  Untransfected  cells  showed  no  background 
fluorescence (example cell visible in C).  
 
DG1  localises  to  the  cytosol,  with  stronger  staining  towards  the  membrane.  Published 
images  show  staining  adjacent  to  the  membrane,  in  common  with  the  image  above, 
although did not display quite as strong cytosolic staining (MacPherson et al., 2004b). The 
localisation of individually transfected DG2 P1 and P2 are discussed in chapter 3, but shall 
be repeated here. In agreement with published data (MacPherson et al., 2004b), DG2P1 
localised predominantly to the membrane in S2 cells. Published images of DG2P2 are of 166 
V5-tagged DG2P2, stained with anti-V5 monoclonal antibody and also a vertebrate anti-
cGK rabbit polyclonal antibody, anti-cGKI, from (Markert et al., 1995). Images with anti-
V5 antibody show solely localisation to the membrane, while those stained with anti-cGKI 
antibody also showed localisation within the cytosol, stronger towards the membrane. The 
DG2P2 construct in my possession was tagged with c-Myc. Staining with an anti-c-Myc 
antibody  produced  similar  staining  to  the  published  anti-cGKI  stained  images, 
predominantly showing localisation to the membrane, with staining in the cytosol, stronger 
towards  the  membrane.  This  may  be  a  characteristic  of  the  antibody;  however, 
untransfected  cells  show  no  background  staining.  The  c-Myc  tag  may  alter  protein 
localisation;  however  the  tag  is  one  amino  acid  smaller  than  the  V5  tag  used  in 
Macpherson et al, 2004, and so this is doubtful. A third alternative, and perhaps the most 
likely, is that conditions in those images using anti-c-Myc and anti-cGKI antibodies were 
more sensitive, and so fluorescence was detected that was not detected in anti-V5 images. 
Polyclonal antibodies designed against a novel epitope were unfortunately not delivered on 
time to test untagged DG2P2. 
5.3.2 Co-transfection of c-Myc-cGK and YFP-DmPDE11 RB long in 
S2 cells 
In order to screen for co-localisation, S2 cells were co-transfected with YFP-DmPDE11 
RB long and c-Myc-DG1, and the subcellular localisation of the proteins was ascertained 
by confocal microscopy (figure 5.3). 
Figure 5.3: Confocal images of S2 cells co-transfected with YFP-DmPDE11 RB long 
(green)  and  c-Myc-DG1.  Subcellular  localisation  of  c-Myc-DG1  was  ascertained  by 
staining  with  anti-c-Myc  monoclonal  antibody,  TRITC  secondary  (red).  Nuclei  were 
stained with DAPI (blue).  
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Shown are two examples of doubly transfected S2 cells; two images are shown because in 
some  cells,  YFP-DmPDEB  long  showed  lower  levels  of  membrane  localisation  when 
compared to S2 cells expressing YFP-B long only, suggesting that DG1 may mediate the 
internalisation of the protein (figure 5.5 A). This is interesting, as DG1 is not endogenously 
expressed in S2 cells (Chintapalli et al., 2007). In either case, the two proteins show a large 
degree of co-localisation within the cytosol. DG1 localisation does not appear to alter when 
co-expressed  with  DmPDE11RB  long.  It  appears  that  within  the  cytosol, 
(immuno)fluorescence of both proteins increases around what appear to be vacuoles, or 
some other organelle (figure 5.5 B, white arrows).  
In order to screen for co-localisation, S2 cells were co-transfected with YFP-DmPDE11 
RB  long  and  c-Myc-DG2P1,  and  the  subcellular  localisation  of  the  proteins  was 
ascertained by confocal microscopy (figure 5.4). 
Figure 5.4: Confocal image of an S2 cell co-transfected with YFP-DmPDE11 RB long 
(green) and c-Myc-DG2P1. Subcellular localisation of c-Myc-DG2P1 was ascertained by 
staining  with  anti-c-Myc  monoclonal  antibody,  TRITC  secondary  (red).    Nuclei  were 
stained with DAPI (blue).  
 
In YFP-DmPDE11 RB long and c-Myc-DG2P1 co-transfected S2 cells, the proteins show 
a  large  degree  of  co-localisation.  Localisation  of  DG2P1  is  altered  when  compared  to 168 
individually transfected S2 cells, as the protein shows increased cytosolic localisation, and 
localises to foci within the cytosol similar to those of by PDE11B long. This finding was 
observed in several doubly transfected cells. The two proteins co-localise within these foci 
(white arrows), although DG2P1 shows localisation to additional foci that PDE11B long 
does not localise to. The two proteins co-localise to the membrane, where each protein has 
regions of increased intensity, and furthermore this variation in intensity shows a very 
similar pattern for the two proteins.  
In order to screen for co-localisation, S2 cells were co-transfected with YFP-DmPDE11 
RB  long  and  c-Myc-DG2P2,  and  the  subcellular  localisation  of  the  proteins  was 
ascertained by confocal microscopy (figure 5.5). 
Figure 5.5: Confocal image of an S2 cell co-transfected with YFP-DmPDE11 RB long 
(green) and c-Myc-DG2P2. Subcellular localisation of c-Myc-DG2P1 was ascertained by 
staining  with  anti-c-Myc  monoclonal  antibody,  TRITC  secondary  (red).  Nuclei  were 
stained with DAPI (blue).  
 
An overlay of PDE11B long and DG2P2 shows that the proteins show a large degree of co-
localisation, predominantly at the membrane, although also in the cytosol. Both proteins 
are excluded from what appear to be vacuoles or some other organelle (white arrows). The 
subcellular localisation of each protein does not noticeably change between co-transfected 
cells and individually transfected cells. 
5.4 Kinase assay from DG2 immunoprecipitate 
As DmPDE11 was shown to co-localise with DG2, it was reasoned that DmPDE11 may 
affect  cGK  activity,  and  that  a  reduction  in  DmPDE11  transcript  levels  and  therefore 
protein levels might lead to an increase in cGK activity, due to an increase in localised 
[cGMP] concentration. In order to test this hypothesis, DG2 was immunoprecipitated from 
Malpighian tubule lysate of UAS-PDE11 RNAi (line 9), and c42/UAS-PDE11 RNAi (line 169 
9) progeny using specific anti--DG2 antisera, and the immunoprecipitate was subjected to 
a kinase assay, which uses a bovine PDE5 substrate (“glasstide”) to measure ATP transfer 
and thus levels of total kinase activity, as detailed in materials and methods (figure 5.6).  
Figure 5.6: Malpighian tubules display a qualitative increase in kinase activity when 
PDE 11 expression is reduced in tubule principle cells via expression of a UAS-PDE11 
RNAi transgene with the GAL4 driver c42.  N=3 for each genotype, error bars show 
standard error of the mean. Statistical significance was not achieved, as determined by a 
two-way T-test. 
 
 
 
 
 
 
 
 
 
 
When  DmPDE  11  expression  was  reduced  in  Malpighian  tubule  principal  cells,  total 
cGMP-dependant protein kinase activity of the whole tubule was qualitatively increased, 
but  no significant  difference was  seen. However, the qualitative increase suggests that 
further analysis would be worthwhile; kinase assays at various concentrations of cGMP for 
each  genotype  would  generate  two  response  curves,  which  would  show  whether  cGK 
activity was affected by DmPDE11 expression levels. 
UAS-PDE11 RNAi (line 9)
c42/UAS-PDE11 RNAi (line 9)
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5.5 DmPDE11  C  long  and  short  co-immunoprecipitate 
with DG1, DG2P1, and DG2P2 
Appendix  4  shows  data  obtained  by  Day  and  Sebastian  that  provide  evidence  of  an 
interaction between  DmPDE11 and the cGKs,  although only DG2P2  has  been directly 
identified as co-immunoprecipiting, where it was shown to associate with DmPDE11 by 
MALDI-TOF  MS  analysis  of  DmPDE11  immunoprecipitate.  The  interaction  of  these 
proteins was investigated using co-immunoprecipitation, where immunoprecipitation was 
performed of c-Myc tagged cGK, and V5- and YFP-tagged DmPDE11, and the potential 
binding  partner  screened  by  immunoblot  using  anti-tag  antibodies.  Direct  capture 
immunoprecipitation was employed for c-Myc and V5 tags, and indirect capture in the case 
of the YFP tag. That is, anti-c-Myc and –V5 antibodies were coupled to solid-state support, 
whereas  anti-GFP  (which  recognise  YFP)  antibodies  were  captured  using  Protein-A 
conjugated sepharose beads. These methods are detailed in materials and methods. 
5.6 Immunoprecipitation  of  V5-tagged  DmPDE11B, 
immunoblot of c-Myc-tagged cGK  
In  order  to  determine  which  cGKs  interact  with  DmPDE11B,  coimmunoprecipitations 
were performed from the lysate of 3 x 10
6 S2 cells co-transfected with one of YFP-tagged 
DmPDE11 RB and RC long and short, and one of c-Myc tagged DG1, DG2P1, or DG2P2. 
Additionally, 3 x 10
6 S2 cells were singly-transfected with YFP-tagged DmPDE11 RB 
long and short, and with c-Myc tagged DG1, DG2P1, or DG2P2, and the lysate from these 
used as negative controls (Figure 5.7). 
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Figure 5.7: Immunoprecipitation of V5-PDE11B is enhanced when co-expressed with 
c-Myc-cGK.    S2  cells  were  transfected  with  V5-DmPDE11RB  long  (lane  1),  V5-
DmPDE11RB  short  (lane  2),  V5-DmPDE11RB  long  +  c-Myc-DG1  (lane  3),  V5-
DmPDE11RB short + c-Myc-DG1 (lane 4), V5-DmPDE11RB long + c-Myc-DG2P1 (lane 
5), V5-DmPDE11RB short + c-Myc-DG2)1 (lane 6), V5-DmPDE11RB long + c-Myc-
DG2P2 (lane 7), V5-DmPDE11RB short + c-Myc-DG2P2 (lane 8), c-Myc-DG1 (lane 9), 
c-Myc-DG2P1  (lane  10),  c-Myc-DG2P2  (lane  11).  Anti  V5  immunoprecipitation 
performed with anti-V5 affinity gel (Invitrogen), blot probed with Anti c-Myc monoclonal. 
The predicted sizes of these (c-Myc tag included) are:  DG1 89 kDa, DG2P1 123kDa, 
DG2P2 85 kDa 
 
 
 
 
 
 
 
 
 
 
While a qualitative increase was seen in all double-transfected immunoprecipitations above 
negative  controls  (i.e.,  singly  transfected  immunoprecipitations),  background  was  still 
apparent in cGK-only controls, and so the interaction could not be verified. This result was 
obtained several times. 
5.7 c-Myc cGK immunoprecipitation, anti-YFP DmPDE11 
immunoblot 
As a preliminary experiment to gauge conditions, without negative controls other than 
mock transfected S2 cells, S2 cells were co-transfected with one of c-Myc tagged DG1, 
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DG2P1,  or  P2,  and  one  of  YFP-tagged  DmPDE11RC  long  or  short.  Lysates  were 
precleared by incubation with rabbit serum (as EZview™ Red protein A affinity gel uses 
affinity purified anti-c-Myc rabbit polyclonal antibody), then incubated with EZview™ 
Red protein A affinity gel (Sigma). Supernatant was then incubated with EZview
™ Red 
Anti-c-Myc Affinity Gel, then washed 3 x in 3T3 lysis buffer, and processed for SDS-page 
and immunoblotting. The figure is shown with a cropped, zoomed view of the DmPDE11C 
long bands for clarity (figure 5.8). 
 
Figure 5.8: YFP-DmPDE11C long co-IPs with DG2.  anti-YFP immunoblot of anti-c-
Myc  immunoprecipitated  DmPDE11-YFP/cGK-c-Myc  overexpressing  S2  cell  lysate. 
Sample precleared in protein A beads, pulled down using 10μl anti-c-Myc proteinA beads, 
immunoblotted with a pool of anti-GFP monoclonal antibodies. The predicted sizes of 
these (tag included) are:  YFP-DmPDE11C long: 182 kDa, YFP-DmPDE11C short: 152 
kDa. 
 
 
 
 
 
 
 
 
 
 
 
Bands of the predicted size were obtained of YFP-DmPDE11C long in c-Myc DG2P1 and 
DG2P2/YFP-DmPDE11  RC  long  co-transfected  S2  cell  immunoprecipitate.  No  other 
bands of the predicted size are visible for the other experimental conditions.  
181 kDa 
115 kDa 
82 kDa 
64 kDa 
Y
F
P
-
Dm
P
D
E
11
R
C
S
/
c
-
M
y
c
-
D
G
2
P
2
 
Y
F
P
-
Dm
P
D
E
11
R
C
L/
 
c
-
M
yc
-
D
G
2
P
2
 
Y
F
P
-
Dm
P
D
E
11
R
C
S
/
 
c
-
M
yc
-
D
G
2
P
1
 
Y
F
P
-
Dm
P
D
E
11
R
C
L
/
 
c
-
M
yc
-
D
G
2
P
1
 
Y
F
P
-
 
Dm
P
D
E
11
R
C
S
/
 
c
-
M
yc
-
D
G
1
 
Y
F
P
-
Dm
P
D
E
11
R
C
L/
 
c
-
M
yc
-
D
G
1
 
M
ock
 173 
Thus, the experiment was repeated, with an aim to reduce background, while boosting the 
signal of those interactions not confirmed by this experiment, and including DmPDE11 
transfected S2 cells as further controls. To boost the signal, the concentration of S2 cell 
lysate  used  was  doubled,  an  increased  amount  of  antibody  used,  and  an  increased 
incubation time in immunoblotting were used. To reduce background binding, the amount 
of beads used for antibody/protein capture was halved, the % Triton-X 100 in the lysis 
buffer used was increased from 1% to 1.5%, and more extensive washing was performed, 
where the amount of wash buffer was doubled, and the three wash steps were extended to 
10 min rotation at 4°C. For the immunoblot, block and wash steps were extended. The blot 
is shown in figure 5.9. 
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Figure 5.9: YFP-DmPDE11C long and short co-IP with DG1 and DG2. (A) S2 cells 
were  transiently  transfected  with  YFP  tagged  DmPDE11  RC  long  and  short,  both 
individually and in combination with c-Myc tagged DG1, DG2P1, and DG2P2. cGK was 
immunoprecipitated using c-Myc affinity gel, and the immunoblot was probed with ʱGFP 
antibody  that  recognises  YFP  in  order  to  screen  for  co-immunoprecipitation  of 
DmPDE11C and cGK. Expected band sizes: DmPDE11 RC long: 182 kDa, DmPDE11 RC 
short:  152kDa.  (B)  Control  ʱc-Myc  immunoblot  of  c-Myc-cGK  immunoprecipitations, 
where an equal amount of beads were analysed by western blotting. Expected band sizes: 
c-Myc-DG1: 88.0 c-Myc-DG2P1: 122.5 kDa c-Myc-DG2P2: 84.5 kDa (C) Control ʱGFP 
immunoblot of equal amounts of S2 cell lysate prior to immunoprecipitation with c-Myc 
affinity gel. Expected band sizes: DmPDE11 RC long: 182 kDa, DmPDE11 RC short: 
152kDa. 
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This experiment yielded bands of the predicted size for all experimental conditions, bar the 
negative controls, and the DmPDE11C long/DG2P2 immunoprecipitation which gave a 
band  in  the  prior  experiment.  An  aliquot  of  each  cell lysate was  analysed by  western 
blotting, to ensure equal DmPDE11C expression in each lysate, which was confirmed (data 
not shown).. The experiment should be repeated two more times, and repeated with YFP 
tagged DmPDE11 RB long and short. 
5.8 Discussion 
cGMP  signalling  is  known  to  be  highly  compartmentalised,  and  so  the  subcellular 
localisation of DmPDE11A and DG2 were investigated in chapter 3, where DmPDE11A 
was shown to colocalise with DG2P1 and P2 in S2 cells. As CG34341 was now known to 
encode four isoforms that differ in sequence from the originally predicted DmPDE11A, the 
c-Myc  tagged  cGKs  DG1,  DG2P1,  and  DG2P2  were  co-expressed  with  YFP-
DmPDE11RB long in S2 cells, to see if the proteins still showed co-localisation in light of 
DmPDE11B localising predominantly to the cell membrane, as opposed to the cytoplasmic 
localisation  of  DmPDE11A.  Each  cGK  displayed  strong  co-localisation  with  YFP-
DmPDE11B  long.  DG1  is  not  endogenously  expressed  in  S2  cells  (Chintapalli  et  al., 
2007). Co-transfection of S2 cells with c-Myc-DG1 and YFP-DmPDE11RB long yielded 
some  S2  cells  in  which  YFP-DmPDE11B  long  showed  a  lower  degree  of  membrane 
localisation. This could be mediated by a number of factors; direct association with the 
protein and sequestration to the cytosol, or modulation of localisation by phosphorylation, 
either of the PDE or some other substrate that then interacts with the PDE. While PKA has 
been  shown  to  modulate  the  subcellular  localisation  of  PDE10A  by  phosphorylation 
(Kotera et  al., 2004), no examples have been shown where cGK alters the subcellular 
localisation of a PDE. 
YFP-DmPDE11B long also co-localises with c-Myc tagged DG2 P1 and P2, where the 
localisation of c-Myc-DG2P1 is altered, with increased cytosolic expression, in which the 
protein localises to foci. This increases co-localisation, as DmPDE11B long also localises 
to the cytosol, and foci within the cytosol, although these foci do not necessarily contain 
both proteins. 
When this experiment was performed, anti-DG1, anti-DG2, and anti-PDE11 antibodies had 
been  designed  against  new  epitopes,  with  the  intention  of  apply  these  to 
immunocytochemistry of Malpighian tubules and other tissues to screen for co-localisation 
between the four DmPDE11 isoforms and the cGKs in vivo. However, the antibodies were 177 
produced behind the anticipated schedule, by which time my time in the laboratory had 
finished. 
YFP  tagged  DmPDE11B  long  and  short  isoforms  in  tubule  localise  to  the  apical  and 
basolateral membranes, which overlaps with the localisation of the cGKs in tubule. DG1 
localises to the basolateral membrane and the cytosol, DG2P1 localises to the apical and 
basolateral membranes, and DG2P2 localises to the apical membrane (MacPherson et al., 
2004b). In S2 cells, DmPDE11B long was shown to co-localise with DG1, DG2P1, and 
DG2P2.  The  DmPDE11C  isoforms  localise  to  some  unidentified  organelle  or  vesicle, 
which  does  not  overlap  with  the  subcellular  localisation  of  any  of  the  cGKs  in  the 
Malpighian  tubule  (other  than  perhaps  DG1,  which  localises  to  the  cytosol  but 
predominantly to the basolateral membrane). Although the co-immunoprecipitation data 
reported  in  this  chapter  relates  to  both  DmPDE11B  and  DmPDE11C  isoforms,  if  co-
localisation is mediated by domains common to the B and C isoforms, it is possible that 
although  both  isoforms  can  potentially  interact,  that  the  in  vivo  localisation  of  these 
isoforms may dictate whether or not any interaction with the cGKs actually occur. To 
confirm this, immunocytochemistry of Malpighian tubules co-staining for cGK and each 
DmPDE11  isoform  would  demonstrate  if  in  vitro  demonstrations  of  interactions  are 
potentially relevant in vivo. Clearly, the generation of tagged cGK expressing flies would 
allow  co-immunoprecipitation  to  be  applied  to  fly.  Alternatively,  the  availability  of 
specific  anti-cGK  and  anti-DmPDE11  antisera  would  allow  these  to  be  used  in 
immunoprecipitation; use of specific antisera against organisms and not cell systems is 
considered  the  gold  standard  for  co-immunoprecipitation.  The  tubule  would  be  a 
physiologically relevant tissue to use, as the cGKs have been shown to play roles in fluid 
secretion (MacPherson et al., 2004b), and cG-PDE function also modulates the process 
(MacPherson et al., 2004a). Furthermore, DG1 has a limited expression pattern, with high 
expression in the tubule and hindgut, and slight expression in head (and the tissues within). 
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Chapter 6 
Investigation of the DmPDE11/cGK interaction using 
peptide arrays 
6  Chapter 6 
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6.1 Summary 
In  this  chapter,  peptide  arrays  were  used  to  investigate  if  the  interaction  between 
DmPDE11  and  the  cGMP-dependent  kinases  is  direct,  and  if  so,  identify  the  peptide 
sequence  within  these  proteins  responsible  for  these  interactions.  Peptide  arrays 
representing the sequences of DmPDE11, DG1, and DG2 were generated using an autospot 
robot. The open reading frames of the genes encoding of these proteins were fused in-
frame into either pGEX-6P-1 or pET-28-c expression vectors in  fragments  to  generate 
Glutathione-S-Transferase-  (GST)  or  HIS6-tagged  proteins  respectively.  These  were 
transformed into BL21 (DE3) cells, and expression was analysed in terms of protein size, 
non-proteolysis,  and  solubility  by  western  blotting.  In  all  cases,  HIS6  tagged  fusion 
proteins were found to yield protein with more desirable characteristics, and so these were 
used to overlay the peptide arrays. Large scale purification was undertaken, and purified 
protein was then overlaid on the arrays, which were probed with HRP conjugated anti-HIS5 
antibody. These arrays were compared to negative controls, which were probed with a 
HIS6 protein derived from empty pET-28-c vector, then with antibody as above. Putative 
direct interactions were found between DG1 and DmPDE11, where three regions were 
identified on a DG1 peptide array that were immunoreactive when probed with a HIS6-
fused truncate of DmPDE incorporating the second GAF domain and the catalytic domain. 
Likewise when the PDE11 array was probed with a HIS6-fused DG1 C terminal truncate, 
two  putative  regions  of  interaction  were  found.  Taken  alongside  the  co-
immunoprecipitation  data  presented  in  chapter  five,  this  provides  evidence  of  a  direct 
interaction that should be verified by alanine substitution arrays, or in vivo work.  Attempts 
to affinity purify DG1N-HIS6 failed, and so the DmPDE11 array was not probed with this 
fragment. Peptide array experiments to determine whether the interaction between DG2 
and DmPDE11 presented in chapter 5 is direct did not yield conclusive data, and so should 
be researched further. 
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6.2 Introduction 
Chapter six describes the use of peptide arrays to investigate the interactions between the 
four  isoforms  of  PDE11,  and  the  cGKs  DG1,  and  DG2  presented  in  chapter  5.  Spot 
synthesis, the technique of synthesising multiple peptides or peptide chains simultaneously 
onto  a  membrane,  was  first  described  in  1992  (Frank,  1992).  The  screening  of  these 
peptide  libraries  with  overlaid  protein,  metal  and  DNA  was  described  the  next  year 
(Kramer  et  al.,  1993).  The  process  of  mapping  protein-protein  interaction  sites  was 
validated in a paper that forms the basis for current peptide array techniques (Reineke et 
al., 1996). The process sees the entire sequence of a protein of interest arrayed onto a 
membrane by an autospot robot using F-moc chemistry in spots of 25 amino acids, 25mers, 
which overlap by 20 amino acids. Thus each subsequent spot represents a 5 amino acid 
frameshift within the sequence. These peptide arrays are probed with soluble, recombinant 
protein, which is tagged with a protein tag. This tag acts both as an affinity tag, which 
permits the affinity purification of the protein, and as an epitope tag, which allows the use 
of  an  anti-tag  antibody  to  identify  those  25mer  spots  which  have  bound,  interacting 
protein.  A  primary,  “antibody  only”  experiment  identifies  spots  that  are  present  as 
background, i.e., they are immunoreactive in the absence of overlaid protein of interest. 
Tagged protein of interest is then overlaid on the array, and the array probed with anti-tag 
antibody; immunoreactive spots not present in the initial control experiment are considered 
as putative sites of interaction. 
In the course of this study, Glutathione-S-Transferase (GST) and HIS6 tagged proteins 
were  generated.  The  HIS6  tag  is  highly  suitable  for  use  in  peptide  arrays,  due  to  the 
availability of specific monoclonal antibodies, the small size of the tag, and thus minimal 
disruption of protein structure, and its reversible affinity for metal matrices, which aids in 
protein purification. The GST tag is larger, and so may compromise overall protein levels 
and structure, but acts as a solubilisation tag, which aids in the solubilisation of the protein, 
and thus may prevent the formation of inclusion bodies. Its affinity for glutathione allows 
its  affinity  purification,  and  again  there  are  specific  antibodies  available.  For  HIS6, 
negative controls are performed by overlaying an array with purified HIS6 peptide, then 
immunoblotting with anti-HIS5-HRP coupled mouse monoclonal antibody (Qiagen). GST 
negative  controls  are  performed  with  a  monoclonal  anti-Glutathione-S-Transferase 
antibody (Sigma-Aldrich).  181 
Like yeast two-hybrid, false positives and false negatives can occur. Expressing a fusion 
protein transgenically in E. coli can yield proteins that do not behave as they would in 
mammalian systems.  Misfolding may occur, the protein may be unavoidably degraded 
during  cell  lysis  and  subsequent  protein  purification,  or  inclusion  bodies  may  form, 
rendering the protein insoluble. As the tertiary structure of an individual domain may be 
influenced  by  other  domains  within  the  protein,  a  truncated,  transgeneically  expressed 
protein may  adopt  a novel  structure, which may  alter the protein‟s  binding properties, 
which in turn may result in false positive or false negative interactions. The conformation 
of  the  spotted  peptide  may  not  be  suitable  to  facilitate  binding,  or  the  spot  may  be 
immunoreactive in  negative controls,  thus  masking the interaction site.  The array may 
present epitopes that do not reside on the surface of the protein in vivo, which may result in 
false positive interactions. Despite this, the system offers an unparalleled opportunity to 
not only detect if a protein-protein interaction is direct, but to identify those amino acids 
responsible for the interaction. 
Ideally,  the  generation  of  both  peptide  arrays  and  tagged  recombinant  protein  for  two 
potential interactors should yield reciprocal binding sites. This data can be confirmed by 
alanine substitution arrays, which sequentially replace each amino acid within the stretch 
of  sequence  positive  for  an  interaction  with  an  alanine  residue,  which  renders  the 
interaction  null  if  that  residue  was  vital  for  the  interaction  (Gibbs  and  Zoller,  1991; 
Uttamchandani  et  al.,  2003);  in  this  case,  it  is  the  non-immunoreactive  spots  that  are 
informative.  
Taken together, it is clear that any positives are considered putative, but where an array is 
confirmed by an alanine array, which identifies individual amino acids essential for the 
interaction, this knowledge can then be used to screen for any resultant phenotypes when 
this  interaction  is  disrupted.  This  can  be  achieved  through  the  generation  of  a  protein 
mutated at this site, or via the generation of peptides representing this sequence, which will 
act as a dominant-negative when present in excess, or by generating protein mutant at this 
site. This can be used in co-immunoprecipitation to confirm that an interaction has been 
rendered null, or a transgenic animal or cell can then be subjected to a functional assay in 
which the mutant protein has been implicated.  
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6.3 Generation of peptide arrays 
Peptide  arrays  representing  the  sequence  of  DmPDE11  RB  and  RC,  and  DG1  were 
produced in collaboration with Dr. Alan Dunlop of the Houslay laboratory. Two arrays 
representing  the  sequence  of  DG2  were  produced  by  Dr  George  Baillie  as  part  of  a 
previous collaboration with Dr Matt Macpherson. 
 
6.4 Design of truncate fusion protein 
The E. coli pET and pGEX expression systems will facilitate a maximum of 2kb of ORF 
sequence.  As  the  DmPDE11  and  cGK  ORFs  are  significantly  larger  than  this,  it  was 
necessary  to  generate  tagged  truncates  which  would  still  incorporate  entire  functional 
domains,  as  protein-protein  interactions  can  occur  at  the  level  of  domain-domain 
interactions (DDIs) (Pawson and Nash, 2003). The amino acid sequences were analysed 
using  InterProScan  (Zdobnov  and  Apweiler,  2001).  InterProScan  uses  a  total  of  ten 
databases  including  PFAM,  SMART,  and  PROFILE  to  define  each  functional  domain 
within the protein (Quevillon et al., 2005). As each database gives a different prediction as 
to the extent of each domain, the region of truncation was determined by selecting regions 
that are not designated as domains by any of the tools, with the rationale that domains will 
not be truncated with this approach. 
 
6.4.1 Consideration of Drosophila cGK literature 
DG1 and DG2 were isolated in 1989 (Kalderon and Rubin, 1989). Phylogenetic analysis 
suggested that DG1 is most closely related to mammalian type II cGK, and DG2 is most 
closely related to mammalian type I cGK (Jarchau et al., 1994). As well as this work there 
are of course a number of papers focusing on these important Drosophila enzymes. As 
such there is further information pertaining to the location of domains within DG1 and 
DG2; indeed, the InterProScan database uses some of these domains in its analysis. A 
dimerisation domain is believed to reside within the amino terminal of both DG1 and DG2, 
but amino acid similarity with the dimerisation domain of mammalian cGK is so low that 
InterProScan does not predict the domain. The exact size and location is unknown in both 
enzymes and is thus not shown. Likewise, a regulatory domain is believed to be present in 183 
each enzyme, but low homology prevents computational prediction of its localisation (Heil 
et al., 1987; Monken and Gill, 1985; Takio et al., 1984). It is believed to be directly N-
terminal of the CNB domains. The bovine regulatory domain acts as a substrate analogue 
and binds to the catalytic domain at a lower affinity than cGMP, and thus impairs function 
in the absence of cGMP. However, Kalderon and Rubin believe that homology of this 
regulatory domain is low enough in both DG1 and DG2 that the mode of regulation may 
differ in Drosophila.  
 
6.4.2 DG1 
The amino acid sequence of DG1 was analysed using Interproscan (table 6.1). 
 
Table 6.1: Interproscan analysis of DG1 
Domain Program Site
Cyclic nucleotide binding domain PFAM  203-285 322-415
SMART  185-299 304-428
PROFILE 185-301 304-427
Protein kinase, core PROFILE 457-717
AGC Kinase, C terminal SMART  718-768
PROFILE 718 - 768  
 
InterProScan analysis revealed a length of sequence between the twin cyclic nucleotide 
binding domains and the kinase domain around halfway through the protein which was not 
designated as a domain, and so the constructs were generated using this as the boundary. 
DG1 is 768 amino acids in length. The N terminal truncate is 427 amino acids in length 
and extends to the end of the second of the cyclic nucleotide binding (CNB) domains, and 
incorporates the dimerisation and regulatory domains. The C terminal  truncate extends 
from the end of the second CNB domain to the end of the protein, thus incorporating the 
kinase,  ATP  binding  domains,  and  the  AGC  (cAMP-dependent,  cGMP-dependent  and 
protein kinase C) kinase C-terminal domain, a regulatory domain conserved between a 
diverse range of kinases (Kannan et al., 2007; Newton, 2003) and consists of 341 amino 
acids (figure 6.1).  
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Figure  6.1:  Primary  structure  of  DG1,  showing  regions  used  to  generate  fusion 
proteins. Shaded cylinders represent domains. Drawn to scale. 
 
 
 
 
 
                      N terminal truncate                                  C terminal truncate 
 
 
6.4.3 DG2  
The amino acid sequence of DG2 was analysed using Interproscan (table 6.2). 
 
Table 6.2: Interproscan analysis of DG2 
Domain Program Site
Cyclic nucleotide binding domain PFAM  538-623 656-749
SMART  520-636 656-749
PROFILE  520-635 638-761
Protein kinase, core PROFILE  777-1036
AGC Kinase, C terminal SMART  1037-1088
PROFILE  1037-1088  
 
DG2  P1  is  1088  amino  acids  in  length;  DG2  P2,  the  other  active  DG2  isoform  in 
Drosophila  (MacPherson  et  al.,  2004),  is  a  truncate  of  this  and  is  represented  entirely 
within the DG2 P1 sequence (http://flybase.org/reports/FBgn0000721.html). InterProScan 
analysis shows that the CNB domain starts at amino acid 520, and so this was picked as the 
boundary.  The  N  terminal  truncate  is  519  amino  acids  long,  and  incorporates  the 
CNB1  CNB2  Catalytic domain 
AGC kinase 
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dimerisation and regulatory domains. The C terminal truncate is 569 amino acids long and 
incorporates the ATP binding, twin CNB, protein kinase, and the AGC kinase C terminal 
domains (figure 6.2). 
 
Figure 6.2: Primary structure of DG2 (P1), showing regions used to generate fusion 
proteins. Shaded cylinders represent domains. Drawn to scale. 
 
 
 
   
                 N terminal truncate                                     C terminal truncate 
 
6.5 DmPDE11 
The amino acid sequence of DmPDE11 was analysed using Interproscan (table 6.3). 
 
Table  6.3:  Interproscan  analysis  of  DmPDE11.  Amino  acids  refer  to  those  of 
DmPDE11B long. 
Domain Program Residues
3'5'-cyclic nucleotide phosphodiesterase PFAM 859-1097
PROSITE  900-911
GAF PFAM  419 - 572 604 - 754
SMART 419 - 582 604 - 764 
 
As a size of 2kb was the maximum size of insert that the E. coli expression vectors could 
facilitate,  the  ~4.5kb  DmPDE11  ORF  was  cloned  as  three  fusion  protein  truncates. 
CNB1  CNB2   
 
AGC kinase 
C terminal 
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InterProScan  analysis  dictated  that  the  best  three-way  split  would  be  two  N  terminal 
truncates, incorporating sequence from the unique B or C isoform N termini, until the end 
of the first GAF domains, and thus the B isoform N terminal fragment incorporates 582 
amino acids, and the C isoform N terminal fragment incorporates 538 amino acids. The 
“Middle” truncate incorporates sequence ranging from the start of the second GAF domain 
until the end of the catalytic PDEase domain, and consists of 515 amino acids. The “End” 
C terminal truncate extends from the end of the catalytic domain to the end of the long C-
terminus, and consists of 354 amino acids (figure 6.3).  
 
Figure 6.3: Primary structure of DmPDE11, showing regions used to generate fusion 
proteins. Shaded cylinders represent domains. Drawn to scale. 
 
 
 
                  N terminal truncate                       “Middle” truncate                 “End” truncate   
 
The unique sequence within the short C terminal is represented in the PDE11 peptide 
array; as the sequence is so short, and co-immunoprecipitations show an interaction with 
both the long and short isoforms, it was assumed that it would not mediate the interaction. 
6.6 Cloning of ORFs into expression vectors 
Primers  were  designed  to  generate  E.  coli  expression  constructs  for  all  of  the  above 
truncates, using pET-28-c, a gene fusion vector with an N terminal HIS6-thrombin-T7 tag, 
and pGEX-6P-1, a gene fusion vector with an N terminal Glutathione S-Transferase (GST) 
tag.  All  ORFs  were  amplified  using  proofreading  DNA  polymerase  from  previously 
verified plasmid DNA, with primers designed to incorporate restriction sites not present in 
 
GAF1   GAF2    Long C terminus 
Catalytic 
 domain 
 
Unique B/C  
 N-termini 
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the ORF, but present in the multiple cloning site to permit direction cloning of the inserts. 
These PCR fragments were digested with the appropriate restriction enzymes, and ligated 
into  digested  expression  vector.  These  were  transformed  into  Stratagene  Gold 
ultracompetent cells, and plasmid DNA was recovered from multiple colonies by miniprep 
and screened using both digestion and PCR analysis.  
 
6.7 Expression of constructs 
As pET and pGEX constructs were generated for each gene, it was sought to determine 
which of these, in each case, provided the greater amount of pure, non-degraded protein by 
performing small scale growth and induction to analyse by western blot. In each case, 
BL21 (DE3) pLysS competent cells were transformed with plasmid DNA, and a colony 
used to generate a 3ml culture, which was grown to an OD600 of ≥0.6 – ≤1.0 at 37˚C with 
shaking. Of 1 ml, 100μl was spun down, the pellet used as a non-induced control, and 
900μl  to  make  a  glycerol  stock.  The  remaining  2ml  was  induced  with  0.4mM  IPTG 
(pGEX) or 0.1mM IPTG (pET) for two hours. Two 1 ml aliquots were spun down and 
lysed, one in IGEPAL lysis buffer to completely solubilise the cellular protein, the other in 
the appropriate native lysis buffer using L3 sonication, both with protease inhibitor and 
lysed on ice. These were run alongside the non induced control (also lysed in IGEPAL 
with an identical dilution factor) on an SDS page gel, and western blotting was performed 
with the appropriate antibody. 
Comparison between HIS6- and GST-tagged protein lysate showed HIS6 tagged protein 
showed higher levels of immunoreactivity, and lower levels of background, for which most 
of the GST lysates displayed high levels (data not shown). The HIS6 protein also displayed 
lower  levels  of  degradation.  Although  this  may  have  been  down  to  a  poor  anti-GST 
antibody, the HIS6 tagged protein expression did not appear to need any modification of 
protocol (with the exception of the DmPDE11 End fragment, which gave an equally poor 
yield when tagged with GST), and thus these were affinity purified using Ni-NTA columns 
for use with the arrays, as detailed in materials and methods. 188 
6.8 Purification of HIS6 protein 
HIS6 protein was purified using a Ni-NTA column as described in materials and methods. 
5 μl aliquots of lysate (following application to column), wash fraction, and the 1 ml HIS6 
eluates were analysed by western blotting. 
6.8.1 HIS6 
HIS6 protein was generated by the transformation of pET-28-c vector into BL21 (DE3) 
pLysS competent cells, for use as a negative control. The HIS6 protein has an expected size 
of ~3 kDa. Affinity purified fractions were analysed by western blotting (figure 6.4). 
 
Figure 6.4: HIS6 purified peptide. HIS6 peptide, from pET-28-c vector. 14% SDS-PAGE 
gel. Lane 1: run-through lysate applied to column, lane 2: wash fraction, lanes 3 – 11: 
purified fractions. 1
◦ antibody anti-HIS6 mouse monoclonal HRP conjugated.  
 
 
 
 
 
 
 
Western analysis of HIS6 purified protein yielded a band of the predicted size, and showed 
no unspecific bands. The protein purified to a high concentration. 
 
6.8.2 DmPDE11BN-HIS6 
DmPDE11BN-HIS6  protein  (BN-HIS6)  was  generated  by  the  transformation  of 
DmPDE11RBN-pET-28-c  vector  into  BL21  (DE3)  pLysS  competent  cells.  BN-HIS6 
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protein has  an expected size of ~67 kDa. Affinity purified fractions  were analysed by 
western blotting (figure 6.5). 
 
Figure 6.5: BN-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: run-through lysate 
applied to column, lane 2: wash fraction, lanes 3-10: purified fractions, lanes 11 and 12: 
fractions purified at a higher imidazole concentration. 
 
 
 
 
 
BN-HIS6 purified protein was of the predicted size, recovered at a high concentration, 
higher in those fractions containing a high concentration of imidazole, and showed little 
degradation, increased in the higher imidazole elates; as such these were not used.  
 
6.8.3 DmPDE11CN-HIS6 
DmPDE11CN-HIS6  (CN-HIS6)  protein  was  generated  by  the  transformation  of 
DmPDE11RCN-pET-28-c  vector  into  BL21  (DE3)  pLysS  competent  cells.  CN-HIS6 
protein has  an expected size of ~61 kDa. Affinity purified fractions  were analysed by 
western blotting (figure 6.6) 
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Figure 6.6: CN-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, lane 
2:  wash  fraction, lanes  3-9:  purified fractions,  lanes  10 and 11:  fractions  purified at  a 
higher imidazole concentration. 
 
 
 
 
 
 
CN-HIS6  purified  protein  was  of  the  expected  size  (lane  9),  was  recovered  at  a  low 
concentration only from those fractions eluted using a high concentration of imidazole, and 
showed no appreciable degradation. 
 
6.8.4 DmPDE11 Middle-HIS6 
DmPDE11 Middle-HIS6 protein was generated by the transformation of Middle-pET-28-c 
vector into BL21 (DE3) pLysS competent cells. Middle-HIS6 protein has an expected size 
of ~62 kDa. Affinity purified fractions were analysed by western blotting (figure 6.7). 
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Figure 6.7: Middle-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9 purified fractions: lanes 10 and 11: fractions purified at a 
higher imidazole concentration.  
 
 
 
 
 
Middle-HIS6 purified protein was of the expected size, and was recovered at a reasonable 
concentration. The protein showed no appreciable degradation.  
6.8.5 End-HIS6 
DmPDE11 End-HIS6 protein was generated by the transformation of End-pET-28-c vector 
into BL21 (DE3) pLysS competent cells. End-HIS6 protein has an expected size of 41 kDa. 
Affinity purified fractions were analysed by western blotting (figure 6.8). 
Figure 6.8: End-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, lane 
2:  wash  fraction, lanes  3-9:  purified fractions,  lanes  10 and 11:  fractions  purified at  a 
higher imidazole concentration. 
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Although protein of the predicted size purified at high concentration, the protein showed 
high levels of degradation. Furthermore a non-specific band of ~64 kDa co-purified with 
the fusion protein. Subsequent to this attempt, incubation with MgSO4 for 30 min prior to 
application to the column prevented the 64 kDa protein, which the literature suggests is the 
common  contaminant  DnaK,  from  co-purifying,  although  the  immunoblot  of  the 
subsequent  western  blot  was  “dirty”;  although  the  bands  were  clearly  visible,  the  blot 
would  not  scan  clearly,  and  so  is  not  shown.  In  lanes  with  a  higher  concentration  of 
protein, immunoreactive protein that had not migrated from the wells was present, which 
suggests that the protein forms inclusion bodies at high concentrations. The gel shown has 
two lanes  with  protein  of the  correct  size, with little degradation (lanes  7 and 9);  the 
compromised transfer showed bands equally pure without DnaK, and so these eluates were 
applied to the array. 
6.8.6 DG1N-HIS6 
DG1N-HIS6 protein was generated by the transformation of DG1N-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG1N-HIS6 yielded soluble protein of ~50 kDa at the 
analytical stage, yet no protein was observed in western blots of Ni-Nta column purified 
protein.  This  was  despite  attempts  to  optimise  the  purification  protocol,  by  excluding 
imidizole from the binding buffer, using a reduced-strength wash buffer, varying the length 
of the binding step, and performing the purification as quickly as possible to minimise 
degradation (data not shown). 
 
6.8.7 DG1C-HIS6 
DG1C-HIS6 protein was generated by the transformation of DG1C-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG1C-HIS6 protein has an expected size of ~42 kDa. 
Purified fractions were analysed by western blotting (figure 6.9). 
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Figure 6.9: DG1C-HIS6 purified protein. 10% SDS-PAGE gel. Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
 
 
 
 
 
Protein of the predicted size purified at high concentration under elution conditions of high 
levels of imidazole (lanes 10 and 11). The protein showed mild levels of degradation, but 
these bands were less strong than the desired size of band. Subsequent to this first attempt, 
incubation  with  MgSO4  for  30  min  prior  to  application  to  the  column  prevented  co-
purification with the ~64 kDa protein, identified as DnaK, from co-purifying, although the 
transfer of this gel was compromised as above and so is not shown.  
6.8.8 DG2N-HIS6 
DG2N-HIS6 protein was generated by the transformation of DG2N-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG2N-HIS6 protein has an expected size of ~60 kDa. 
Purified fractions were analysed by western blotting (figure 6.10). 
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Figure 6.10: DG2N-HIS6 purified protein. 10% SDS-PAGE gel.  Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
 
 
 
 
DG2N-HIS6 purified protein ran as two bands, one of the expected size, and one ~5 kDa 
larger.  Reasons  for  this  are  unknown;  perhaps  the  protein  was  subjected  to  a  post 
translational modification. Protein was recovered at a reasonable concentration where an 
increased  concentration  of  imidazole  was  used,  and  showed  no  degradation,  in  lanes 
outside of the lysate and wash. 
6.8.9 DG2C-HIS6 
DG2C-HIS6 protein was generated by the transformation of DG2C-pET-28-c vector into 
BL21 (DE3) pLysS competent cells. DG2C-HIS6 protein has an expected size of ~67 kDa. 
Purified fractions were analysed by western blotting (figure 6.11). 
 
Figure 6.11: DG2C-HIS6 purified protein. 10% SDS-PAGE gel.  Lane 1: soluble lysate, 
lane 2: wash fraction, lanes 3-9: purified fractions, lanes 10 and 11: fractions purified at a 
higher imidazole concentration. 
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DG2C-HIS6 purified protein was of the expected size, highly pure, recovered at a low 
concentration from elution conditions of increased imidazole concentration, and showed no 
discernable degradation outside of the wash fraction. 
 
6.9 Screening of peptide libraries for direct interactions 
In  order  to  identify  non-specific  immunoreactive  spots,  each  array  was  probed  with 
purified HIS6 protein at a concentration approximately equimolar to that of the purified 
gene –  HIS6 fusion protein subsequently applied, and detected with  an anti-HIS5 HRP 
conjugated  monoclonal  antibody,  using  several  lengths  of  exposure.  Arrays  were  then 
probed with a protein of interest fused to HIS6 at 10 μg/ml, and probed with an anti-HIS5 
HRP  conjugated  monoclonal  antibody  as  before.  Putative  direct  interactions  were 
identified  by  comparing  control  arrays  with  gene-HIS6  probed  arrays;  where  a  spot  is 
immunoreactive on the array probed with the gene-HIS6 that is not immunoreactive on the 
control array, it is considered a putative interaction site. Arrays were stripped between 
probes. The technique is described in detail in materials and methods. 
6.10 PDE11 Array 
A peptide array representing the sequence of DmPDE11, including sequence of the unique 
N-termini  of  the  B  and  C  isoforms,  and  the  unique  sequence  of  the  short  isoform  C 
terminus, was produced in collaboration with Dr Allan Dunlop, and was probed with cGK 
fusion protein in order to detect putative interaction sites. 
6.10.1  PDE11 array probed with HIS6 
As a control, the PDE11 array was probed with a control peptide, HIS6, at a concentration 
approximately equimolar to that of the gene – HIS6 fusion proteins that were subsequently 
applied,  and  non-specific  spots  were  identified  with  an  anti-HIS5  HRP  conjugated 
monoclonal antibody (figure 6.12). 
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Figure 6.12: PDE11 array probed with HIS6. The DG2 array was probed with HIS6 
protein. Non-specific spots were identified by staining with an anti-HIS5 HRP conjugated 
monoclonal antibody. Arrays exposed to film for 10 minutes. 
 
 
There  is  a  large  degree  of  background.  Rows  of  immunoreactive  spots  contain  either 
HIS5mers, which matches the specificity of the ʱHIS5 antibody used, or contain HIS5mers 
with a single amino acid substitution (such as HHHNH, in the case of the two rows near 
the top left of the array), suggesting that conditions permit antibody binding to epitopes 
that are not 100% specific. The C terminal region of PDE11 has two histidine rich regions, 
which are represented in two strips of spots, 864-871, and 882-888.  
 
6.10.2  PDE11 array probed with DG1C-HIS6 
The PDE11 array was probed with DG1C-HIS6 protein. Specific interacting spots were 
identified  by  staining  with  an  anti-HIS5  HRP  conjugated  monoclonal  antibody,  and 
comparing these to a control exposed for 10 minutes (figure 6.13). 
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Figure 6.13: PDE11 array probed with DG1C-HIS6, shown alongside HIS6 control. 
The PDE11 array was probed with DG1C-HIS6 protein. Interacting spots were identified 
by staining with an anti-HIS5 HRP conjugated monoclonal antibody. Putative interaction 
sites are highlighted with a solid or dashed line. Array exposed to film for 1 minute. 
 
 
PDE11 array probed with HIS6. Array exposed to film for 10 minutes. 
 
 
Spots 729 – 732 (highlighted with a solid line) and spot 763 (highlighted with a dashed 
line)  are  immunoreactive  after  a  mere  30  seconds  of  exposure  on  the  PDE11  array 
challenged with DG1C-HIS6 and are negative on both HIS6 controls, suggesting that these 
regions interact with the sequence of DG1 represented by DG1C-HIS6, which consists of 
the final 341 amino acids of the protein, thus incorporating the kinase, and ATP binding 
domains.  These  spots  correspond  the  sequence 
VHEADKGSFSRVFDFEANDLSEEEATSRTSPYESRFPINI (amino acids 630-669), and 
VHFRLHDFKFDDIHFEDDDTLKACL (amino acids 800 - 824) within DmPDE11, using 
DmPDE11 B long as a reference. These residues fall within the second GAF domain, and 
the region between the second GAF domain and the catalytic domain respectively, and as 
such both are found in the region of PDE11 shared by all four isoforms, and are included in 
Middle-HIS6 (figure 6.14).  198 
Figure 6.14: PDE 11, with putative regions of interaction with the C terminus of DG1. 
Exposures of equal time (5 minutes) shown. Top array control, bottom array probed with 
DG1C-HIS6. 
 
 
 
 
 
 
 
 
 
Analysis of both regions with NetPhosK predicts no putative cGK phosphorylation sites in 
either  region  of  putative  interaction.  However,  NetPhosK  predicts  serine  798  (of 
DmPDE11B long) to be phosphorylated by cGK with a score of 0.68 (Blom et al., 2004), 
two  amino  acids  immediately  proximal  to  the  25mer  of  spot  763  showing  strong 
immunoreactivity. Indeed this spot is immunoreactive in the DG1C-HIS6 probed PDE11 
array compared to control, but not to a convincing extent. 
 
6.10.3  PDE11 array probed with DG2N-HIS6 
The DmPDE11 peptide array was probed with DG2N-HIS6 in order to detect any putative 
interaction sites. Specific interacting spots were identified by staining with an anti-HIS5 
HRP conjugated monoclonal antibody, and comparing these to a control exposed for 10 
minutes, as this has similar background (figure 6.15). 
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Figure 6.15: PDE11 array probed with DG2N-HIS6, shown alongside HIS6 control. 
The PDE11 array was probed with DG2N-HIS6 protein. Interacting spots were identified 
by staining with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film 
for 1 min. 
 
 
PDE11 array probed with HIS6. Array exposed to film for 10 min. 
 
 
Compared to the HIS6-probed control PDE11 array, the DG2N-HIS6 probed PDE11 array 
showed a stronger average signal for each length of exposure, and as such the DG2N-HIS6 
probed array exposed for 1 min is compared to a HIS6 control PDE11 array of ten minutes. 
Curiously, there are a number of spots positive in control blots that were not strongly 
immunoreactive in the DG2N-HIS6 probed array even after a 20 min exposure. The reason 
for this is unknown. Comparison of the DG2N-HIS6 probed PDE11 array with control does 
not show any novel spots. As such, there is no evidence of interaction. It does, however, 
merit further investigation. Use of a different anti-(poly)HIS antibody may reduce the non-
specific immunoreactivity of non-specific immunoreactive spots, which would allow the 
array to be re-probed with DG2N-HIS6. Alternatively, probing the array with GST-fused 
DG2N would give a different set of non-specific immunoreactive spots, and thus perhaps 
be more informative.  
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6.10.4  PDE11 array probed with DG2C-HIS6 
The DmPDE11 peptide array was probed with DG2C-HIS6 in order to detect any putative 
interaction sites. Specific interacting spots were identified by staining with an anti-HIS5 
HRP conjugated monoclonal antibody, and comparing these to a control exposed for 10 
minutes, as this has similar background (figure 6.16). 
Figure 6.16: PDE11 array probed with DG2C-HIS6, shown alongside HIS6 control. 
The DG2 array was probed with HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for 5 min. 
 
PDE11 array probed with HIS6. Array exposed to film for 10 min. 
 
 
When the PDE11 array is probed with DG2C-HIS6, spots 729-730, represented by a solid 
black  line  (VHEADKGSFSRVFDFEANDLSEEEATSRTS,  amino  acids  630-659)  and 
763, represented by a dashed line (VHFRLHDFKFDDIHFEDDDTLKACL, amino acids 
800 - 824) are immunoreactive when compared to the HIS6 probed control. These spots 
were  also  immunoreactive  when  overlaid  with  DG1C-HIS6.  However  these  spots  are 
considerably weaker than those seen in the DG1C-HIS6 probed PDE11 array, and as the 
DG2C-HIS6 result was obtained subsequently to the DG1C-HIS6 result, a stripping issue 
cannot  be  ruled  out.  A  further  two  regions  are  immunoreactive  in  DG2-HIS6  probed 201 
PDE11 array, that show no detectable immunoreactivity on HIS6 probed control PDE11 
blots;  spot  652,  represented  by  a  double  solid  line 
(THANGQTSSSRGGSGATTPVRKISA, amino acids 245-269) and 703, represented by a 
double dashed line (amino acids 500-524), are immunoreactive in the DG2C-HIS6 probed 
blot.  In  all  cases,  “specific”  immunoreactive  spots  do  not  display  immunoreactivity 
comparable  to  putative  positive  spots  returned  by  other  arrays  are,  and  as  such  it  is 
desirable that the array be re-probed, or alanine substitution arrays generated representing 
these areas to verify the interaction. Certainly, these are not immunoreactive to an extent 
that they can be considered to constitute putative sites of interaction. 
 
6.11 DG1 Array 
A peptide array representing the sequence of DG1 was produced in collaboration with Dr 
Allan Dunlop, and was probed with Middle-HIS6 protein, as a putative direct interaction 
was found when the PDE11 array was probed with DG1C-HIS6 protein. Time did not 
permit the probing of the array with the other DmPDE11 fusion proteins. One aspect of the 
protocol was changed for the DG1 arrays; ECL Plus Western Blotting Detection Reagent 
(Amersham) was used, which gives a wider dynamic range compared to ECL Western 
Blotting Detection Reagent. This had the effect of reducing the necessary time of exposure, 
and also had increased reactivity with the membrane itself. As such, blots of 5 minutes or 
over had overly high levels of background, and so these are not shown. 
6.11.1  DG1 array probed with HIS6 
As a control, the DG1 array was probed with a control peptide, HIS6, at a concentration 
approximately equimolar to that of the gene – HIS6 fusion proteins that were subsequently 
applied,  and  non-specific  spots  were  identified  with  an  anti-HIS5  HRP  conjugated 
monoclonal antibody (figure 6.17). 
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Figure  6.17:  DG1  array  probed  with  HIS6.  The  DG2  array  was  probed  with  HIS6 
protein. Non-specific spots were identified by staining with an anti-HIS5 HRP conjugated 
monoclonal antibody. Array exposed to film for 2 min 30 s. 
 
6.11.2  DG1 array probed with DmPDE11 Middle-HIS6 
The  DG1  peptide  array  was  probed  with  Middle-HIS6  in  order  to  detect  any  putative 
interaction sites (figure 6.18).  
Figure 6.18: DG1 array probed with Middle-HIS6, shown alongside HIS6 control. The 
DG2  array  was  probed  with  Middle-HIS6  protein.  Interacting  spots  were  identified  by 
staining with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film 
for 1 min. 
 
PDE11 array probed with HIS6. Array exposed to film for 2 min 30 s. 
 
 
Spots  104-105,  highlighted  by  a  solid  line, 
(LVKLHREIHKLKSVLQQTTNNLNVTREIHK, amino acids 60-90)   are  strongly 
immunoreactive compared to control probed arrays, and furthermore these spots give no 
immunofluorescence in a control exposed for 5 minutes (data not shown). There are two 
further spots that give immunofluorescence in the Middle-HIS6 probed DG1 peptide array; 203 
spots  169-170,  highlighted  by  a  dashed  line 
(EETELRTLSRGDYFGEQALINEDKRTANII, amino acids 360-390), and spots 233-235 
highlighted  by  a  double  solid  line 
(ISRWAVQLIKRLCRDVPSERLGYQTGGIQDIKKHK,  amino  acids  680-715)  (figure 
6.19). 
 
Figure 6.19: DG1, with putative regions of interaction with sequence represented by 
the Middle-HIS6 fusion protein. Exposures of 1 min (Middle-HIS6 probed) and 2 min 30 
s (HIS6 probed) shown. Top array control, bottom array probed with DG2C-HIS6. 
 
 
 
 
 
 
The first two putative regions of interaction identified in the Middle-HIS6 probed DG1 
array  localise  to  a  region  of  the  N  terminus  not  well  characterised  –  the  N  terminus 
contains  the  dimerisation  and  regulatory  domains,  but  the  exact  location  of  these  is 
unknown - and to the second CNB domain. The third putative region of interaction falls 
within the catalytic domain of the enzyme, which is sequence represented by the DG1 C 
terminal  truncate.  DG1C-HIS6  showed  two  putative  regions  of  interaction  within 
DmDPE11 when applied to the PDE11 array. As two of the putative regions of interaction 
with PDE11 are represented by DG1N-HIS6, it would be desirable to probe the PDE11 
peptide array with this truncation in order to screen for a reciprocal interaction. Alanine 
substitution arrays would provide further proof that these regions interact, and identify 
individual amino acids within these regions vital to the interaction.  
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6.12 DG2 Array 
A peptide array representing the sequence of DG2 P1, which incorporates the amino acid 
sequence of DG2 P2 in its entirety, was available from a collaboration between Dr Matt 
Macpherson and Dr George Baillie. As putative direct interactions were found when the 
PDE11 array was probed both DG2 HIS6 fusion proteins, the DG2 array was probed with 
every HIS6-tagged fragment of DmPDE11, in order to detect any putative interaction sites. 
6.12.1  HIS6 Control 
As a control, the DG2 array was probed with a control peptide, HIS6, at a concentration 
approximately equimolar to that of the gene - HIS6 fusion proteins that were subsequently 
applied,  and  non-specific  spots  were  identified  with  an  anti-HIS5  HRP  conjugated 
monoclonal antibody (figure 6.20). 
 
Figure  6.20:  DG2  array  probed  with  HIS6.  The  DG2  array  was  probed  with  HIS6 
protein. Non-specific spots were identified by staining with an anti-HIS5 HRP conjugated 
monoclonal antibody. Array exposed to film for 15 min. 
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6.12.2  DG2 array probed with DmPDE11-HIS6 
6.12.2.1  BN-HIS6  
The  DG2  array  was  probed  with  BN-HIS6  protein.  Specific  interacting  spots  were 
identified  by  staining  with  an  anti-HIS5  HRP  conjugated  monoclonal  antibody,  and 
comparing these to the equivalent control (figure 6.21). 
Figure 6.21: DG2 array probed with  BN-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with BN-HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for 15 min. 
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DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
The BN-HIS6 probed array showed a weaker signal than other DG2 array exposures; the 
reason for this is unknown. The BN-HIS6 probed DG2 array show no novel spots when 
compared  to  the  HIS6  control  DG2  array.  This  data  suggests  that  there  is  no  direct 
interaction between DG2, and the section of DmPDE11B represented by BN-HIS6, which 
incorporates from the unique B N-terminus until the end of the first GAF domain.  
6.12.3  CN-HIS6 
The  DG2  array  was  probed  with  CN-HIS6  protein.  Specific  interacting  spots  were 
identified  by  staining  with  an  anti-HIS5  HRP  conjugated  monoclonal  antibody,  and 
comparing these to the equivalent control (figure 6.22). 
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Figure 6.22: DG2 array probed with CN-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with CN-HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for fifteen 
minutes. 
 
DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
The CN-HIS6 probed DG2 array shows no novel spots when compared to the HIS6 control 
DG2 array. This data suggests that there is no direct interaction between DG2, and the 208 
section of DmPDE11C represented by CN-HIS6, which incorporates from the unique C N-
terminus until the end of the first GAF domain. 
6.12.3.1  Middle-HIS6 
The  DG2  array  was  probed  with  Middle-HIS6  protein.  Specific  interacting  spots  were 
identified  by  staining  with  an  anti-HIS5  HRP  conjugated  monoclonal  antibody,  and 
comparing these to a control exposed for 15 min as this showed equivalent background 
(figure 6.23). 
Figure 6.23: DG2 array probed with Middle-HIS6, shown alongside HIS6 control. The 
DG2  array  was  probed  with  Middle-HIS6  protein.  Interacting  spots  were  identified  by 
staining with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film 
for 5 minutes. 
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DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
The Middle-HIS6 probed DG2 array showed a strong signal after 5 min of exposure, and so 
this is compared to a HIS6 control array exposed for 15 min. Comparison shows no novel 
spots when compared to the HIS6 control DG2 array. There are two spots that appear after 
5 min on the Middle-HIS6 array that are barely visible after 15 min of exposure on the 
HIS6 control blot. However, as background is higher on the  Middle-HIS6 probed DG2 
array  than  control,  it  would  be  desirable  to  repeat  the  assay,  using  a  different  anti-
(poly)HIS antibody, or a GST-tagged Middle fragment. 
6.12.3.2  End-HIS6 
The  DG2  array  was  probed  with  End-HIS6  protein.  Specific  interacting  spots  were 
identified  by  staining  with  an  anti-HIS5  HRP  conjugated  monoclonal  antibody,  and 
comparing these to a control exposed for 15 min as this showed equivalent background 
(figure 6.24). 
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Figure 6.24: DG2 array probed with End-HIS6, shown alongside HIS6 control. The 
DG2 array was probed with End-HIS6 protein. Interacting spots were identified by staining 
with an anti-HIS5 HRP conjugated monoclonal antibody. Array exposed to film for two 
minutes thirty seconds. 
   
DG2 array probed with HIS6. Array exposed to film for fifteen minutes. 
 
At an exposure time of 2 min 30 s, novel spots are seen at E22 – J22 (highlighted by a 
solid  line),  representing  the  sequence 
SNAPHSSTTVDAPPRPADVDVATVPVATPAPPPQQPVSNLFYADYQKLQP,  C16  – 211 
D16  (highlighted  by  a  double  solid  line),  representing  the  sequence 
YHQPSPGSSQPVAIPGATCHSPTQLQPPNT,  G16  -  H16  (highlighted  with  a  dashed 
line), representing the sequence SPTQLQPPNTLNLQQQMQSLRISGCTPSGT, and C9 
(highlighted  by  a  double  dashed  line),  representing  the  sequence 
RGDYIVRQGARGDTFFIISKGKVRV. However, multiple spots present as background 
on the control DG2 array are not immunoreactive on End-HIS6 probed DG2 array. The 
reason  for  this  is  unknown.  Furthermore,  background  was  sufficient  on  the  End-HIS6 
probed array at exposure times of five or more minutes to obscure previously clear spots. 
When  purifying  higher  concentrations  of  End-HIS6  protein,  non-mobile,  insoluble, 
immunoreactive protein transferred to the membrane in a manner that suggested it had not 
migrated from the wells; i.e., it had formed inclusion bodies, and so End-HIS6 is partially 
insoluble,  which  most  likely  explains  the  high  levels  of  background.  The  array  was 
repeated with a different batch of purified protein in an attempt to reduce background, but 
as the DG2 array had been stripped twice, the exposures actually had more background and 
so again these results are omitted. These issues prevent these data from being taken to 
indicate a putative interaction. Were the experiment to be repeated, soluble protein would 
be  necessary.  Optimisation  of  growth  conditions  was  attempted,  but  clearly  optimum 
conditions  were  not  achieved.  The  addition  of  Triton-X  100  when  purifying  the 
recombinant  protein  may  render  the  protein  soluble.  Were  this  approach  to  fail,  the 
generation  of  an  N-and  C-terminal  tagged  End-GST  fusion  protein  may  yield  a  more 
soluble protein. However, repeat of the experiment would also need a new DG2 array to be 
produced, as those used have been stripped numerous times. 
6.13 Discussion 
In this chapter, peptide arrays were used to determine whether the interaction between 
DmPDE11 and the cGKs DG1, and the DG2 isoforms P1 and P2 are direct or indirect. A 
peptide array representing the sequence of DmPDE11, including the novel N-termini of the 
B and C isoforms, and the novel sequence of the C-termini of the short isoforms was 
generated, and probed with HIS6 fused cGK protein. While DG1N-HIS6 was expressed at 
the predicted size, repeated attempts to affinity-purify the protein failed. The PDE11 array 
was probed with DG1C-HIS6 peptide. Comparison of the control and DG1C-HIS6 probed 
PDE11 arrays reveals two areas of putative interaction. The first occurs within the second 
of the GAF domains. GAF domains perform a multitude of roles, and are present in several 
classes of protein (Martinez et al., 2002a). They have been shown to modulate the function 212 
of several mammalian PDEs. The GAF domains of PDE2, PDE5 (Zoraghi et al., 2004), 
and PDE11 have been shown to bind cGMP, and the GAF domain of PDE10 binds cAMP  
(Gross-Langenhoff  et  al.,  2006).  GAF  domains  have  been  shown  to  mediate 
oligomerisation in PDE2 (Martinez et al., 2002b), PDE5 (Zoraghi et al., 2005), PDE6ʱβ 
and  PDE6ʱﾴʱﾴ  (Muradov  et  al.,  2003),  and  PDE11A  (Weeks  et  al.,  2007),  where 
phosphorylation  of  two  cGK  phosphorylation  sites  in  the  N  terminus  of  the  PDE11A 
modulates the process (Gross-Langenhoff et al., 2008). GAF domains function to relieve 
autoinhibition in PDE2 (Martinez et al., 2002b) and PDE5 (Rybalkin et al., 2003).  GAF 
domains have also been implicated in protein-protein interaction, where binding of cGMP 
to the GAF domains of PDE6 R mediates the interaction of the catalytic domain with the 
inhibitory subunit Pγ (D'Amours and Cote, 1999). Within this context, a direct protein-
protein interaction with DG1 at this site could have any number of implications. Were 
DG1 interaction at this site to affect any of these processes, this would modulate PDE11 
activity, and therefore modulate the activity of the cGK itself. Within this region there are 
no cGK or PKA consensus phosphorylation sites. The second putative area of interaction 
lies between the second GAF domain and the catalytic site of DmPDE11. Although this 
area  contains  no  putative  cGK  phosphorylation  sites,  there  is  a  putative  cGK 
phosphorylated serine residue two amino acids proximal to the immunoreactive 25mer. 
Furthermore, this 25mer represents an entire putative phosphorylation site, and this spot is 
immunoreactive  when  compared  to  control.  However,  this  spot  was  only  mildly 
immunoreactive compared to its neighbour, visible after 5 minutes opposed to 10 seconds. 
This area of DmPDE11A has had no function ascribed to it as yet; furthermore the putative 
phosphorylation site is not present in HsPDE11A. As such the significance of this putative 
interaction is not clear. An in vitro or in vivo phosphorylation assay would show whether 
or not PDE11 is a bona fide phosphorylation target of DG1. These sites of interaction can 
only be considered putative; an alanine substitution array representing these spots would 
confirm whether the interaction is bona fide, and would identify essential residues in the 
region.  
As both of the regions identified in the PDE11 array as putative regions of interaction with 
DG1C-HIS6 fell within the PDE11 Middle-HIS6 protein, and time remaining in the lab was 
short, the DG1 array was only overlaid with this DmPDE11 fusion protein. Three putative 
regions of direct interaction were identified. The first putative region of interaction maps to 
the N-terminus of the DG1, which contains the dimerisation and regulatory domains. The 
second maps to the second CNB domain, and the third to the catalytic domain. The first 
two regions of interaction are incorporated within the DG1 N terminal truncate. As such it 213 
is  desirable  that  this  protein  is  applied  to  the  PDE11  array,  in  order  to  screen  for  a 
reciprocal interaction. The third putative region of interaction is represented within the 
DG1  C  terminal  truncate,  which  showed  two  putative  regions  of  interaction  within 
DmDPE11 when applied to the PDE11 array. Again, alanine substitution arrays would 
provide further proof that these regions interact, and identify individual amino acids within 
these regions vital to the interaction. However, the putative data corresponds with the co-
immunoprecipitation data presented in chapter 5. Further putative regions of interaction 
may be identified if the DG1 array is probed with the other DmPDE11 truncations, and so 
it is desirable that these assays are performed. Importantly, such an interaction must be 
confirmed  by  two  other  methods;  as  an  interaction  has  been  shown  using  co-
immunoprecipitation,  yeast  two  hybrid  or  mutagenesis  and  subsequent  co-
immunoprecipitation would confirm the interaction as direct. 
The PDE 11 array was probed with DG2N-HIS6, which incorporates the dimerisation and 
regulatory domains,  and DG2C-HIS6, which incorporates the twin  CNB, catalytic, and 
AGC kinase C terminal domains, in order to determine putative sites of protein-protein 
interaction. Two putative sites of interaction were identified when the PDE11 array was 
probed with DG2N-HIS6, one immediately proximal to, and one immediately distal to the 
twin GAF domains. However, these spots were mildly immunoreactive in control arrays of 
equivalent background. Despite this, immunoreactivity of these spots on the DG2N-HIS6 
probed array was significantly, convincingly stronger. Repeat of the array using DG2N 
tagged  with  GST  would  clarify  if  the  immunoreactivity  was  indeed  due  to  bound, 
interacting protein, assuming these spots would not be immunoreactive in control blots. 
Alanine substitution arrays would likely suffer similar background if probed with DG2N-
HIS6 protein, and so these would also benefit from use with GST tagged DG2N protein. 
When probed with DG2C-HIS6, four putative sites of interaction were identified, including 
two in common with the two identified in DG1C-HIS6 probed PDE11 array, in the GAF-B 
domain, and immediately distal to this GAF domain. The two novel regions were found in 
GAF-A, and in the N terminus of PDE11. However, all four regions, although not at all 
immunoreactive in control blots, showed immunoreactivity at a lower intensity than on 
spots “positive” on other blots. As such none of these interactions are as convincing, and 
require further investigation; either a repeat of the assay, or use of GST tagged DG2C 
fragment.  
The DG2 peptide array was probed with (DmPDE11)BN-HIS6, CN- HIS6, Middle-HIS6, 
and End-HIS6 protein. Background for this array was higher than the other two arrays 214 
probed, despite none of the 25mers containing 5x or 4xHISmers. The arrays were produced 
over a year before they was used; were new arrays to be generated background may be 
reduced. The two fusion proteins representing the N termini of DmPDE11B and C showed 
no putative interactions with the DG2 array. When probed with Middle-HIS6, a number of 
spots  showed  a  higher  intensity  than  on  the  control  array,  but  no  novel  spots  were 
identified. Probing with the End fragment identified two putative regions of interaction. 
However, there were a number of issues with this array, including apparent problems with 
the solubility of End-HIS6, and as such the data cannot be taken to indicate a putative 
direct interaction. As the End fragment is small, tagging this fragment with N- and C-
terminal GST tags would still result in a protein of a size that would facilitate expression in 
E. coli, and as the GST tag increases solubility, would hopefully prevent the formation of 
inclusion bodies, and reduce the background seen in the End-HIS6 overlaid DG2 array. 
Anti (poly)HIS antibodies recognise 4xHISmers or 5xHISmers. In the course of this study, 
an  anti-HIS5  monoclonal  antibody  was  employed,  which  resulted  in  the  unavoidable 
immunoreactivity  of  spots  containing  5xHISmers,  and  thus  “non-specific”  interactions 
with antibody prevent the identification of a putative interaction with overlaid protein on 
any of these spots. The occurrence of these spots was unavoidable in the PDE11 array, as 
the C terminal of DmPDE11 contains histidine-rich regions. However, the antibody also 
showed  non-specific  interaction  with  spots  containing  4xHISmers,  and  indeed  spots 
containing no HISmers, and so background levels were higher than anticipated. This would 
justify the additional probing of these arrays with GST (or other) tagged protein, as a 
higher number of non-immunoreactive spots would be probed with protein of interest, and 
thus the likelihood of false negative results would be lowered. 
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Characterisation of the role of DmPDE11 in immunity 
7  Chapter 7 
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7.1 Summary 
This chapter describes work performed on DmUAS-PDE11 RNAi and DmPDE11 deletion 
lines  to  investigate  the  role  of  this  phosphodiesterase  in  immunity.  Data  previously 
obtained suggested that cGMP and PDE11 may modulate diptericin levels in Drosophila. 
PDE11  has  also  been  implicated  in  whole  organism  survival  under  septic  immune 
challenge from E. coli. The role of PDE11 in immunity was investigated in flies with 
reduced PDE11 transcript levels, both in UAS-PDE11 RNAi flies, with expression driven 
either in  Malpighian  tubule principal  cells  or  ubiquitously,  and in  the PDE11 deletion 
mutant PDE11▲121, by septic challenge with E. coli. The data suggests a role for PDE11 
in immunity, but needs further investigation. 
7.2 cGMP modulates innate immunity in Drosophila 
As  discussed  in  the  introduction,  NO  has  been  shown  to  play  an  important  role  in 
Drosophila  immunity.  NOS  modulates  the  immune  response  to  lipopolysaccharides 
through  the  upregulation  of  diptericin  (Foley  and  O'Farrell,  2003).  In  the  Malpighian 
tubule, NOS has been shown to be upregulated following immune challenge, and has been 
shown to activate the IMD pathway (McGettigan et al., 2005). NO can activate cGMP 
signalling  by  the  activation  of  sGC.  Recent  findings  show  that  cGMP  modulates 
expression of AMPs in the Malpighian tubule in a dose dependent manner. When tubules 
are  incubated  with  nanomolar  [cGMP],  there  is  an  increase  in  diptericin  expression, 
whereas incubation with micromolar [cGMP] reduces diptericin transcription. This effect 
is not seen in the fat body (Aitcheson). 
cGMP  dependent  protein  kinases  have  been  shown  act  as  immune  effector  proteins. 
Diptericin expression is increased when DG1 is overexpressed in the principal cells of the 
tubule, whereas overexpression of DG2 P1 or P2 has the opposite effect, resulting in a 
reduction of diptericin expression (Aitcheson, 2009a). Furthermore, modulation of cGK 
expression in only the principal cells of the tubule is sufficient to modulate whole fly 
survival, when septically challenged with the gram-negative bacteria E. coli (Aitcheson, 
2009e). In the Malpighian tubule, cGKs have been shown to affect the translocation of the 
transcription facor Relish, an NF-kappaB homologue (Dushay et al., 1996), to the nucleus, 
downstream  of  imd.  This  modulation  of  Relish  localisation  occurs  in  an  antagonistic 
manner, via an unknown mechanism. DG1 appears to positively regulate the translocation 217 
of  Relish  to  the  nucleus;  overexpression  of  DG1  results  in  Relish  translocation  to  the 
nucleus, even in the absence of immune challenge, whereas knockdown of DG1 via RNAi 
inhibits  this  translocation,  even  under  immune  challange.  DG2,  conversely,  appears  to 
inhibit Relish translocation to the nucleus. Overexpression of DG2 P1 or P2 inhibits Relish 
translocation  to  the  nucleus,  even  under  immune  challenge  (Aitcheson,  2009b).  cGK 
function is tightly regluated by PDEs.  The Malpighian tubule expresses all of the PDEs 
(Day et al, 2005), and so there are several candidates to modulate the immune function of 
the cGKs. 
 
Data  obtained  by  Aitcheson  implicating  PDE11  in  the  immune  response  against  gram 
negative bacteria is summarised in appendix 5. Briefly, her findings were that increased 
cGMP  in  the  Malpighian  tubule  decreases  diptericin  expression,  and  that  this  can  be 
phenocopied by the reduction of PDE11 transcript levels in the principal cell. Furthermore, 
it  was  found  that  immune  challenge  of  UAS-PDE11  RNAi/c42  progeny  (thus  PDE11 
expression is reduced in tubule principal cells) results in reduced survivorship compared to 
UAS-PDE11 RNAi (line 1) parental control. As such, the role of PDE11 in immunity was 
investigated. 
 
7.3 Immune  challenge  of  UAS-PDE11  RNAi  driven  in 
tubule principal cells 
I investigated the role of PDE11 in immunity using UAS-PDE11 RNAi line 9, as this line 
had been shown to give knock down of PDE11 expression by Q-PCR analysis, as detailed 
in chapter 3. These lines differ in the chromosomal localisation of the pWIZ-based UAS-
PDE11 RNAi insertion. Thus, the two lines may achieve differing knockdowns, and any 
difference in results could be due to the extent of the knock down achieved by the RNAi. 
E. coli was grown overnight to static phase, harvested by centrifugation, and the flies were 
stabbed with a 0.35mm bore needle dipped into the E. coli solution; mock stabbings were 
performed with a dry needle, as detailed in materials and methods. The experiment had an 
additional control to the experiment of Aitcheson presented in appendix 5, the addition of 
c42 mock- and E. coli-challenged survival assays. The below data represents the pooling of 
two survival experiments, with one set of controls (figure 7.1). 218 
Figure 7.1: c42/UAS-PDE11 RNAi immune assay. No significant decrease in survival 
upon challenge with E. coli using a 0.35mm gauge needle was recorded when PDE11 
expression was reduced via expression of PDE11 RNAi, driven in tubule principal cells. 
Error bars show standard error of the mean. Survivorship on Y axis shown between 50 – 
100% for clarity. 
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Although the number of mock controls was lacking, there was no decrease in survival in 
the c42/UAS-PDE11 RNAi (line 9) progeny when compared to survival of the parental 
strains under challenge of E. coli. 
 
7.4 Immune  challenge  of  UAS-PDE11  RNAi  driven 
ubiquitously 
It was reasoned that if PDE11 plays a vital immune role in barrier epithelia and perhaps 
other tissues, expression of UAS-PDE11 RNAi ubiquitously using the Act5C-GAL4/GFP 
CyO driver line would lead to an increased immune phenotype, were such a phenotype to 
exist. Although DmUAS-PDE11 RNAi (line 9) is 90% lethal at the larval stage when 
driven ubiquitously by Act5C-GAL4, the cross is non-lethal at 18˚C, and the adults viable. 
Thus, UAS-PDE11 RNAi (line 9) parental flies were crossed with the Act5C-GAL4/GFP 
CyO driver line, and these flies were subjected to immune challenge with E. coli as above 
(figure  7.2).  Negative  control  genotypes  used  were  Canton  S,  and  the  other  resultant 
progeny  from  the  UAS-PDE11  RNAi  (line  9)  x  Act5C-GAL4/GFP  CyO  cross,  UAS-
PDE11 RNAi (line 9)/GFP CyO. As a positive control, Relish e20, a complete Relish null 219 
mutant (Hedengren et al., 1999), were also assayed. Relish is an NF-κB homologue found 
in the imd antimicrobial pathway. This data is excluded for clarity, but total death was seen 
within two days maximum in every assay performed  
 
Figure  7.2:  cAct5c-GAL4/UAS-PDE11  RNAi  immune  assay.  Survival  experiment 
showing no significant decrease in survival upon challenge with E. coli using a 0.35mm 
gauge needle when PDE11 expression is reduced via expression of UAS-PDE11 RNAi 
when driven ubiquitously. Error bars show standard error of the mean. Survivorship on Y 
axis shown between 60 – 100% for clarity. 
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This  experiment  was  performed  in  triplicate,  and  the  data  were  merged.  None  of  the 
experiments showed a significant, or even a qualitative reduction in survival in flies where 
PDE11 expression had been ubiquitously reduced, when analysed individually or when the 
data were pooled. 
 
7.4.1 DmPDE11 deletion line  
The PDE11RB deletion line (courtesy of Prof. David Morton, Oregon), PDE11▲121, is 
balanced over the homozygous lethal balancer CyO. The existence of straight winged, red 
eyed flies demonstrates that the deletion is homozygous viable. The increased proportion 
of del/CyO flies suggests that the deletion has a lethality effect (table 7.1). 
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Table 7.1: PDE11▲121 produces viable homozygous flies when balanced with CyO. 
Heterozygous  deletion  flies  were  crossed  and  the  progeny  scored  for  the  phenotypic 
marker CyO. Del/Del = PDE11▲121/ PDE11▲121, +/+, Del/CyO = PDE11▲121/CyO; 
+/+ 
 
♂ ♀
Del/Del 14 16
Del/CyO 30 26 
 
However, Q-PCR with RB specific primers has not been performed, and so it is not clear if 
the deletion is a true null. Homozygous males have a deeper red eye colour than females; 
the reason for this is unknown; perhaps there is another insertion on the Y. Homozygous 
PDE11▲121  males  are  sterile,  and  this  contributed  to  the  fact  that  for  individual 
experiments, a sufficient number of PDE11▲121 flies were not obtained to perform both 
an E. coli and a mock immune challenge, and as such flies were only challenged with E. 
coli,  with  the  rationale  that  it  would  increase  the  chances  of  finding  a  significant 
phenotype,  and  that  this  could  later  be  verified  by  the  inclusion  of  mock-challenge 
controls. This lack of flies also dictated the pooling of homozygous and heterozygous flies; 
ideally,  the  two  genotypes  would  be  assayed  separately  within  the  same  experiment. 
Pooled  PDE11▲121/CyO  and  PDE11▲121/PDE11▲121  flies  were  assayed  for  an 
immune phenotype by septic challenge with E. coli as above, alongside the wild type fly 
Canton S, as a negative control, and Relish e20 deletion flies as a positive control (figure 
7.3). This figure represents the pooling of 6 datasets.  
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Figure 7.3: DmPDE11∆121 immune assay. Survival experiment showing a significant 
decrease in survival upon challenge with E. coli using a 0.35mm gauge needle in PDE11 
homozygous  and heterozygous deletion flies  (pooled) compared to  controls. Error bars 
show standard error of the mean. Survivorship on Y axis shown between 60 – 100% for 
clarity. 
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PDE11▲121 flies showed significantly lower survivorship than E. coli challenged Canton 
S flies, where P< 0.0001 using a Log-rank (Mantel-Cox) test. 
The  above  assay  was  repeated  with  the  appropriate  mock  stabbed  controls,  assaying 
homozygous and heterozygous deletion flies separately. Injections were performed using a 
Nanoject II Auto nanoliter injector, where E. coli was grown to an OD600 of 2.0 (which 
represents static phase), harvested by centrifugation, resuspended in an equal volume of 
PBS,  and  injected  in  a  volume  of  69nl  just  below  the  first  abdominal  turgite.  This 
represents  a  lower  dose  than  stabbing  with  a  0.35mm  needle,  although  the  difference 
cannot be quantified as the dose delivered with a 0.35mm needle is impossible to quantify. 
Mock stabbings were performed with PBS. The data presented represents the pooling of 
two immune assays (figure 7.4). 
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Figure 7.4: DmPDE11∆121 immune assay. Survival experiment showing no difference 
in survival upon challenge with E. coli using a Nanoject II Auto nanoliter injector between 
PDE11 homozygous or heterozygous deletion flies (pooled) and PBS injected controls. 
Error bars show standard error of the mean. Survivorship on Y axis shown between 80 – 
100% for clarity. 
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No difference in survival following immune challenge was seen between Canton S and 
homozygous or heterozygous PDE11▲121 flies. 
 
7.5 Conclusion for the role of DmPDE11 in immunity 
Epithelial tissues have been shown to play a major role in immunity, expressing all of the 
known anti microbial peptides (Tzou et al., 2000), and the Malpighian tubule in particular 
has been shown to act as critical immune tissue, where NO and cGMP signalling play vital 
roles in the imd immune pathway (Aitcheson, 2009c; Davies and Dow, 2009; McGettigan 
et al., 2005). As a dual specificity PDE expressed in all epithelia (Chintapalli et al., 2007), 
DmPDE11 is capable of modulating cGMP signalling, and thus the role of DmPDE11 in 
immunity was investigated by subjecting flies with reduced PDE11 transcript levels to an 
immune challenge, and screening for a change in mortality. PDE11 deletion and UAS-
PDE11 RNAi lines were used to reduce DmPDE11 transcript levels both ubiquitously, and 
in a tissue specific manner. 
UAS-PDE11 RNAi line 9 was crossed to the Malpighian tubule GAL4 driver line c42, and 
both parental lines and the resultant progeny were subjected to an E. coli stabbing assay. 
The progeny did not display an increase in mortality under immune challenge. If reduction 223 
of DmPDE11 transcript levels in the Malpighian tubule did not impact upon fly survival, 
then it was reasoned that a ubiquitous knock down of transcript levels may produce a 
phenotype. Thus, UAS-PDE11 RNAi (line 9) was crossed to the ubiquitous GAL4 driver 
line Act5C-GAL4. Progeny from this cross displayed no apparent increase in mortality 
when compared to parental controls. As the extent of the knockdown conferred by RNAi 
may not  have been sufficient  to  confer a survival  phenotype, the PDE11 deletion  line 
PDE11▲121 was subjected to multiple E. coli stabbing assays, where a 0.35mm needle 
was dipped into an E. coli solution and survivorship recorded, and the data pooled. The 
data  revealed  a  highly  (P<  0.0001)  significant  reduction  seen  in  PDE11▲121  line 
compared to Canton S under E. coli challenge. Where Canton S flies showed around 10% 
mortality after 100 h, PDE11▲121 showed around 20% mortality. However, homozygous 
and heterozygous flies were pooled in the above experiments, and a mock injection was 
not included, which is critical to proving that a reduction in survival is not due to increased 
susceptibility to the stab itself or a general reduction in the flies‟ viability.  
As a lethality phenotype would be expected to be more pronounced in the homozygous 
null mutant that in the heterozygous, the experiment was repeated, with the genotypes 
assayed separately, using a new delivery system that permitted tighter control of the dose 
delivered, at the cost of having to reduce the dose of E. coli. Perhaps as a result of this 
reduced dose, no difference in survival was seen between Canton S controls and either 
homozygous or heterozygous PDE11 deletion flies. As such, a repeat of this experiment at 
the original dose would be desirable, including the mock stab controls. In addition to this, 
the extent of the deletion must be determined.  
UAS-PDE11 RNAi line 9 did not show any immune phenotype when crossed to the GAL4 
lines c42 and Act5c. Given that a reduction in survival was identified where UAS-PDE11 
RNAi line 1 was crossed to c42 and the progeny subjected to immune assay alongside a 
parental control (Aitcheson, 2009e), as detailed in appendix 5, it may be that a higher 
knockdown was  achieved with  these flies. As such, Q-PCR using the primers used to 
screen line 9 should be used on line 1, and if a higher knockdown is achieved then that fly 
line  should  be  employed.  However,  it  is  also  possible  that  the  apparent  reduction  in 
survival of the UAS-PDE11 RNAi (line 1) when crossed to c42 could be due to the low 
number of flies used for certain genotypes screened.  
If  PDE11  does  indeed  play  a  immune  role,  it  is  not  a  vital  one;  where  a  significant 
reduction  in  survivorship  was  achieved  when  assaying  PDE11▲121,  the  increase  in 
mortality was ~10% greater than controls after 100 hours at ~20% compared to ~10%, 224 
whereas the Relish e20 deletion mutant showed 100% mortality after around a day. As the 
deletion has not been shown to be a true null, there may be sufficient expression of PDE11 
to mask the phenotype to an extent.  
If indeed it is shown that a reduction in PDE11 transcript levels reduces survival against E. 
coli,  it  may  relate  to  the  finding  in  the  Malpighian  tubule  that  expression  of  the 
antimicrobial peptide diptericin is modulated by cGMP. When tubules are incubated in 
cGMP, diptericin expression is reduced compared –cGMP incubated controls. Non cell-
permeable extracellular cGMP is transported into the tubule (Riegel et al., 1998), and can 
induce cellular signalling events such as fluid transport (Davies et al., 1995). This suggests 
that the large decrease in diptericin expression induced by the incubation in 100μM cGMP 
is caused by transport of extracellular cGMP into the tubule, and by a subsequent increase 
of intracellular cGMP. 
This  increase  in  cGMP,  and  the  subsequent  reduction  in  diptericin  expression,  is 
phenocopied by reduction of PDE11 transcript levels in Malpighian tubule principal cells, 
as c42/UAS-PDE11 RNAi (line 1) tubules not incubated in cGMP display a similar level 
of  diptericin  expression  to  UAS-PDE11  RNAi  (line  1)  parental  tubules  incubated  in 
cGMP.  Furthermore,  c42/UAS-PDE11  RNAi  (line  1)  incubation  with  cGMP  does  not 
further decrease diptericin expression. This data is presented in appendix 5 (Aitcheson, 
2009c, d).  This would suggest that PDE11 modulates an immune induced cGMP signal in 
a  manner  relevant  to  Diptericin  expression,  which  directly  affects  Drosophila  survival 
under immune challenge. This would be the first time a PDE had been shown to play an 
immune role. Taken together, the data in this chapter suggests that the role of DmPDE11 in 
immunity deserves further investigation. 
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Chapter 8 
A study of H. Sapiens PDE11A using the Malpighian 
tubule, a polarised epithelial tissue 
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8.1 Summary 
The  HsPDE11A  family  has  recently  been  characterised  biochemically,  but  the 
physiological role it plays it not well understood. Drosophila PDE11 was first described in 
2005, and has four splice variants. Using the powerful genetic model organism Drosophila 
melanogaster, we have further investigated this family of phosphodiesterases, both fly and 
human, in an organotypic context. HsPDE11A3 expression is confined to testis in both rat 
and human (Yuasa et al., 2001), and has been shown to regulate spermatozoa physiology 
(Seftel,  2005).  DmPDE11  -/-  null  male  mutants  are  infertile,  and  so  function  may  be 
conserved. 
The  DmPDE11  isoforms  were  aligned  with  all  HsPDE11A  isoforms,  compared  with 
respect to sequence identity and homology, and were subjected to phylogenetic analysis. 
These results suggested that HsPDE11A3 is a DmPDE11 orthologue. 
HsPDE11A3 pP[UAST] constructs were generated, and the transgene expressed in S2 cells 
and  fly.  The  protein  showed  predominantly  nuclear  localisation  when  expressed  in  S2 
cells. In Malpighian tubule principal cells at low levels of expression, the protein localised 
predominantly to the nucleus, but was localised to the cytosol when the transgene was 
driven by stronger GAL4 expression. 
8.2 Introduction 
The  Human  phosphodiesterase-11A  (PDE11)  family  consists  of  four  splice  variants 
HsPDE11A1 (PDE11A 004), HsPDE11A2 (PDE11A 003), HsPDE11A3 (PDE11A 002), 
and HsPDE11A4 (PDE11A 001) (Fawcett et al., 2000; Hetman et al., 2000; Yuasa et al., 
2000). I will use the common nomenclature HsPDE11A1-4 herein.  HsPDE11A isoforms 
hydrolyze  cAMP  and  cGMP  via  a  conserved  carboxyl-terminal  (C-terminal)  catalytic 
domain. The amino-termini (N-termini) of the four isoforms vary in length and amino acid 
sequence. HsPDE11A2, HsPDE11A3, and HsPDE11A4 contain one or more GAF (cGMP-
binding  phosphodiesterase,  Anabaena  adenylyl  cyclase,  and  Escherichia  coli  FhlA) 
domains, which have been shown to affect oligomerisation, and affinity both for substrates 
as well as the structurally unrelated inhibitors vardenafil and tadalafil (Weeks et al., 2007). 
The structure of the four isoforms is shown in figure 8.1. 
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Figure 8.1: PDE11A1-4. Diagram shows the PDE11A isoforms. S = Serine, Black bar = 
catalytic domain, light blue bar = GAF-A domain, white bar = GAF-B domain, angled 
dashed bar = unique sequence. Modified from (Weeks et al., 2007).  
 
8.3 Alignment  of  DmPDE11-B  and  -C  protein  against 
HsPDE11A protein 
Previous published work assigned D. Melanogaster PDE11 as a homologue of H. sapiens 
PDE11A3 or A4 (Day et al., 2005), due to high sequence similarity at the amino acid level, 
the dual-specificity PDE activity of the enzymes, and the twin  GAF domains of these 
isoforms (figure 8.2). 
 
Figure  8.2:  DmPDE11  contains  twin  GAF  domains  and  a  dual-specificity  PDEase 
domain, in common with HsPDE11A. 
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This analysis was performed with the amino acid sequence of DmPDE11RA. This has been 
replaced on Flybase with two new isoforms, DmPDE11RB and DmPDE11RC; two novel 
short isoforms were cloned in the course of this study, so that both the DmPDE11RB and 
DmPDE11RC have long and short isoforms, as detailed in chapter 4. As such,  further 
homology analysis was performed. Following alignment of protein sequence, (materials 
and methods 1.12), percentage identity/similarity was calculated following alignment of 
each  of  the  DmPDE11  isoforms  with  the  HsPDE11A  gene  family  using  ClustalW 
alignment (table 8.1).   
 
Table  8.1:  HsPDE11A1-4  similarity/identity  with  DmPDE11.  Percentage  similarities 
and identities of amino acid sequences between DmPDE11 and each HsPDE11A isoform 
were calculated using ClustalW alignment. 
DmPDE11RBl vs Identity (%) Similarity (%)
HsPDE11A1 (004) 15.8 22
HsPDE11A2 (003) 17.8 25.8
HsPDE11A3 (002)  20.5 29.7
HsPDE11A4 (001) 22.7 33.6
DmPDE11RBs vs Identity (%) Similarity (%)
HsPDE11A1 (004) 19.7 27.5
HsPDE11A2 (003) 22.2 32.2
HsPDE11A3 (002)  25.6 37.1
HsPDE11A4 (001) 28.3 42
DmPDE11RCl vs Identity (%) Similarity (%)
HsPDE11A1 (004) 16.3 22.7
HsPDE11A2 (003) 18.4 26.6
HsPDE11A3 (002)  21.1 30.6
HsPDE11A4 (001) 23.4 34.7
DmPDE11RCs vs Identity (%) Similarity (%)
HsPDE11A1 (004) 20.5 28.6
HsPDE11A2 (003) 32.1 33.4
HsPDE11A3 (002)  26.6 38.5
HsPDE11A4 (001) 29.4 43.6  
 
For each Drosophila PDE11 isoform, the order of highest – to – lowest sequence similarity 
and  identity  with  the  HsPDE11A  1-4  isoforms,  is  HsPDE11A4,  HsPDE11A3, 
HsPDE11A2, HsPDE11A1. Interestingly, it is apparent that between the four Drosophila 
PDE11  isoforms,  the  short  isoforms  of  B  and  C  have  higher  sequence  similarity  and 
identity to each HsPDE11A isoform compared to their respective long isoforms, and that 
the  long  and  short  C  isoforms  have  higher  sequence  similarity  and  identity  to  each 229 
HsPDE11A isoform,  when compared to  their respective B isoforms,.  That  the short C 
terminus  isoforms  are  of  higher  homology  than  those  with  a  long  C  terminus  is  not 
surprising, as the human isoforms do not have an extended C terminus. This may suggest 
that the C terminus evolved later, to perform some unknown function; as shown in chapter 
4, it does not affect protein localisation.  
 
The  above  analysis  scores  positively  for  identical  or  similar  amino  acids  following 
sequence alignment. However, it does not negatively score for gaps, or highly dissimilar 
amino acids. Sequences were aligned with using a gonnet series matrix, and a best tree 
Phylogram  was  generated  using  neighbour-joining  tree  building  and  uncorrected  “p” 
distance calculation. As a control,  bootstrap  analysis (1000  repetitions) was  performed 
(materials and methods 1.12). Distance between nodes is presented in phylogenetic units, 
where  a  value  of  0.1  corresponds  to  a  difference  of  approximately  10%  between  two 
sequences. The data is presented in figure 8.3. 
 
Figure  8.3:  Phylogenetic  analysis  comparing  DmPDE11  with  HsPDE11A  1-4. 
Sequences were aligned using a gonnet series matrix, and a Phylogram was generated. 
Distances  between  nodes  shown  in  phylogenetic  units.  Bootstrap  analysis  (1000 
repetitions) was performed; numbers at branches refer to the % occurrence of the branch. 
Table shows distance between nodes in phylogenetic units. B long (A), B short (B), C long 
(C), C short (D). d = D. melanogaster, h = H. sapiens. 
 
A 
 
dPDE11 B long
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
hPDE11A 002 {a3}
0.264
0.264
0.007
0.011
-0.019
0.019
0.019
-0.019230 
 
hPDE11A001 {a4} hPDE11A 002 {a3} hPDE11A 003 {a2} hPDE11A 004 {a1}
Dm PDE11 B long  0.5785 0.5385 0.5325 0.5134  
 
B 
 
 
hPDE11A001 {a4} hPDE11A 002 {a3} hPDE11A 003 {a2}hPDE11A 004 {a1}
Dm PDE11 B short  0.5796 0.5399 0.5343 0.5155
 
 
 
 
 
 
dPDE11 B long
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 78
 98
 98
dPDE11 B short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
0.265
0.265
0.01
0.007
-0.019
0.019
0.019
-0.019
dPDE11 B short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 77
 77
 98231 
C 
 
hPDE11A 004 {a1} hPDE11A 003 {a2} hPDE11A 002 {a3} hPDE11A 001 {a4}
Dm PDE11 C long  0.5785 0.5385 0.5325 0.5134  
 
D 
 
 
hPDE11A001 {a4} hPDE11A 002 {a3} hPDE11A 003 {a2} hPDE11A 004 {a1}
Dm PDE11 C short  0.5796 0.5399 0.5343 0.5155
 
dPDE11 C long
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
0.264
0.264
0.011
0.007
-0.019
0.019
0.019
-0.019
dPDE11 C long
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 77
 98
 98
dPDE11 C short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
0.265
0.265
0.01
0.007
-0.019
0.019
0.019
-0.019
dPDE11 C short
hPDE11A 002 {a3}
hPDE11A 004 {a1}
hPDE11A 001 {a4}
hPDE11A 003 {a2}
 80
 80
 98232 
In contrast to the above results, a ClustalW algorithm-generated phylogenetic tree shows 
that each Drosophila PDE11 isoform aligns in order of closest to furthest to HsPDE11-A1, 
-A2,  -A3,  then  -A4.  For  each  DmPDE11  isoform,  HsPDE11-A1  was  assigned  as  the 
closest orthologue, scoring ~0.02 phylogenetic units (~2%) less than -A2. HsPDE11-A2 
and  -A3  were  typically  separated  by  less  than  0.05  phylogenetic  units  (~0.5%). 
Intriguingly,  HsPDE11A4,  which  scored  highest  for  sequence  similarity/identity  with 
DmPDE11, was designated the most distant of orthologues, 0.04 phylogenetic units (~4% 
distal).  However,  when  bootstrap  analysis  is  considered,  it  is  notable  that  at  the 
branchpoints separating HsPDE11A3 from HsPDE11-A1, -A2, and –A4, occur in ≤ 80% 
of the bootstrap replicates of each phylogenetic tree. Likewise, for the small isoforms of 
DmPDE11 B and C, the branchpoint separating hPDE11-A2 and –A4 occurred in ≤80% of 
the bootstrap replicates of each phylogenetic tree. What is consistent is the occurrence of 
the  branchpoint  between  HsPDE11-A4  and  -A2,  at  98%  for  each  phylogenetic  tree, 
suggesting that the higher phylogenetic distance allocated to HsPDE11A4 is perhaps the 
one  significant  finding  of  this  analysis.  Thus,  as  with  the  Day  2006  analysis  of 
DmPDE11A, DmPDE11 B long, B short, C long, and C short isoforms were designated as 
HsPDE11A3  orthologues.  That  HsPDE11A4  shows  the  highest  sequence 
similarity/identity  with  the  DmPDE11  isoforms,  yet  shows  the  highest  phylogenetic 
distance from each of the DmPDE11 isoforms when considering phylogenetic analysis, 
suggests that the N terminus of this protein may be of recent evolutionary origin. These are 
two  Ser  residues  (S117  and  S162)  N  terminal  of  the  GAF-A  and  GAF-B  domains  of 
HsPDE11A4  which  have  been  shown  to  be  phosphorylated  by  PKA  and  cGK,  which 
reduce the EC50 for cGMP ~3 fold when phosphorylated (Gross-Langenhoff et al., 2008). 
Analysis of DmPDE11 B and C for putative phosphorylation sites N terminal of the GAF 
domains  returns  three  Ser  residues  that  return  a  high  score  for  either  PKA  or  cGK 
phosphorylation,  although  only  S268  (B  isoform)/S224  (C  isoform)  is  predicted  as  a 
putative  phosphorylation  site  (threshold  <  0.5  using  the  NetPhosK  phosphorylation 
prediction tool (Blom et al., 2004)) for both cGK and PKA (figure 8.4). 
 
 
 
 233 
Figure 8.4: Prediction of phosphorylation by PKA and cGK on residues N-terminal of 
the  GAF  domains  of  DmPDE11.  Sequences  were  analysed  for  putative  PKA/cGK 
phosphorylation sites using the NetPhosK phosphorylation prediction tool (Blom et al., 
2004). 
   
S-258 (B isoform)/ S-214 (C isoform)    PKA    0.74 (TSSSRGGSGATTPUR) 
S-268 (B isoform)/ S-224 (C isoform)    PKA    0.67 (TTPVRKISAHEFFRG)    
S-268 (B isoform)/ S-224 (C isoform)    cGK    0.77 (TTPVRKISAHEFFRG)       
S-306 (B isoform)/ S-262 (C isoform)    PKA    0.70 (NGSVGGSCSNLQNV)  
 
Following this analysis, constructs to express HsPDE11A3, with and without a YFP tag, 
were generated for expression in flies and S2 cells. 
 
8.3.1 Generation of constructs 
pP{UAST}  and  pP{YFP  UAST}  constructs  for  the  expression  of  HsPDE11A3  were 
generated for expression in flies and S2 cells, using a pcDNA3.1 HsPDE11A3 plasmid as 
template, generously provided by Prof. Miles Houslay. Primers were designed to amplify 
the HsPDE11A3 ORF with unique restriction sites at the 5‟ and 3‟ ends. Reverse primers 
with and without a stop codon were designed, to facilitate in-frame fusion to a YFP tag. 
The ORF was amplified with Pfu DNA polymerase, TOPO cloned into a TOPO vector to 
generate pMT/V5 TOPO HsPDE11A3 (stop) and pMT/V5 TOPO HsPDE11A3 (no stop), 
and sequenced for fidelity (data not shown). The ORF was digested from the TOPO vector, 
gel purified, and directionally ligated into digested pP{UAST} and pP{YFP UAST}.  
 
8.3.2 Western blot to confirm expression of transgene 
To  confirm  that  HsPDE11A3  will  express  in  Drosophila,  S2  cells  were  transiently 
transfected  with  pMT/V5  TOPO-HsPDE11A3  (no  stop),  and  the  lysate  subjected  to 
western analysis (figure 8.5). 234 
Figure  8.5:  Western  analysis  of  S2  cell  lysate  transiently  transfected  with  (1)  no 
plasmid control (2) pMT/V5 TOPO-HsPDE11A3 (no stop). Equal amounts of protein 
(20 g) were separated on a 10% SDS acrylamide gel, blotted and probed with anti-V5 
mouse monoclonal primary antibody at 1:2000, anti-mouse HRP-conjugated secondary at 
1:5000. Band sizes were calculated by comparison to Amersham Full-Range Rainbow
™ 
Molecular Weight Markers. 
 
 
 
 
 
 
 
When fused in-frame with a V5 tag, the HsPDE11A3 ORF encodes a protein of 79 KDa. 
S2 cell lysate produced a single immunoreactive band not present in the negative control, 
which runs to the expected size. An additional band at ~55 kDa was also present in mock-
transfected S2 cell lysate, and so was non specific. As such it was accepted that YFP-
HsPDE11A3 is faithfully translated into a stable protein product in S2 cells. 
 
8.3.3 Anti-HsPDE11A polyclonal antibody design 
Antibodies  were  designed  against  two  epitopes,  QRQTKTKDRRFNDE  and 
SKGEYDWNIKNHRD, selected on the basis of antigenicity. The epitope sequences were 
screened for short near-exact matches against the Drosophila proteome using the BLASTP 
tool  (http://www.ensembl.org/Multi/blastview),  and  returned  no  significant  hits.  
QRQTKTKDRRFNDE is on the boundary between sequence unique to HsPDE11A3, and 
sequence shared with HsPDE11A4 within GAF-A. In future, were a HsPDE11A3-specific 
polyclonal antibody required, an antibody-specific peptide QRQTKTKDRR would only 
purify antibody specific to HsPDE11A3 by epitope purification. SKGEYDWNIKNHRD is 
160 kDa 
105 kDa 
75 kDa 
50 kDa 
P
DE11
A3
 
Mock
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found in HsPDE11A-002, -006, -203, 003, 004, 202, 204, 001. Antibodies were generated 
by Genososphere Biotech. Antibodies were IgG purified, and the purified IgG fraction was 
epitope purified (materials and method 1.7). 
 
8.3.4 Antibody testing 
Immunocytochemistry  was  performed  on  S2  cells  transiently  co-transfected  with  YFP-
HsPDE11A3 pP[UAST] and DES GAL4 as a GAL4 source, using pre- and post-immune 
serum at 1:100, 1:500, IgG purified antibody at 1:50, and epitope purified antibody at 1:2, 
staining with anti-rabbit TEXAS RED secondary antibody at a 1:500 dilution. For both 
antibodies, none of the YFP fluorescent cells displayed positive texas red staining above 
background staining, even using serum (data not shown). The antibody was not tested 
using western analysis. 
 
8.3.5 Immunocytochemistry 
8.3.5.1  Expression in S2 cells 
HsPDE11A3 protein subcellular localisation was determined in S2 cells. S2 cells were 
transiently transfected with YFP-HsPDE11A3 pP{UAST}, using DES GAL4 as a GAL4 
source. Cells were fixed, and DAPI stained to stain the nucleus (figure 8.6).  
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Figure  8.6:  Localisation  of  YFP-HsPDE11A3  in  S2  cells.  S2  cells  were  transiently 
transfected with pP{UAST} HsPDE11A3 YFP, using DES GAL4 as a GAL4 source. Cells 
were fixed and stained with DAPI to visualise nuclei. YFP-HsPDE11A3 (green), DAPI 
(blue). 
 
In S2 cells, YFP-HsPDE11A3 is predominantly localised to the nucleus, and also shows 
cytoplasmic localisation, strongest at the membrane.  
8.3.5.2  Localisation in Malpighian tubule 
YFP-HsPDE11A3 expression was driven in tubule principal cells by the c42 GAL4 driver 
line. Tubules were fixed, and YFP-HsPDE11 expression visualised (figure 8.7). 
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Figure 8.7: Localisation of YFP-HsPDE11A3 in the Malpighian tubule driven with 
c42 GAL4. UAS YFP-HsPDE11A3 transgenic flies were crossed to c42 GAL4, a principal 
cell GAL4 driver line. The Malpighian tubules were dissected, fixed, and imaged using 
confocal microscopy. YFP-HsPDE11A3 (green). 
 
Expression of YFP-HsPDE11A3 in c42 GAL4/YFP-HsPDE11A3 progeny occurred at low 
levels, hence the high level of background noise in the confocal image. However, although 
DAPI  staining  was  not  employed,  expression  appears  similar  to  that  of  S2  cells; 
predominantly  nuclear,  with  some  cytoplasmic  (basolateral)  expression.  To  drive 
expression levels to a higher level, UAS-YFP-HsPDE11A3 flies were crossed to a heat 
shock GAL4 driver line. Following three thirty minute 37˚C heat shocks, expression levels 
were much higher, and the localisation of the protein changed (figure 8.8).  
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Figure 8.8: Localisation of YFP-HsPDE11A3 in the Malpighian tubule driven with 
heat shock GAL4. UAS YFP-HsPDE11A3 transgenic flies were crossed to heat shock 
GAL4, a ubiquitous GAL4 driver line. The Malpighian tubules were dissected, fixed, and 
the  nuclei  visualised  by  DAPI  staining,  and  imaged  using  confocal  microscopy.  YFP-
HsPDE11A3 (green), DAPI (blue). 
 
When YFP-HsPDE11A3 expression is driven by heat shock GAL4, there is a dramatic 
change in protein subcellular localisation. The protein is now excluded from the nucleus, 
and shows localisation to the basolateral membrane, and the apical microvilli. It appears 
that localisation is dependent upon protein concentration. Imaging of Malpighian tubules 
from YFP-HsPDE11A3/HSG4 exposed to varying lengths of heat shock would confirm 
this. 
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8.3.6 Update of gene model 
The gene model for HsPDE11A in the March 2009 release of Ensemble was as described 
above 
(http://mar2009.archive.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG0000012865
5).  The  June  2009  release 
(http://jul2009.archive.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128655
) contained several newly predicted transcripts, from the same gene (table 8.2). 
 
Table 8.2: The newly predicted  HsPDE11A isoforms. Only protein  coding isoforms 
shown (adapted from Ensemble). 
Name   Transcript ID   Protein ID   Description
PDE11A4 (001) ENST00000286063  ENSP00000286063  protein coding
PDE11A3 (002) ENST00000358450  ENSP00000351232  protein coding
PDE11A2 (003) ENST00000389683  ENSP00000374333  protein coding
PDE11A1 (004) ENST00000409504  ENSP00000386539  protein coding
PDE11A-006  ENST00000433879  ENSP00000416884  protein coding
PDE11A-007  ENST00000436700  ENSP00000406922  protein coding
PDE11A-201  ENST00000431253  ENSP00000410190  protein coding
PDE11A-202  ENST00000449286  ENSP00000390599  protein coding
PDE11A-203  ENST00000450799  ENSP00000387964  protein coding
PDE11A-204  ENST00000457922  ENSP00000402534  protein coding  
Beyond the isoforms listed in table 8.2, a further five transcripts,  HsPDE11A005, and 
HsPDE11A009  –  012,  are  processed  transcripts  that  are  not  translated  into  a  protein 
product. The transcript and protein structure of these newly predicted HsPDE11A isoforms 
are found in figure 8.9 (Ensemble). 
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Figure  8.9:  Transcript and  Protein structure (where translated) of all  HsPDE11A 
isoforms.  From  Ensemble, 
(http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128655).  For 
protein  structure,  Yellow:  low  complexity  region.  Blue:  superfamily  domain.  Green: 
SMART domain. Red: prints domain. Grey: Pfam domain. Orange: PROSITE patterns. 
Multiple colours: variations. Scale bar: amino acid position 
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HsPDE11A-006, -007, -201 and -203 are further truncations of the N terminus compared 
to  the  original  HsPDE11A1-A4  isoforms,  truncated  beyond  the  GAF  domains  to  the 
catalytic domain. Of the newly predicted HsPDE11A isoforms, only HsPDE11A-202 and -
204 contain a GAF domain. 
In order to determine if any of these new isoforms were of higher sequence homology to 
DmPDE11,  sequence  similarity/identity  was  calculated  (tables  8.3  –  8.6).  Phylogenetic 
analysis was performed as above between the two previously closest aligned, HsPDE11A 
001 {A4} and HsPDE11A 002 {A3}, and the two newly predicted isoforms 202 and 204, 
as these contain GAF domains; HsPDE11A 202 contains one GAF domain, and HsPDE11 
204 contains one whole and one partial GAF domain (figure 8.10). 
Table  8.3:  DmPDE11  B  long  similarity/identity  with  the  HsPDE11A  gene  family. 
Percentage similarities and identities of amino acid sequences between DmPDE11 B long 
and all the HsPDE11A isoforms were calculated using ClustalW alignment. 
 
DmPDE11RBl vs Identity (%) Similarity (%)
hPDE11A1 (004) 15.8 22
hPDE11A2 (003) 17.8 25.8
hPDE11A3 (002) 20.5 29.7
hPDE11A4 (001) 22.7 33.6
hPDE11 006 13.7 19.9
hPDE11 007 1.7 4
hPDE11A 201  4.8 7.1
hPDE11A 202  17.8 25.8
hPDE11A 203  15.8 22.1
hPDE11A 204 19 27.4  
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Figure 8.10: Phylogenetic analysis comparing DmPDE11 B long with HsPDE11A-001 
(A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and a 
Phylogram  was  generated.  Distances  between  nodes  shown  in  phylogenetic  units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
 
hPDE11A 001 {A4} hPDE11A {002 A3} hPDE11A 202 hPDE11A 204
Dm PDE11 B long  0.5785 0.5385 0.5317 0.5267  
 
Table 8.4:  DmPDE11 B short similarity/identity with the HsPDE11A gene family. 
Percentage similarities and identities of amino acid sequences between DmPDE11 B short 
and all the HsPDE11A isoforms were calculated using ClustalW alignment. 
DmPDE11RBs vs Identity (%) Similarity (%)
hPDE11A1 (004) 19.7 27.5
hPDE11A2 (003) 22.2 32.2
hPDE11A3 (002) 25.6 37.1
hPDE11A4 (001) 28.3 42
hPDE11 006 17.1 24.9
hPDE11 007 2.1 5
hPDE11A 201  6 8.9
hPDE11A 202  22.2 32.2
hPDE11A 203  19.7 27.6
hPDE11A 204 23.7 34.2  
 
dPDE11 B long
hPDE11A 204
hPDE11A 202
hPDE11A 001 {a4}
hPDE11A 002 {a3}
0.265
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0.009
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-0.013
0.017
-0.019
0.019
dPDE11 B long
hPDE11A 002 {a3}
hPDE11A 204
hPDE11A 202
hPDE11A 001 {a4}
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Figure 8.11: Phylogenetic analysis comparing DmPDE11 B short with HsPDE11A-
001 (A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and 
a  Phylogram  was  generated.  Distances  between  nodes  shown  in  phylogenetic  units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
hPDE11A 001 {A4} hPDE11A 002 {A3} hPDE11A 202 hPDE11A 204
Dm PDE11 B short  0.5818 0.5429 0.537 0.5317  
 
Table  8.5:  DmPDE11  C  long  similarity/identity  with  the  HsPDE11A  gene  family. 
Percentage similarities and identities of amino acid sequences of DmPDE11 C long and all 
the HsPDE11A isoforms were calculated using ClustalW alignment. 
DmPDE11RCl vs Identity (%) Similarity (%)
hPDE11A1 (004) 16.3 22.7
hPDE11A2 (003) 18.4 26.6
hPDE11A3 (002) 21.1 30.6
hPDE11A4 (001) 23.4 34.7
hPDE11 006 14.1 20.6
hPDE11 007 1.8 4.1
hPDE11A 201  5 7.3
hPDE11A 202  18.4 26.6
hPDE11A 203  16.3 22.8
hPDE11A 204 19.6 28.2  
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Figure 8.12: Phylogenetic analysis comparing DmPDE11 C long with HsPDE11A-001 
(A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and a 
Phylogram  was  generated.  Distances  between  nodes  shown  in  phylogenetic  units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
 
 
hPDE11A 001 {A4} hPDE11A 002 {A3} hPDE11A 202 hPDE11A 204
Dm PDE11 C long  0.5785 0.5385 0.5317 0.5267  
 
 
 
 
 
 
 
dPDE11 C long
hPDE11A 002 {a3}
hPDE11A 204
hPDE11A 202
hPDE11A 001 {a4}
0.265
0.265
0.008
0.009
-0.013
0.017
-0.019
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dPDE11 C long
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Table 8.6: DmPDE11  C short similarity/identity with the HsPDE11A gene family. 
Percentage similarities and identities of amino acid sequences between DmPDE11 C short, 
and all the HsPDE11A isoforms were calculated using ClustalW alignment. 
 
DmPDE11RCs vs Identity (%) Similarity (%)
hPDE11A1 (004) 20.5 28.6
hPDE11A2 (003) 32.1 33.4
hPDE11A3 (002) 26.6 38.5
hPDE11A4 (001) 29.4 43.6
hPDE11 006 17.8 25.9
hPDE11 007 2.2 5.2
hPDE11A 201  6.3 9.2
hPDE11A 202  23.1 33.5
hPDE11A 203  20.5 28.7
hPDE11A 204 24.6 35.5  
 
Figure 8.13: Phylogenetic analysis comparing DmPDE11 C short with HsPDE11A-
001 (A4), -002 (A3), -202, -204. Sequences were aligned using a gonnet series matrix, and 
a  Phylogram  was  generated.  Distances  between  nodes  shown  in  phylogenetic  units. 
Bootstrap analysis (1000 repetitions) was performed; numbers at branches refer to the % 
occurrence of the branch. Table shows distance between nodes in phylogenetic units. 
 
 
hPDE11A 001 {A4} hPDE11A 002 {A3} hPDE11A 202 hPDE11A 204
Dm PDE11 C short  0.5818 0.5429 0.537 0.5317  
dPDE11 C short
hPDE11A 002 {a3}
hPDE11A 204
hPDE11A 202
hPDE11A 001 {a4}
0.267
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0.008
0.009
-0.013
0.016
-0.019
0.019
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When sequence similarity/identity is considered, HsPDE11A3 has the highest homology to 
each  DmPDE11  isoform  compared  to  HsPDE11A4,  HsPDE11202,  and  HsPDE11204. 
Phylogenetic analysis was again employed. However, bootstrap analysis this time returned 
no lower than 95% at any branch of the phylogenetic tree, suggesting that this data is of 
greater significance. Figures 8.10 – 8.13 suggests that amino acid sequence specific to 
HsPDE11A4 is of furthest phylogenetic distance from the DmPDE11 isoforms, although 
this  branchpoint  is  of  the  lowest  %  score  when  considering  bootstrap  analysis. 
HsPDE11A3 is of around 0.01 phylogenetic units more distal than 202 and 204 to the 
DmPDE11  isoforms  in  each  phylogenetic  tree,  which  equates  to  around  1%  lower 
homology.  The  bootstrap  analysis  assigns  98%  or  99%  to  the  branchpoint  separating 
HsPDE11A3 from the other isoforms, and so a difference in phylogenetic units of ~0.01 
may not be significant. HsPDE11A204 is virtually identical to HsPDE11A3, except for the 
unique N terminus of HsPDE11A3, two adjacent, changed amino acids, and a single amino 
acid deletion. As such, the unique N terminus of HsPDE11A3 should be used to determine 
which is closer. The unique N terminus of HsPDE11A3 was aligned with DmPDE11 B 
long using ClustalW analysis (figure 8.14). 
 
Figure 8.14: The unique N-terminus of HsPDE11A002 (A3) aligns with DmPDE11 B 
long from amino acid ~435 of DmPDE11 B long to amino acid ~530.  
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The unique sequence of the N terminus of HsPDE11A3 was found to align between amino 
acids 435 – 530, sequence common to both the B and C DmPDE11 isoforms. Alignment of 
HsPDE11A  204  with  DmPDE11  B  long  revealed  an  alignment  from  amino  acid  530 
onwards (figure 8.15). 
Figure 8.15: HsPDE11A 204 aligns with DmPDE11 B long from amino acid 530 of B 
long onwards. First ~400 amino acids of ClustalW alignment shown. 
 
 
Multiple methods of sequence analysis designate amino acids 420 to 750 (using B long as 
a reference) of DmPDE11 as encoding twin GAF domains (figure 8.16). 
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Figure 8.16: DmPDE11 (B long shown) has twin GAF domains between amino acids 
420 to 750. From Ensemble. 
  
As the unique N terminus of HsPDE11A3 aligns within this region, and furthermore aligns 
to sequence just adjacent to the region of GAF-A that HsPDE11204 aligns to, it would 
appear that this sequence constitutes novel GAF-A sequence, and thus forms a novel GAF-
A. As such, it was considered that the designation of HsPDE11A3 as the closest DmPDE11 
homologue/orthologue remains valid. 
 
8.4 Conclusions and future work 
Using Drosophila melanogaster to study the in vivo function of vertebrate PDEs has been 
shown  to  be  worthwhile  in  previous  studies.  The  vertebrate  PDE11A  family  has  been 
characterised biochemically, but the physiological role it plays it not well understood, with 
the only role so far assigned is a role in spermatogenesis. Drosophila PDE11 was first 
described in 2005, which also has four splice variants. The four isoforms of DmPDE11 
were aligned with the HsPDE11A isoforms, and compared in terms of sequence identity 
and  homology,  and  were  subjected  to  phylogenetic  analysis.  These  results,  when 
considered alongside the strong homology between the unique N terminus of HsPDE11A3 
and  GAF-A  of  DmPDE11,  suggest  that  HsPDE11A3  is  the  closest  orthologue  to 
DmPDE11 of the HsPDE11A isoforms. 
HsPDE11A3 pP[UAST] and HsPDE11A3pP [YFP UAST] constructs were generated, and 
the transgene expressed in S2 cells and fly. The protein showed predominantly nuclear 
localisation when expressed in S2 cells, and the principal cells of the Malpighian tubule at 
low levels of expression, but was localised to the cytosol when the transgene was driven by 
stronger  GAL4  expression.  Analysis  of  HsPDE11A3  using  the  PREDICTNLS  nuclear 
localisation  signal  prediction  tool  shows  that  the  protein  does  not  contain  a  nuclear 
localisation signal (Cokol et al., 2000). Therefore, it must be piggybacking its way into the 250 
nucleus with another protein. As for the change in localisation at higher concentration, 
reasons for this are unknown. Immunohistochemical studies concerning HsPDE11A have 
tended to focus on the distribution among tissues (D'Andrea et al., 2005; Loughney et al., 
2005); one study looked at the subcellular localisation of HsPDE11A, which was shown to 
localise to the cytosol of nerve cell bodies of the trigeminal ganglion (Kruse et al., 2009). 
The  nuclear  localisation  of  two  PDEs  has  been  investigated;  PDE1A  localises  to  the 
nucleus  in  neointimal  synthetic  vascular  smooth  muscle  cells,  but  localises  to  the 
cytoplasm  in  contractile  vascular  smooth  muscle  cells.  The  basis  for  this  change  in 
localisation  is  not  currently  understood  (Nagel  et  al.,  2006).  Certain  PDE9A  isoforms 
localise to the nucleus, but this is due to a nuclear localisation signal (Wang et al., 2003). 
Thus,  the  mechanism  of  translocation  of  HsPDE11A3  to  the  nucleus  is  unknown,  but 
appears to be dependent of the concentration of protein. 
Transgenic expression in Drosophila of HsPDE11A3 gives a protein of the predicted size, 
which  shows  a  distinct  subcellular  localisation.  Time  did  not  permit  to  perform  PDE 
assays, and so it is unknown whether the PDE is active in Drosophila. PDE11 -/- mice 
display reduced sperm concentration, rate of forward progression, and percentage of live 
spermatozoa (Wayman et al., 2005), and inhibition of HsPDE11A has also been shown to 
negatively  impact  spermatozoa  quality  (Pomara  and  Morelli,  2005),  as  HsPDE11A 
regulates spermatozoa physiology  (Seftel, 2005).  DmPDE11 -/- null mutant males are 
infertile, as detailed in chapter 4, and so function may be conserved. Spermatogenesis in 
Drosophila is highly analogous to mammalian spermatogenesis (White-Cooper, 2009), and 
so Drosophila could be used to delineate the role of HsPDE11A in spermatogenesis. 
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Chapter 9 
Summary and further work 
9   
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9.1 Summary 
Initial attempts to characterise DmPDE11 focused on two resources; the DmPDE11RA 
ORF, and UAS-PDE11 RNAi flies. While work performed on the ORF of DmPDE11RA 
ultimately proved to be void, due to the replacement of the gene model with two newly 
predicted ORFs, B and C, which encoded two novel polypeptides, work performed on the 
RNAi line is fortunately still valid, due to the targeted sequence being conserved in the B 
and C isoforms. The role of DmPDE11 in the Ca
2+ response to capa-1 was investigated, as 
Ca
2+ and cGMP crosstalk occurs in non-excitable cells (Bruce et al., 2003). No difference 
in the cytoplasmic calcium response was seen in tubules with reduced DmPDE11 transcript 
levels compared to control. Treatment of tubules with cGMP induces fluid transport (Dow 
et al., 1994), and the possible involvement of  DmPDE11 in modulation of this cGMP 
signal and therefore fluid secretion was investigated by driving DmPDE11 RNAi in the 
principal cells of the Malpighian tubule and comparing the cG-induced fluid secretion of 
these to parental control, where no difference was seen. 
Flybase release 5.2 predicted that the previously predicted gene model for CG34341 was 
incorrect.  The  previously  predicted  transcript,  DmPDE11RA,  was  replaced  by  two 
transcripts,  DmPDE11RB  and  DmPDE11RC.  These  transcripts  were  shown  to  be 
transcribed in vivo by a combination of RT-PCR from cDNA from several tissue sources, 
and by the analysis of EST databases not used in the Flybase analysis. In the course of this 
analysis, a novel exon/exon boundary was identified within exon 17, where the novel exon 
18  encodes  4  amino  acids,  followed  by  a  stop  codon.  This  results  in  a  truncated 
polypeptide.  RT-PCR  analysis  demonstrated  that  both  DmPDE11RB  and  RC  were 
transcribed with both full length and a truncated isoforms. The generation of transgenic 
flies expressing these isoforms tagged with YFP allowed the verification of these isoforms 
as  bona  fide  dual  specificity  PDEs.  Importantly,  the  RNAi  lines  generated  against 
DmPDE11RA targeted a region unchanged in the new isoforms, and so work done with 
these lines remained valid. 
Analysis of the subcellular localisation of these isoforms showed that DmPDE11B and C 
display markedly different subcellular localisation, and that the long and short isoforms of 
these do not show distinct subcellular localisation. DmPDE11B localises predominantly to 
the apical and basolateral membranes of the Malpighian tubule, and DmPDE11C localises 
to an unknown organelle or vesicles. 253 
 As DmPDE11B and C only differ in the sequence of the first exon, this must encode 
protein sequence that influences the subcellular localisation of the protein. Indeed, analysis 
of the protein sequence of DmPDE11B with the coiled coil prediction software COILS 
(Lupas et al., 1991) predicts a coiled coil in the unique N terminus. Coiled coils facilitate 
the formation of homo- and heteromeric protein-protein interactions (Strauss and Keller, 
2008),  and  thus  protein  complexes  (Langosch  and  Heringa,  1998).  The  subcellular 
localisation of this isoform to the membrane suggests that this region may be responsible 
for an interaction with a protein that tethers DmPDE11 to the membrane. The differing 
subcellular localisation  of the B and C isoforms  will lead the isoforms  to  sample and 
modulate  different  pools  of  cyclic  nucleotides,  and  thus  they  may  modulate  different 
aspects of the cyclic nucleotide signalling pathway (Omori and Kotera, 2007). 
DmPDE11  was  shown  to  co-localise  with  the  cGKs  DG1  and  DG2.  This  may  be  of 
extreme importance, since phosphorylation of PDE11A4 and PDE5A by cGKs has been 
shown to modulate catalytic function (Corbin et al., 2000; Gross-Langenhoff et al., 2008; 
Turko et al., 1998; Yuasa et al., 2000), and the co-localisation and mutual modulation of 
function of PDE5 and cGK1β in platelets is essential in modulating IP3R mediated Ca
2+ 
release from the ER (Wilson et al., 2008). DG2 modulates the cG-PDE activity of an 
unidentified  PDE  in  the  Malpighian  tubule  (MacPherson  et  al.,  2004),  and  so 
demonstrating  that  the  subcellular  localisation  of  these  overlap  renders  any  interaction 
worthy of further investigation. 
Peptide arrays were used to show whether any interaction between these proteins may be 
direct. A DmPDE11 array probed with the C-terminal half of DG1 (from the end of the 
second nucleotide binding domain onwards) tagged with HIS6 gave a number of positive 
spots compared to control, and the reciprocal assay, where a DG1 array was probed with a 
HIS6 tagged fragment representing the middle of DmPDE11 (from the second GAF domain 
to the end of the catalytic domain) also gave positive spots. However, this data must be 
considered  preliminary,  as  alanine  substitution  arrays  have  not  been  performed,  and 
peptide arrays must be validated by a further two pieces of interaction data such as co-IP 
and  Y2H  analysis,  and  in  this  case  only  co-IP  data  has  been  obtained.  Peptide  arrays 
investigating  a  putative  DG2/DmPDE11  interaction  were  non-informative,  and 
unfortunately N-terminal DG1 truncate could not be successfully purified and so was not 
applied to the DmPDE11 array. 
Previous  findings  by  Lorraine  Aitcheson  suggested  that  DmPDE11  may  modulate 
expression  of  the  anti-microbial  peptide  diptericin,  and  that  a  reduction  in  DmPDE11 254 
expression  in  principal  cells  of  the  Malpighian  tubule  affects  survival  upon  immune 
challenge with E. coli. The possibility that flies with reduced DmPDE11 transcript levels 
may be immunocompromised was investigated by delivering a septic challenge with E. 
coli  to  a  DmPDE11  deletion  line,  DmPDE11∆121,  and  UAS-DmPDE11  RNAi  flies 
crossed to GAL4 driver lines. UAS-DmPDE11 RNAi was crossed to Act5c GAL4 and c42 
driver  lines,  which  drive  expression  ubiquitously,  and  in  the  principal  cells  of  the 
Malpighian tubule respectively. The progeny of these crosses did not display a reduction in 
survivorship when compared to controls. DmPDE11∆121 flies showed a highly significant 
reduction  in  survivorship  following  immune  challenge,  although  100  hours  following 
septic challenge, these flies only displayed survivorship ~13% lower than Canton S E. coli 
stabbed control. This is a fairly modest, although significant, reduction in survivorship, 
which suggests that the immune role played by DmPDE11 is not a vital one. 
HsPDE11A is the most recently characterised PDE family (Fawcett et al., 2000; Yuasa et 
al., 2000). Phylogenetic analysis of the HsPDE11A gene family suggests that the closest 
homologue to DmPDE11 is HsPDE11A3, which is expressed exclusively in testis in both 
rat and human (Yuasa et al., 2001), and regulates spermatozoa physiology (Seftel, 2005). 
As DmPDE11 -/- males are infertile, function may be conserved. As the physiological role 
of PDE11 is not well understood, HsPDE11A3 pP[UAST] constructs were generated, and 
the transgene expressed in S2 cells and fly. The protein showed predominantly nuclear 
localisation with lower levels of protein in the cytoplasm when expressed in S2 cells. In 
Malpighian tubule principal cells, HsPDE11A3 localised to the nucleus at low levels of 
expression, but was excluded from the nucleus when the transgene was driven by stronger 
GAL4  expression.  Such  a  change  to  the  subcellular  localisation  may  be  crucial  to  its 
function, and so further study of HsPDE11A3 in Drosophila would be worthwhile. 
9.2 Future work 
cA- and cG-PDE assays of HsPDE11A3 
Time  did  not  permit  the  verification  of  HsPDE11A3  cA-  and  cG-  PDE  activity  when 
transgenically expressed in Drosophila. This would be necessary to demonstrate that the 
enzyme is functional when heterologously expressed, and would justify the use of these 
flies to characterise a role for HsPDE11A3 in vivo. 
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DmPDE11C localisation 
As  YFP-tagged  DmPDE11C  transgenic  flies  were  generated,  the  identification  of  the 
unknown  organelle  could  be  identified  by  either  co-staining  of  each  organelle  using 
specific antibodies, or by the crossing of these flies to GFP tagged proteins known to 
localise to a particular organelle, and screening for co-localisation. If the localisation is to 
vesicles, these could be purified, and this fraction subjected to western blotting to confirm 
the presence or absence of DmPDE11C. 
 
HsPDE11A3 localisation 
HsPDE11 localisation appeared to be dependent upon levels of protein, where at lower 
concentrations the protein localises to the nucleus, and at high concentration, the protein is 
excluded  from  the  nucleus.  Truncation  mutants  could  be  assayed  for  subcellular 
localisation, in an effort to identify the sequence that modulates this shift in localisation. 
Identification of proteins that interact with DmPDE11 
Although this assay has been performed, the availability of a new polyclonal antibody 
against  DmPDE11  would  allow  the  immunoprecipitation  of  the  enzyme,  and  the 
identification of any putative interactors by analysis of the immunoprecipitate by MALTI-
TOF mass spectrometry.  
Co-immunoprecipitation of DmPDE11 and the cGKs using specific antisera 
Specific antisera against DmPDE11, and the cGKs DG1 and DG2 were generated during 
the course of this study, but unfortunately were produced after my time in the laboratory 
had finished. Upon verification that these antibodies can recognise their antigens both in 
immunoprecipitation  and  western  blot,  co-immunoprecipitations  could  be  performed 
against fly lysate. Co-immunoprecipitation from tissue using specific antisera is considered 
the gold standard in co-immunoprecipitation, and would provide evidence of an interaction 
in vivo. 
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Screen for co-localisation of DmPDE11 and the cGKs in vivo 
In order for a putative protein-protein interaction to be relevant, proteins must occupy an 
overlapping subcellular localisation. During the course of this study it was ascertained that 
DmPDE11B  long  and  short  localise  to  the  apical  and  basolateral  membranes  of  the 
Malpighian  tubule,  whereas  DmPDE11C  long  and  short  localised  to  an  unidentified 
organelle, or to vesicles. DG1 localises to the basolateral membrane and to the cytosol, 
DG2P1 localises to the apical and basolateral  membranes, and DG2P2 localises to the 
apical membrane. Of these, only DG1 could potentially interact with DmPDE11C, which is 
wholly localised within the cytosol. 
Modulation of PDEs by DG2 
When compared to control, DmPDE11 RA overexpressing S2 cells showed no significant 
increase in either cA-, or cG-PDE activity. Co-expression of either DG2P1 or DG2P2 with 
DmPDE11RA  further  reduced  both  cA-  and  cG-PDE  activity.  Although  N=1  for  each 
condition, this suggests that over-expressed cGK modulates phosphodiesterase activity or 
protein  levels.  The  experiment  mirrors  a  finding  in  flies  overexpressing  DG2P1  and 
DG2P2  in  tubule  principal  cells,  the  tubules  of  which  show  a  drastic  reduction  in 
endogenous PDE activity (Macpherson and Day, 2005). The Malpighian tubule could be 
used to further investigate this. Q-PCR of each PDE gene in DG2 overexpressing tubules 
would reveal whether DG2 modulated PDE activity by a reduction in transcript levels. The 
availability of GST- and HIS6 tagged cGK and DmPDE11 raises the possibility of in vitro 
phosphorylation  assays;  if  DmPDE11  is  found  to  be  phosphorylated,  the  targeted 
mutagenesis of residues predicted as cGK substrates would allow the identification of each 
phosphorylation site. 
 
Confirmation of DmPDE11 role in immunity 
Assay of an increased number of DmPDE11∆121 and other DmPDE11 deletion mutants, 
alongside  the  appropriate  controls,  would  confirm  whether  DmPDE11  has  a  role  in 
immunity.  As  DmPDE11∆121  showed  only  a  modest,  but  significant,  reduction  in 
survivorship, it may be that multiple phosphodiesterases modulate the immune response, 
and this redundancy leads a knock-down of DmPDE11 transcript levels to have a modest 257 
effect.  Immune  challenge  of  flies  treated  with  a  broad-spectrum  phosphodiesterase 
inhibitor may reveal whether this is the case. 
Repeat of DG2 probed DmPDE11 peptide arrays 
Although several putative sites of protein-protein interaction were identified on the PDE11 
array, when probed with both the N- and C-terminal HIS6 tagged DG2 proteins, there was 
non-specific immunoreactivity at each of these sites on the control PDE11 array. Repeat 
using GST-tagged protein would potentially give different background, and so the putative 
interaction at these sites could be confirmed, in which case an alanine array would be 
generated and overlaid. 
Repeat of DmPDE11 probed DG2 peptide arrays 
Middle-HIS6 and End-HIS6 probed DG2 arrays were compromised; Middle-HIS6 overlaid 
DG2 array showed higher levels of background staining, and so putative spots could not be 
taken  as  evidence  of  an  interaction,  while  End-HIS6  overlaid  arrays  showed  staining 
significantly dissimilar to control blots, and so novel immunoreactive spots could not be 
taken as putative interaction sites. Repeat of these assays with GST-tagged protein would 
again  give  a  different  background,  and  hopefully  allow  the  identification  of  putative 
interaction sites. 
Confirmation of direct DmPDE11-DG1 interaction 
Several sites were determined on DmPDE11 and DG1 which may be regions of direct 
protein-protein  interaction.  Alanine  substitution  arrays  would  confirm  whether  these 
regions  are  indeed  sites  of  protein-protein  interaction,  and  furthermore  would  identify 
those key amino acids within these regions vital for the interaction. As peptide array data 
must be verified by a further two methods, yeast two hybrid and co-IP of deletion mutants 
would confirm the interaction. 
DG1N probed DmPDE11 array 
DmPDE11 and DG1 showed several putative interaction sites on both proteins. Three sites 
were identified within DG1, two of which corresponded to the N terminal fusion protein. 
This fusion protein gave protein of the predicted size at the analytical stage, but failed to 
yield protein following immunoprecipitation. Use of a GST-tagged DG1N terminal fusion 258 
protein would hopefully allow the affinity purification of the protein, and subsequently the 
probing  of  the  DmPDE11  array,  in  order  to  identify  additional  putative  regions  of 
interaction.  
This work has confirmed that DmPDE11RB and RC are transcribed in vivo, and that RB 
and RC each have a short isoform. These show closest homology with HsPDE11A3 in 
terms of sequence. Transgenic Drosophila melanogaster were generated which express 
each of these proteins, and it is hoped that these tools will be used to further characterise 
these biomedically relevant enzymes. Furthermore, the identification of a putative direct 
interaction between DmPDE11 and the cGKs needs to be explored further, as this raises 
the possibility of a new level of feedback in cGMP signalling between the main effectors 
of the pathway, cGMP-dependent protein kinases, and the main regulator of the pathway, 
phosphodiesterases. 
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Appendices 
Appendix 1: Projects undertaken that were halted when the new DmPDE11 sequence 
predictions were released 
Yeast Two Hybrid 
In order to investigate whether the interaction between DmPDE11A and the cGKs was 
direct, a Yeast Two Hybrid screen was undertaken.  The N and C termini of DmPDE11RA, 
and the complete ORFs of DG2P1 and P2 were amplified with proofreading polymerase, 
sequenced  for  fidelity  (data  not  shown),    digested,  and  cloned  into  pACT2  AD,  an 
activation domain vector, and pGBKT7, a DNA binding domain vector. The cloning for 
this  was  completed,  and  the  constructs  were  transformed  and  screened  for  expression. 
However this approach was abandoned in favour of peptide arrays, which not only show 
whether an interaction is direct, but show the peptides responsible for the interaction. This 
data was presented in chapter six. 
Yeast and expertise kindly supplied by Dr. Joe Gray. 
TAP-tagging 
Retrieval  of multi-subunit  protein complexes  utilising tandem  affinity  purification, and 
their subsequent purification via -mass spectrometry (TAP-tagging) is a technique that was 
pioneered in Yeast (Riguat et al, 1999,) and first used in Drosophila in 2004 (Veraska, 
2004.) TAP-tagging is similar to epitope tagging, except multiple tags are used instead of 
one. The technique involves the cloning of a protein of interest, fused in-frame to a “tap-
tag” at either the C or N terminus. The “tap tag” in our possession consists of two IgG 
binding  domains  of  Protein  A  from  Staphylococcus  aureus  and  a  calmodulin  binding 
peptide, which are separated by a TEV protease cleavage site (Rigaut et al, 1999). The 
TEV protease site allows the release of the protA units from the matrix-bound IgG under 
native  conditions,  which  should  keep  native  interactions  intact,  and  thus  permit  the 
purification of interacting protein complexes. Following the elution of these proteins, mass 
spectrometry is used to identify each individual protein. The presence of two tags allows a 
two-step purification process, which provides a reduction in protein background, while the 
native conditions should not inhibit protein binding, thus preventing the loss of proteins 
from the complex. 
The tap-tag can be combined with the UAS/GAL4 binary expression system. This allows a 
cell-specific identification of any interactors, at specific points in the fly‟s development, 260 
and to a tissue specific level if the daunting number of dissections could be overcome. 
When this process is coupled to mass spectrometry, proteins at the sub-picomolar range are 
readily identifiable (Bauer and Kuster, 2003). 
The  aim  of  the  TAP  tagging  project  was  to  identify  any  proteins  that  interact  with 
DmPDE11 and DG2P1. Stable S2 cell lines expressing the TAP-tagged DmPDE11RA, 
DG1, DG2P1 and DG2P2 were generated by co-transfection with a pCoHygro plasmid, 
and selection with hygromycin-B. However these were not validated for expression, as this 
coincided with the release of Flybase release 5.2. The stock was immortalised. 
 
Appendix 2: Data pertaining to DmPDE11 catalytic activity in S2 cells and fly 
 
Analysis of PDE (and PDE truncate) catalytic activity in S2 cells 
Attempts to express full length DmPDE11 in S2 cells failed (Day, 2005). As such the 
catalytic domain was cloned into pMT/V5-His-TOPO, again in frame with the C-terminal 
V5 tag, and subjected to cA- and cG-PDE assays alongside DmPDE6 and DmPDE8 (figure 
A2.1) (Day, 2005).  
 
Figure A2.1: PDE activity of DmPDE6, DmPDE8 and DmPDE11 catalytic domain 
constructs. S2 cell lysate was assayed for cG and cA-specific PDE activity at a spread of 
substrate  concentrations.  Activities  represent  PDE-transfected  activity  minus  mock 
transfected activity. Specific PDE activity expressed as pmol cGMP or cAMP/mg/min. 
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Analysis of DmPDE11 immunoprecipitate by PDE assays 
DmPDE11 was verified as a dual specificity PDE by immunoprecipitation using specific 
polyclonal antisera from head lysate, and subjecting this IP to cA- and cG-PDE assays 
(figure A2.2) (Day et al., 2005) 
 
Figure  A2.2:  DmPDE11A  shows  significant  cA-  and  cG-PDE  activity  when 
immunoprecipitated,  and  subjected  to  cN-PDE  assays.  Immunoprecipitate  of 
DmPDE11 using specific antisera from head lysate yields significant cA- and cG-PDE 
activity when compared to pre-immune control. N=3. Error bars represent standard error of 
the mean. 
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Appendix 3: DmPDE11B and C isoforms are expressed in hindgut and head 
 
PCR analysis of DmPDE11 expression in hindgut and head 
PCR using primers specific to isoforms  B and C  was performed on hindgut and head 
cDNA  to  determine  if  RB  and  RC  were  expressed  in  each  (figure  A3.1)  (Day  and 
Sebastian, unpublished observations, 2007). 
 
Figure A3.1: DmPDE11 RB and RC are expressed in head and hindgut. PCR (30 
cycles) was performed using primers specific to the N termini of DmPDE11 RB and RC 
using head (A; expected product 315 bp) and hindgut (B; expected product 183bp) cDNA, 
and the products verified by agarose electrophoresis. Band size identified using 100bp 
ladder. For both gels: Lane 1: DmPDE11-RB N-termini, lane 2: DmPDE11-RC N-termini. 
(A)                                                           (B) 
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Appendix 4: Data pertaining to an interaction between DmPDE11 and cGKs 
 
DmPDE1, DmPDE6 and DmPDE11 co-immunoprecipitate with cGK activity 
Immunoprecipitates  of  PDE  1,  6  and  11  using  specific  IgG  purified  antisera  from 
Drosophila head lysate were assayed for cGK activity (figure A4.1) (Day and Sebastian). 
 
Figure  A4.1:  Immunoprecipitation  from  fly  head  lysate  using  Drosophila  anti-
DmPDE1, anti-DmPDE6, and anti-DmPDE11 polyclonal antibodies yields significant 
cGK activity. PDE was immunoprecipitated from fly head lysate using IgG purified anti-
DmPDE1,  anti-DmPDE6,  and  anti-DmPDE11  specific  antisera,  and  IgG  purified  pre-
immune serum (“IgG”), and the immunoprecipitate subjected to a kinase assay against a 
“glasstide” cGK substrate. * denotes significant difference of mean P <0.05 against pre-
immune IgG control. 
 
Immunoprecipitation of DmPDE1, DmPDE6, and DmPDE11 each  yielded a significant 
amount  of  cGK  activity  when  compared  to  pre-immune  control  (Day  and  Sebastian), 
suggesting that each DmPDE interacts with cGK(s).   
 264 
DG1 or DG2 co-immunoprecipitate with cG-PDE activity 
DG1 and DG2 were immunoprecipitated using IgG purified specific polyclonal antisera 
from head lysate, and the immunoprecipitate subjected to cG-PDE assay (figure A4.2) 
(Day and Sebastian).  
 
Figure A4.2: Immunoprecipitation from fly head lysate using Drosophila anti-DG1 
and anti-DG2 polyclonal antibodies yields significant cG-PDE activity. DG1 and DG2 
were immunoprecipitated from fly head lysate using IgG purified anti-DG1 and anti-DG2 
specific antisera, and IgG purified pre-immune serum (“Pre-Im”), and the IP subjected to a 
cG-PDE  assay.  *  denotes  significant  difference  of  mean  P  <0.05  against  pre-immune 
control. 
 
Both the DG1 and DG2 immunoprecipitates  yielded significant cG-PDE activity when 
compared to pre-immune controls (Day and Sebastian), suggesting that both DG1 and DG2 
interact with at least one unidentified cG-PDE.  
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DmPDE11 co-immunoprecipitates with DG2P2 
Wild-type canton S flies were homogenised and subjected to immunoprecipitation with an 
anti-DmPDE11  polyclonal  antibody  which  recognises  all  four  isoforms.  The 
immunoprecipitate was resolved on an SDS-PAGE gel, and individual bands were excised 
and  sequenced  using  Matrix-assisted  laser  desorption/ionisation-time  of  flight  mass 
spectrometry  (MALDI-TOF  MS).  One  band  yielded  several  stretches  of  amino  acids 
corresponding  to  DG2P2  sequence,  that  have  no  significant  homology  to  any  other 
Drosophila protein when BlastP analysis is performed against the Drosophila proteome 
(Day).  
 
Appendix  5:  Previously  obtained  data  implicates  DmPDE11  in  the  gram  negative 
immune response 
 
Diptericin expression is modulated by a pool of cGMP that is in turn modulated by 
PDE11 
When UAS-PDE11 RNAi (line 1) expression is driven in the Malpighian tubule principal 
cell with the GAL4 driver c42, there is a significant reduction in diptericin expression. 
While parental tubules incubated in Schneider‟s solution for three hours, either with or 
without 100μM cGMP, show a significant reduction of diptericin expression in the plus 
cGMP condition, c42/UAS-PDE11 RNAi (line 1) flies show a significantly lower level of 
diptericin expression in both conditions, where the addition of cGMP does not result in a 
further reduction of diptericin expression (figure A5.1) (Aitcheson, 2009a).  
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Figure A5.1: Q-PCR analysis of the affect of cGMP on diptericin expression in the 
Malpighian  tubule.  Q-PCR  for  diptericin  expression  in  the  Malpighian  tubule,  where 
tubules were incubated in Schneider‟s solution for three hours, in the presence or absence 
of  100μM  cGMP.  Error  bars  show  standard  error  of  the  mean  (courtesy  of  Lorraine 
Aitcheson.) 
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Reduction  of  PDE11  transcript  levels  in  Malpighian  tubule  principal  cells  affects 
whole fly survival in response to a septic challenge with E. coli 
UAS-PDE11 RNAi (line 1) flies were crossed to c42 GAL4. UAS-PDE11 RNAi (line 1), 
and c42/UAS-PDE11 RNAi (line 1) flies were either “mock” stabbed with a dry 0.35mm 
needle, or stabbed with a 0.35 gauge needle dipped in an E. coli solution (at static phase) in 
the  abdomen,  and  survival  was  monitored  for  24  hours  (figure  A5.2),  as  detailed  in 
materials and methods (Aitcheson, 2009b). 
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Figure  A5.2:  Preliminary  data  showing  a  reduction  in  survivorship  in  c42/UAS-
PDE11 RNAi compared to controls when septically challenged with E. coli. Survival 
experiment showing a significant decrease in survival upon challenge with E. coli using a 
0.35mm  gauge  needle  when  PDE11  expression  is  reduced  via  expression  of  a  PDE11 
RNAi transgene, driven in tubule principal cells. Error bars show standard error of the 
mean (courtesy of Lorraine Aitcheson.)  
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Following septic challenge with E. coli, c42/UAS-PDE11 RNAi (line 1) flies displayed a 
lower level of survival compared to the negative controls. This experiment was performed 
to N=1, using between 19 to 29 flies for each genotype, where N=3 replicates of 30 flies 
per genotype is necessary to perform statistical analysis.  
 
Appendix 6: Drosophila Media 
 
 Standard growth media per litre of water     10 g agar 
                    15 g sucrose 
                    30 g glucose 
                    35 g dried yeast 
                    15 g maize meal 268 
                            10 g wheat germ 
                    30 g treacle 
                    10 g soya flour 
 
Grape-juice agar                per litre of water 
                    40 g agar 
                    52 g glucose 
                    26 g sucrose 
                    15 g dried yeast 
                    50 % (v/v) blackcurrant diluting juice 
                      1 % (v/v) Nipagin 
 
Appendix 7: Escherichia coli growth media and selective agents 
 
L-broth per litre of water                    10 g Bacto-tryptone 
          5 g dried yeast  
          10 g NaCl 
 
L-agar per litre of water                      10 g Bacto-tryptone 
          5 g dried yeast  
          10 g NaCl 
          15 g Bacto-agar 
 
SOC broth        2 % (w/v) Bacto-tryptone 269 
          0.5 % (w/v) dried yeast 
          10 mM NaCl 
          2.5 mM KCl 
          10 mM MgCl2 
          10 mM MgSO4 
          20 mM glucose 
 
Selective agents 
 
Ampicillin: 100-200 g/ml ampicillin when being grown on L-Agar or in L-Broth. 
 100 mg/ml stock solution (w/v) in 50% H2O, 50% ethanol and stored at -20C. 
Kanamycin:  50  mg/ml  solution  (Sigma)  and  stored  at  4C.  Selection  for  kanamycin 
resistance was performed by the presence of 50 g/ml kanamycin on L-Agar or in L-Broth.  
 
Appendix 8: SDS-PAGE and Western blotting solutions 
 
6 x SDS-PAGE Loading buffer  0.35 M Tris HCl,  pH6.8 
10.28 % (w/v) SDS 
36 % v/v glycerol 
          5 % v/v -mercaptoethanol 
          0.012 % w/v bromophenol blue 
in 0.5 ml aliquots stored at –20C 
Tris-Glycine Running Buffer    per 500 ml of H2O 
          7.2 g Glycine 270 
          1.5 g Tris Base  
          6 ml 10% (w/v) SDS 
Staining Solution      465 ml Brilliant blue R concentrate (Sigma) 
          535 ml H2O 
Destaining Solution      10 % (v/v) Acetic Acid 
45% (v/v) Methanol 
in H2O 
Poncau S Staining Solution    per 500 ml of H2O 
          1.5 g TCA 
          0.5 g Poncau S stain 
Transfer Buffer      per litre of H2O 
          20 % (v/v) Methanol 
          14.4 g Glycine 
          3 g Tris Base 
1 x PBS        137 mM NaCl 
           2.7 mM KCl 
          10 mM Na3PO4                                                                                               
w                                                                     2 mM KH2PO4,          pH 7.4 
From (Sambrook and Russell, 2001) 
 
Appendix 9: Resolving and Stacking gels for SDS-PAGE 
Each solution is sufficient to prepare 2 x 5ml gels   
6 % gel                                                                              
H2O                                                    5.3 ml                           271 
30 % acrylamide mix                            2.0  
1.5 M Tris (pH 8.8)                              2.5 
10 % (v/v) SDS                                   0.1  
10 % (v/v) APS                                   0.1 
TEMED                                              0.008 
7 % gel 
H2O                                                    5ml                                                         
30 % acrylamide mix                            2.3 
1.5 M Tris (pH 8.8)                              2.5 
10 % (v/v) SDS                                   0.1 
10 % (v./v) APS                                  0.1 
TEMED                                              0.007 
10 % gel 
H2O                                                    4.0 
30 % acrylamide mix                           3.3 
1.5 M Tris (pH 8.8)                             2.5 
10 % (v/v) SDS                                   0.1 
10 % (v/v) APS                                   0.1 
TEMED                                              0.004 
 
Sufficient to prepare 2 x 5% 1.5ml stacking gels   
H2O                                                     2.1 ml 
30 % acrylamide mix                            0.5 
1.0 M Tris (pH 6.8)                              0.38                                            272 
10 % (v/v) SDS                                   0.03 
10 % (v/v) APS                                   0.03 
TEMED                                              0.003 
From (Sambrook and Russell, 2001) 
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